FAD3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks

ABSTRACT

A method of gene editing or gene stacking within a FAD3 loci by cleaving, in a site directed manner, a location in a FAD3 gene in a cell, to generate a break in the FAD3 gene and then ligating into the break a nucleic acid molecule associated with one or more traits of interest is disclosed.

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application claims priority to the benefit of U.S.Provisional Patent Application No. 61/697,854, filed Sep. 7, 2012, thedisclosure of which is hereby incorporated by reference in its entirety,and to U.S. Provisional Patent Application No. 61/820,260, filed on May7, 2013, the disclosure of which is hereby incorporated by reference inits entirety.

FIELD OF THE DISCLOSURE

The present disclosure relates generally to compositions and methods foruse in recombinant plant technology (for example, for generating atransgenic plant). More specifically, the present disclosure relates toplant cells and plants including loci within their genomes that may beused for the site-specific introduction of any nucleic acid of interest.

BACKGROUND

Many plants are genetically transformed with exogenous nucleic acids(e.g., transgenes) to introduce desirable traits, for example, toimprove agricultural value. Examples of improvements in agriculturalvalue that can be achieved through genetic transformation include:improved nutritional quality, increased yield, pest or diseaseresistance, drought and stress tolerance, improved horticultural quality(e.g., improved pigmentation and/or growth), herbicide resistance,production of industrially useful compounds and/or materials from theplant, and/or production of pharmaceuticals. The introduction of clonedgenes into plant cells and recovery of stable fertile transgenic plantscan be used to make a genetic modification of a plant stable throughmultiple generations, and thereby allow the genetic engineering of acrop plant.

In methods for genetic transformation and transgenic plant production,exogenous DNA is typically randomly introduced into the nuclear orplastid DNA of a eukaryotic plant cell, followed by isolation of cellscontaining integrated exogenous DNA, and subsequent regeneration of astably transformed plant. Transgenic plants were typically generated byAgrobacterium-mediated transformation technology. Successes with thesetechniques spurred the development of other methods to introduce anucleic acid molecule of interest into the genome of a plant, such asPEG-mediated DNA uptake in protoplasts, microprojectile bombardment, andsilicon whisker-mediated transformation.

In all of these plant transformation methods, however, the exogenousnucleic acids incorporated in the plant genome are integrated randomlyin the genome of the plant cell, and in unpredictable copy number.Terada et al. (2002) Nat Biotechnol 20(10):1030; Terada et al. (2007)Plant Physiol 144(2):846; D'Halluin et al. (2008) Plant Biotechnology J.6(1):93. For example, the transgenes are frequently integrated in theform of sequence repeats, either of the whole transgene or of partsthereof. Such a complex integration pattern commonly adversely impactsthe expression level of the integrated nucleic acid (e.g., bydestruction of transcribed RNA through post-transcriptional genesilencing mechanisms, or by inducing methylation of the integrated DNA).Also, the location of the integration site commonly influences the levelof expression of the integrated nucleic acid. Moreover, the integrationof the exogenous DNA may have a disruptive effect on the region of thegenome where the integration occurs, and thereby influence or disturbthe normal function of that target region to produce undesirableside-effects. The combination of factors including the foregoing resultsin a wide variation in the level of expression of transgene or exogenousDNA (and overall agronomic quality) between different transgenic plantcell and plant lines, even those created by the same methods. Becausethe integration is random, these effects are not able to be controlledby the practitioner while he or she attempts to produce a new plant withdesirable characteristics.

The foregoing considerations necessitate that, whenever the effects ofintroducing a particular exogenous nucleic acid into a plant isinvestigated, a large number of transgenic plant lines must be generatedand analyzed in order to obtain significant results. Likewise, in thegeneration of a transgenic plant containing a particular integratednucleic acid so as to provide the transgenic plant with a desiredphenotype, a large population of independently created transgenic plantlines must be created to allow the selection of a plant line withoptimal expression of the nucleic acid, and with minimal or noside-effects on the overall phenotype and performance of the transgenicplant. These practical considerations take on added importance intransgenic plants created by inserting multiple exogenous nucleic acids(i.e., gene stacking). In such plants, phenomena such aspost-transcriptional gene silencing may be amplified.

Several methods have been developed in an effort to control transgeneinsertion in plants. See, e.g., Kumar and Fladung (2001) Trends PlantSci. 6:155-9. These methods rely on homologous recombination-basedtransgene integration, which has been successfully applied both inprokaryotes and lower eukaryotes. Paszkowski et al. (1988) EMBO J.7:4021-6. However, until recently in plants, the predominant mechanismfor transgene integration has been based on illegitimate recombination,which involves little homology between recombining DNA strands. A majorchallenge in this area is therefore the detection and selectivegeneration of rare homologous recombination events, which are masked byfar more efficient integration events via illegitimate recombination.Moreover, even if the selective generation and detection of targetedhomologous recombination events is achieved, the event must be targetedto a desirable location in the host genome in order to realize themaximum benefit of this strategy.

For example, an assumed benefit of targeted genetic transformation isthe reduction in event-to-event variability of transgene expression, ascompared to transformation events that are obtained from randomintegration. A further assumed benefit is a significant reduction in thenumber of events required to screen introduced nucleic acids, sorttransformation constructs, and produce events that contribute todesirable overall characteristics in the resulting transgenic plant. Acritical factor required to realize these benefits is the identificationof specific locations in the genome where transgene performance isconsistent, and if possible, where adverse effects on the host plant areeliminated or minimized.

Recently, methods and compositions for targeted cleavage of genomic DNAhave been described. Such targeted cleavage events can be used, forexample, to induce targeted mutagenesis, induce targeted deletions ofcellular DNA sequences, and facilitate targeted recombination andintegration at a predetermined chromosomal locus. See, for example,Urnov et al. (2010) Nature 435(7042):646-51; United States PatentPublications 20030232410; 20050208489; 20050026157; 20050064474;20060188987; 20090263900; 20090117617; 20100047805; 20110207221;20110301073; 2011089775; 20110239315; 20110145940; and InternationalPublication WO 2007/014275, the disclosures of which are incorporated byreference in their entireties for all purposes. Cleavage can occurthrough the use of specific nucleases such as engineered zinc fingernucleases (ZFN), transcription-activator like effector nucleases(TALENs), or using the CRISPR/Cas system with an engineered crRNA/tracrRNA (‘single guide RNA’) to guide specific cleavage. U.S. PatentPublication No. 20080182332 describes the use of non-canonical zincfinger nucleases (ZFNs) for targeted modification of plant genomes; U.S.Patent Publication No. 20090205083 describes ZFN-mediated targetedmodification of a plant EPSPS locus; U.S. Patent Publication No.20100199389 describes targeted modification of a plant Zp15 locus andU.S. Patent Publication No. 20110167521 describes targeted modificationof plant genes involved in fatty acid biosynthesis. In addition, Moehleet al. (2007) Proc. Natl. Acad, Sci. USA 104(9):3055-3060 describesusing designed ZFNs for targeted gene addition at a specified locus.U.S. Patent Publication 20110041195 describes methods of makinghomozygous diploid organisms.

However, there remains a need for compositions and methods for modifyingand/or modulating expression of FAD3 genes in plants, includinggeneration of plants with targeted insertions of desired transgenes atthe FAD3 locus.

BRIEF SUMMARY OF THE DISCLOSURE

The present disclosure describes compositions and methods for modulatingexpression of FAD3 genes (e.g., in plants, algae, and fungi) and the useof these loci as sites for the targeted integration of a nucleic acidsequence of interest (e.g., an exogenous nucleic acid sequence) into ahost cell. In some embodiments, a host cell may contain one or moregenomes with one or more FAD3 sequences (e.g., homeologues and/orparalogs), any or all of which may be selectively modified and/ordisrupted. In specific examples, the present disclosure describes FAD3A,FAD3A′, FAD3C′ and/or FAD3C genes, as well as corresponding homeologuesor paralogs, in Brassica napus (i.e., B. napus line, DH12075) and theiruse as loci for targeted integration of a nucleic acid sequence ofinterest. As described herein, though FAD3 genes are involved in fattyacid biosynthesis in the host, their modification or disruption (e.g.,by integration of an exogenous nucleic acid in the FAD3 coding sequence)unexpectedly may have no or minimal adverse effects on the resultanthost organism.

Also described herein is the use of one or more particular FAD3 loci intandem with a polypeptide capable of effecting cleavage and/orintegration of specific nucleic acid sequences within the FAD3 loci.Examples of the use of FAD3 loci in tandem with a polypeptide capable ofeffecting cleavage and/or integration of the FAD3 loci include apolypeptide selected from the group consisting of zinc finger proteins,meganucleases, TAL domains, TALENs, RNA-guided CRISPR-Cas9,recombinases, leucine zippers, CRISPr/Cas and others known to those inthe art. Particular examples include a chimeric (“fusion”) proteincomprising a site-specific DNA binding domain polypeptide and cleavagedomain polypeptide (e.g., a nuclease), such as a ZFN protein comprisinga zinc-finger polypeptide and a FokI nuclease polypeptide. For example,described herein is a demonstration of the in vitro and in vivo efficacyand specificity of particular ZFNs designed to bind and induce doublestranded breaks in FAD3A, FAD 3A′, FAD3A″, FAD3C. FAD3C′, FAD3C″, and incombinations thereof without cleaving corresponding homeologues orparalogs. In some embodiments, particular FAD3 loci may be used with anyof the foregoing polypeptides to effect site-specific integration of anucleic acid of interest that is subsequently expressed in the hostwhile having a minimal adverse impact on the agronomic performance ofthe host.

In certain aspects, described herein are polypeptides comprising aDNA-binding domain that specifically binds to a FAD3 gene. In someembodiments such a polypeptide may also comprise a nuclease (cleavage)domain or half-domain (e.g., a ZFN, a recombinase, a transposase, or ahoming endonuclease, including a homing endonuclease with a modifiedDNA-binding domain, TAL domains, TALENs, RNA-guided CRISPR-Cas9), and/ora ligase domain, such that the polypeptide may induce a targeteddouble-stranded break, and/or facilitate recombination of a nucleic acidof interest at the site of the break. In particular embodiments, aDNA-binding domain that targets a FAD3 locus may be a DNA-cleavingfunctional domain. The foregoing polypeptides may be used in someembodiments to introduce an exogenous nucleic acid into the genome of ahost organism exhibiting homologous recombination (e.g., a plant oranimal species) at one or more FAD3 loci (e.g., a plant or animalspecies) at one or more FAD3 loci. In certain embodiments, theDNA-binding domains comprise a zinc finger protein with one or more zincfingers (e.g., 2, 3, 4, 5, 6, 7, 8, 9 or more zinc fingers), and canwhich is engineered (non-naturally occuring) to bind to any sequencewithin a FAD3 gene. Any of the zinc finger proteins described herein maybind to a target site within the coding sequence of the target gene orwithin adjacent sequences (e.g., promoter or other expression elements).In certain embodiments, the zinc finger protein binds to a target sitein an FAD3 gene, for example, as shown in Table 4. The recognition helixregions of exemplary FAD3-binding zinc fingers are shown in Table 3. Oneor more of the component zinc finger binding domains of the zinc fingerprotein can be a canonical (C2H2) zinc finger or a non-canonical (e.g.,C3H) zinc finger (e.g., the N-terminal and/or C-terminal zinc finger canbe a non-canonical finger).

Also described herein are methods for disrupting or editing a FAD3 gene.Additionally described herein are genetically modified host organisms(e.g., transgenic plants) produced by methods according to embodimentsof the invention. In particular examples, a transgenic organism producedby a method according to an embodiment of the invention may be, withoutlimitation, algae, a fungus, a monocotyledonous plant, a dicotyledonousplant, etc.

The foregoing and other features will become more apparent from thefollowing detailed description of several embodiments, which proceedswith reference to the accompanying figures.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1, panels A to T, show sequence alignment of FAD3 gene sequences(SEQ ID NOs:7-12), generated using AlignX®.

FIG. 2 shows a phylogenetic tree of FAD3 gene sequences generated usingJalview v 2.3 based on neighbour joining distances. The labeledsequences correspond as follows: FAD3A′/A″ is described throughout thisapplication as FAD3A′; Haplotype2 is described throughout theapplication as FAD3C′; Haplotype 1 is described throughout theapplication as FAD3C″; and, Haplotype 3 is described throughout theapplication as FAD3A″.

FIG. 3 shows a plasmid map of pDAB107828.

FIG. 4 shows a plasmid map of pDAB107829.

FIG. 5 shows a plasmid map of pDAS000271.

FIG. 6 shows a plasmid map of pDAS000272.

FIG. 7 shows a plasmid map of pDAS000273.

FIG. 8 shows a plasmid map of pDAS000274.

FIG. 9 shows a plasmid map of pDAS000275.

FIG. 10 shows a plasmid map of pDAS000031.

FIG. 11 shows a plasmid map of pDAS000036.

FIG. 12 shows a plasmid map of pDAS000037.

FIG. 13 shows a plasmid map of pDAB107827.

FIG. 14 shows a plasmid map of pDAB107828.

FIG. 15 shows a plasmid map of pDAS000340.

FIG. 16 shows a plasmid map of pDAS000341.

FIG. 17 shows a plasmid map of pDAS000342.

FIG. 18 shows a plasmid map of pDAS000343.

FIG. 19 is a schematic which shows the locations of the primers andtheir position relative to the start and stop coding of Fad3C. Panel Ashows the location of the primer sites for the wild type Fad3C locus.Panel B shows the location of the primer sites to confirm donorintegration, and the possible orientations by which the donor couldintegrate within the Fad3C locus.

FIG. 20, panels A and B, show sequence alignments after modificationwith the indicated ZFNs and donor plasmids. FIG. 20A shows a sequencealignment amplified from the junction of the tGFP cassette of pDAS000341with Fad3C at the double strand break as recognized by ZFN28051-2A-28052. The “:” indicates the deletions located at the cutsites. SEQ ID NO:300 to SEQ ID NO:313 are shown in the alignment,respectively, in order of appearance. FIG. 20B shows a sequencealignment amplified from the junction of the tGFP cassette of pDAS000343with Fad3C at the double strand break as recognized by ZFN28051-2A-28052 and ZFN 28053-2A-28054. The “:” indicates the deletionslocated at the cut sites. SEQ ID NO:314 to SEQ ID NO:327 are shown inthe alignment, respectively, in order of appearance.

FIG. 21, panels A and B, show sequence alignments of sequence simplifiedfrom the junction of the hph cassette of pDAS000340 with FAD3C at thedouble strand break as recognized by ZFN 28051-2A-28052. “Sample” is aunique identifier for each plant that was assayed. The “:” indicates thedeletions located at the cut sites. The sequences shown in FIG. 21A arefor the 5′ junction and the sequences shown in the FIG. 21B are for the3′ junction. SEQ ID NO:368 to SEQ ID NO:375 and SEQ ID NO: 380 to SEQ IDNO: 381 are shown in the alignment of FIG. 21A, respectively, in orderof appearance. SEQ ID NO:376 to SEQ ID NO:377 and SEQ ID NO: 382 areshown in the alignment of FIG. 21B, respectively, in order ofappearance.

FIG. 22 shows a sequence alignment of sequences amplified from thejunction of the hph cassette of pDAS000342 with FAD3C at the doublestrand break as recognized by ZFN 28053-2A-28054. “Sample” is a uniqueidentifier for each plant that was assayed. The “:” indicates thedeletions located at the cut sites. The sequences shown in the FIG. 22are for the 3′ junction. SEQ ID NO:378 to SEQ ID NO:379 and SEQ ID NO:383 are shown in the alignment, respectively, in order of appearance.

FIG. 23, panels A and B, show a sequence alignment for sequencesamplified from the junction of the hph cassette of pDAS000340 with FAD3Cat the double strand break as recognized by ZFN 28051-2A-28052. The “:”indicates the deletions located at the cut sites. The sequences shown inFIG. 23A are for the 5′ junction and the sequences shown in the box (B)are for the 3′ junction. SEQ ID NO:328 to SEQ ID NO:334 are shown in thealignment of FIG. 23A, respectively, in order of appearance. SEQ IDNO:335 to SEQ ID NO:342 are shown in the alignment of FIG. 23B,respectively, in order of appearance.

FIG. 24, panels A and B, shows a sequence alignment of sequencesamplified from the junction of the hph cassette of pDAS000342 with FAD3Cat the double strand break as recognized by ZFN 28053-2A-28054. The “:”indicates the deletions located at the cut sites. The sequences shown inFIG. 24A are for the 5′ junction and the sequences shown in FIG. 24B)are for the 3′ junction. SEQ ID NO:343 to SEQ ID NO:346 are shown in thealignment of FIG. 24A, respectively, in order of appearance. SEQ IDNO:347 to SEQ ID NO:351 are shown in the alignment of FIG. 24B,respectively, in order of appearance.

SEQUENCE LISTING

The nucleic acid sequences are shown using standard letter abbreviationsfor nucleotide bases, as defined in 37 C.F.R. § 1.822. Only one strandof each nucleic acid sequence is shown, but the complementary strand isunderstood to be included by any reference to the displayed strand.

DETAILED DESCRIPTION I. Overview of Several Embodiments

Embodiments of the invention establish an approach for targetedintegration of exogenous nucleic acids (e.g., transgenes) in a hostgenome without greatly adversely impacting other phenotypes of the hostbeyond those affected by the integrated nucleic acid. Some embodimentsmay be used for “stacking” multiple nucleic acids in a single hostgenome. Such an approach uses the development and deployment of fourinter-connected technologies: targeting technologies allowing theintroduction of double stranded breaks in specific genomic DNA locations(see, e.g., Puchta et al. (1993) Nucleic Acids Res. 21:5034-40; Siebertand Puchta (2002) Plant Cell 14:1121-31; D'Halluin et al. (2008) PlantBiotechnol. J. 6(1):93-102; Cai et al. (2009) Plant Mol. Biol.69(6):699-709; Shukla et al. (2009) Nature 459(7245):437-41); Shan etal. (2103) Nature Biotechnol. 31:686-680; Le et al. (2013) NatureBiotechnol 31: 688-691; Nekrasov et al. (2013) Nature Biotechnol.31:691-693, Ainely et al. (2013) Plant Biotechnol. J. (On Line 19August); delivery technologies allowing the delivery of an optimizedexogenous (donor) nucleic acid (Bibikova et al. (2003) Science300(5620):764); integration technologies involving modification of thehost genes (located either in the homologous recombination or NHEJpathways) so as to increase the HDR or NHEJ frequencies for targeteddonor DNA integration; analytical tools to enrich and characterizetargeted integration events; and specific desired host genomic locations(“performance loci”) that are genetically well-defined and that supportstable gene expression across generations without greatly adverselyaffecting the transformed host organism. See, also, United States PatentPublications 20030232410; 20050208489; 20050026157; 20050064474;20060188987; 20090263900; 20090117617; 20100047805; 20110207221;20110301073; 2011089775; 20110239315; 20110145940; 20080182332;20090205083; 20100199389; 20110167521. For example, in plants, aperformance locus is a locus where the negative impact on the agronomicor quality properties of a transgenic plant wherein a transgene has beeninserted at the locus is negligible or non-existent.

Embodiments described herein take advantage of the unexpected findingthat plant FAD3 genes are performance loci for the targeted insertion ofexogenous nucleic acids (e.g., gene(s); non-coding DNA sequences, suchas an Engineered Landing Pads (ELPs) (U.S. application Ser. No.12/011,735) and Engineered Transgene Insertion Platform (ETIP) (U.S.Application No. 61/697,882); and plant transformation unit(s)). Theubiquitous nature of FAD3 loci in plants, and evidence that alterationor knock-out of FAD3 in canola, corn, sunflower, wheat, cotton, andsoybean does not carry an agronomic or quality penalty, identifies FAD3loci as a broad class of performance loci across commercially-relevantplant species.

Some embodiments utilize site-specific double-stranded DNA cleavage at aFAD3 locus, for example, resulting from the delivery and expression of atarget-site specific DNA recognition and cleavage protein. In specificexamples, such a FAD3-specific DNA recognition and cleavage protein maybe, for example and without limitation, a ZFN; a TALEN; RNA-guidedCRISPR-Cas9 system, a recombinase (e.g., Cre, Hin, RecA, Tre, and FLPrecombinases); a meganuclease, and an engineered protein derived fromany of the foregoing or their equivalents. Cleavage may also be effectedusing the CRISPR/Cas system with an engineered crRNA/tracr RNA (‘singleguide RNA’) to guide specific cleavage. In some embodiments, such adouble-strand break may be repaired via integration of a donor nucleicacid at the cleavage site within the FAD3 performance locus, forexample, by Homology Directed Repair (HDR) or Non-Homologous End Joining(NHEJ).

This disclosure exemplifies the utility of FAD3 loci as performanceloci, for example, by describing the FAD3A or 3C locus in canola(Brassica napus), and corresponding FAD3-specific ZFNs that may beutilized to integrate an exogenous nucleic acid at the FAD3Aor 3C locus.

Embodiments of the present invention address many unsolved problems inthe art. For example, the selectivity of the targeted integrationapproach described herein may reduce or eliminate the necessity ofrepeated field trials required for elimination of unwanted transgenicevents, which trials are costly due to the resources involved and theburdensome regulatory requirements in this area. Furthermore, thetargeted DNA insertion approaches described herein may be particularlybeneficial in the process of transgene stacking.

Although the native nucleotide sequence at an endogenous FAD3 locus maybe used to directly target a nucleic acid of interest, in someembodiments, a nucleic acid may first be targeted to at least one FAD3locus of the host, such that the integration of further nucleic acidmolecules of interest into the host is facilitated. In other examples,nucleotide sequences that are not homologous to native sequences of thehost organism (e.g., essentially randomly generated nucleic acidsequences) that flank a DNA recognition site (e.g., zinc fingerrecognition sites) may be utilized.

II. Terms

As used in this application, including the claims, terms in the singularand the singular forms, “a,” “an,” and “the,” for example, includeplural referents, unless the content clearly dictates otherwise. Thus,for example, a reference to “plant,” “the plant,” or “a plant” alsorefers to a plurality of plants. Furthermore, depending on the context,use of the term, “plant,” may also refer to genetically-similar oridentical progeny of that plant. Similarly, the term, “nucleic acid,”may refer to many copies of a nucleic acid molecule. Likewise, the term,“probe,” may refer to many similar or identical probe molecules.

Numeric ranges are inclusive of the numbers defining the range, andexpressly include each integer and non-integer fraction within thedefined range. Unless defined otherwise, all technical and scientificterms used herein have the same meaning as commonly understood by one ofordinary skill in the art.

In order to facilitate review of the various embodiments described inthis disclosure, the following explanation of specific terms isprovided:

Isolated: An “isolated” biological component (such as a nucleic acid orprotein) has been substantially separated, produced apart from, orpurified away from other biological components in the cell of theorganism in which the component naturally occurs (i.e., otherchromosomal and extra-chromosomal DNA and RNA, and proteins), whileeffecting a chemical or functional change in the component (e.g., anucleic acid may be isolated from a chromosome by breaking chemicalbonds connecting the nucleic acid to the remaining DNA in thechromosome). Nucleic acid molecules and proteins that have been“isolated” include nucleic acid molecules and proteins purified bystandard purification methods. The term also embraces nucleic acids andproteins prepared by recombinant expression in a host cell, as well aschemically-synthesized nucleic acid molecules, proteins, and peptides.

Cross: As used herein in regard to plants, the term “cross” or “crossed”refers to the fusion of gametes via pollination to produce progeny(e.g., cells, seeds, and plants). This term encompasses both sexualcrosses (i.e., the pollination of one plant by another) and selfing(i.e., self-pollination, for example, using pollen and ovule from thesame plant).

Backcrossing: Backcrossing methods may be used to introduce a nucleicacid sequence into a plant. This technique has been widely used fordecades to introduce new traits into plants. Jensen, N., Ed. PlantBreeding Methodology, John Wiley & Sons, Inc., 1988. In a typicalbackcross protocol, the original variety of interest (recurrent parent)is crossed to a second variety (non-recurrent parent) that carries anucleic acid sequence of interest to be transferred. The resultingprogeny from this cross are then crossed again to the recurrent parent,and the process is repeated until a plant is obtained whereinessentially all of the desired morphological and physiologicalcharacteristics of the recurrent plant are recovered in the convertedplant, in addition to the transferred nucleic acid sequence from thenon-recurrent parent.

Introgression: As used herein, the term “introgression” refers to thetransmission of an allele (or modified allele comprising an exogenousnucleic acid) into a genetic background at a particular locus. In someembodiments, introgression of a specific allele at the locus may occurby transmitting the allele to at least one progeny via a sexual crossbetween two parents of the same species, where at least one of theparents has the specific allele form in its genome. Progeny comprisingthe specific allele may be repeatedly backcrossed to a line having adesired genetic background. Backcross progeny may be selected for thespecific allele form, so as to produce a new variety wherein thespecific allele form has been fixed in the genetic background. In someembodiments, introgression of a specific allele may occur byrecombination between two donor genomes (e.g., in a fused protoplast),where at least one of the donor genomes has the specific allele form inits genome. Introgression may involve transmission of a specific alleleform that may be, for example and without limitation, a disrupted ormodified allele; a transgene; a PTU; and an ELP.

Germplasm: As used herein, the term “germplasm” refers to geneticmaterial of or from an individual plant, a group of plants (e.g., aplant line, variety, and family), and a clone derived from a plant orgroup of plants. A germplasm may be part of an organism or cell, or itmay be separate (e.g., isolated) from the organism or cell. In general,germplasm provides genetic material with a specific molecular makeupthat is the basis for hereditary qualities of the plant. As used herein,“germplasm” refers to cells of a specific plant; seed; tissue of thespecific plant (e.g., tissue from which new plants may be grown); andnon-seed parts of the specific plant (e.g., leaf, stem, pollen, andcells). As used herein, the term “germplasm” is synonymous with “geneticmaterial,” and it may be used to refer to seed (or other plant material)from which a plant may be propagated. A “germplasm bank” may refer to anorganized collection of different seed or other genetic material(wherein each genotype is uniquely identified) from which a knowncultivar may be cultivated, and from which a new cultivar may begenerated.

Gene: As used herein, the term “gene” (or “genetic element”) may referto a heritable genomic DNA sequence with functional significance. A genemay be a native nucleic acid, or a nucleic acid that has been integratedinto the genome. The term “gene” may also be used to refer to, forexample and without limitation, a cDNA and/or an mRNA encoded by aheritable genomic DNA sequence.

Nucleic acid molecule: As used herein, the term “nucleic acid molecule”may refer to a polymeric form of nucleotides (i.e., ribonucleotides,deoxyribonucleotides, and/or a modified form of either of theforegoing). A “nucleic acid molecule” as used herein is synonymous with“nucleic acid” and “polynucleotide.” The term includes both sense andanti-sense strands of RNA, cDNA, genomic DNA, and synthetic forms andmixed polymers thereof. The term includes any topological conformation,including single-stranded, double-stranded, partially duplexed,triplexed, hairpinned, circular, and padlocked conformations. A nucleicacid molecule can include either or both of naturally-occurring andmodified nucleotides. Such nucleotides may be linked together bynaturally-occurring and/or non-naturally-occurring nucleotide linkages.

Nucleic acid molecules may be modified chemically or biochemically, ormay contain derivatized nucleotide bases, as will be readily appreciatedby those of skill in the art. Such modifications include, for exampleand without limitation: labels; methylation; substitution of one or moreof the naturally-occurring nucleotides with an analog; andinter-nucleotide modifications (e.g., uncharged linkages, for example,methyl phosphonates, phosphotriesters, phosphoramidates, and carbamates;charged linkages, for example, phosphorothioates andphosphorodithioates; pendent moieties, for example, peptides;intercalators, for example, acridine and psoralen; chelators;alkylators; and modified linkages, for example, alpha anomeric nucleicacids).

Exogenous: An “exogenous” molecule is a molecule that is not native to aspecified system (e.g., a germplasm, variety, elite variety, and/orplant) with respect to nucleotide sequence and/or genomic location(i.e., locus) for a polynucleotide (and with respect to amino acidsequence and/or cellular localization for a polypeptide). Inembodiments, exogenous or heterologous polynucleotides or polypeptidesmay be molecules that have been artificially supplied to a biologicalsystem (e.g., a plant cell, a plant gene, a particular plant species orvariety, and/or a plant chromosome) and are not native to thatparticular biological system. Thus, the designation of a nucleic acid as“exogenous” may indicate that the nucleic acid originated from a sourceother than a naturally-occurring source, or it may indicate that thenucleic acid has a non-natural configuration, genetic location, orarrangement of elements.

In contrast, for example, a “native” or “endogenous” nucleic acid is anucleic acid (e.g., a gene) that does not contain a nucleic acid elementother than those normally present in the chromosome or other geneticmaterial on which the nucleic acid is normally found in nature. Anendogenous gene transcript is encoded by a nucleotide sequence at itsnatural chromosomal locus, and is not artificially supplied to the cell.

Operably linked: A first nucleic acid sequence is operably linked with asecond nucleic acid sequence when the first nucleic acid sequence is ina functional relationship with the second nucleic acid sequence. Forinstance, a promoter is operably linked with a coding sequence when thepromoter affects the transcription or expression of the coding sequence.When recombinantly produced, operably linked nucleic acid sequences aregenerally contiguous and, where necessary to join two protein-codingregions, in the same reading frame. However, elements need not becontiguous to be operably linked.

Promoter: A promoter is a region of DNA that generally is locatedupstream (towards the 5′ region) of a nucleic acid that enhancestranscription of the nucleic acid. Promoters permit the properactivation or repression of the nucleic acid(s) with which they areoperably linked. A promoter contains specific sequences that arerecognized by transcription factors. These factors bind to the promoterDNA sequences and result in the recruitment of RNA polymerase, theenzyme that synthesizes the RNA from the coding region of the nucleicacid. Transformed: A vector “transforms” or “transduces” a cell when ittransfers nucleic acid molecules into the cell. A cell is “transformed”by a nucleic acid molecule when the nucleic acid molecule becomes stablyreplicated by the cell, either by incorporation of the nucleic acidmolecule into the cellular genome or by episomal replication. As usedherein, the term “transformation” encompasses all techniques by which anucleic acid molecule can be introduced into a cell. Examples include,but are not limited to: transfection with viral vectors; transformationwith plasmid vectors; electroporation (Fromm et al. (1986) Nature319:791-3); lipofection (Feigner et al. (1987) Proc. Natl. Acad. Sci.USA 84:7413-7); microinjection (Mueller et al. (1978) Cell 15:579-85);Agrobacterium-mediated transfer (Fraley et al. (1983) Proc. Natl. Acad.Sci. USA 80:4803-7); direct DNA uptake; and microprojectile bombardment(Klein et al. (1987) Nature 327:70).

Introduced: As used herein, the term “introduced,” when referring totranslocation of an exogenous nucleic acid into a cell, refers to theincorporation of the nucleic acid into the cell using any methodologyavailable in the art. This term encompasses nucleic acid introductionmethods including, for example and without limitation, transfection;transformation; and transduction.

Transgene: As used herein, the term “transgene” refers to an exogenousnucleic acid coding sequence of interest. For example, a transgene mayencode an industrially or pharmaceutically useful compound, or anexpression product that contributes to a desirable agricultural trait(e.g., herbicide resistance or pest resistance). In a further example, atransgene may be an antisense nucleic acid, wherein expression of theantisense nucleic acid inhibits expression of a target nucleic acidsequence. A transgene may comprise regulatory sequences operably linkedto the transgene (e.g., a promoter). In some embodiments, a nucleic acidmolecule of interest to be introduced by site-specific targeting at aFAD3 locus is a transgene. However, in other embodiments, a nucleic acidmolecule of interest may be a PTU, an ELP, an ETIP, or an endogenousnucleic acid sequence (e.g., wherein additional, exogenous genomiccopies of the endogenous nucleic acid sequence are desired).

Elements can also include DNA that encodes for a structural RNA, such asshRNA. Such RNA can modify exogenous or endogenous genes including, butnot limited to affecting postings or conferring herbicide resistance.

Recombinant: As used herein, the term “recombinant” refers to a material(e.g., nucleic acid, gene, polynucleotide, and/or polypeptide) that hasbeen altered by human intervention. For example, the arrangement of theparts or elements of a recombinant molecule may not be a nativearrangement, and/or the primary sequence of the recombinant molecule mayhave been changed from its native sequence, e.g., to optimize itsexpression and/or activity. A material may be altered to produce arecombinant material within or removed from its natural environment orstate. As one example, an open reading frame of a nucleic acid isrecombinant if the nucleotide sequence of the open reading frame hasbeen removed from it natural context and cloned into an artificialnucleic acid molecule (e.g., a vector). Protocols and reagents toproduce recombinant molecules (e.g., recombinant nucleic acids) arecommon in the art, and their use is routine. The term “recombinant” mayalso refer herein to a cell or organism that comprises recombinantmaterial (e.g., a plant and/or plant cell that comprises a recombinantnucleic acid). In some examples, a recombinant organism is a transgenicorganism.

Vector: As used herein, the term “vector” refers to a polynucleotide orother molecule that is capable of transferring at least one nucleic acidsegment(s) into a cell. A vector may optionally comprisecomponents/elements that mediate vector maintenance and/or enable itsintended use (e.g., sequences necessary for replication, genes impartingdrug or antibiotic resistance, a multiple cloning site, and/or operablylinked promoter/enhancer elements that enable the expression of a clonedgene). Vectors may be derived, for example, from plasmids,bacteriophages, or plant or animal viruses. A “cloning vector,” “shuttlevector,” or “subcloning vector” generally comprises operably linkedelements to facilitate cloning or subcloning steps (e.g., a multiplecloning site containing multiple restriction endonuclease sites).

Expression Vector: The term “expression vector,” as used herein, refersto a vector comprising operably linked polynucleotide sequences that mayfacilitate expression of a coding sequence in a particular hostorganism. For example, a bacterial expression vector may facilitateexpression of a coding sequence in a bacterium. Likewise, a plantexpression vector may facilitate expression of a coding sequence in aplant cell. Polynucleotide sequences that facilitate expression inprokaryotes may include, for example and without limitation, a promoter;an operator; and a ribosome binding site. Eukaryotic expression vectors(e.g., a plant expression vector) may comprise, for example, promoters;enhancers; termination signals; and polyadenylation signals (and othersequences) that are generally different from those used in prokaryoticexpression vectors.

Sequence identity: The term “sequence identity” or “identity,” as usedherein in the context of two nucleic acid or polypeptide sequences,refers to the residues in the two sequences that are the same whenaligned for maximum correspondence over a specified comparison window. Avalue of sequence identity may be determined by comparing two optimallyaligned sequences (e.g., nucleic acid sequences and amino acidsequences) over a comparison window, wherein the portion of the sequencein the comparison window may comprise additions or deletions (i.e.,gaps) as compared to the reference sequence (which does not compriseadditions or deletions) for optimal alignment of the two sequences. Thesequence identity is calculated as a percentage by determining thenumber of positions at which the identical nucleotide or amino acidresidue occurs in both sequences to yield the number of matchedpositions, dividing the number of matched positions by the total numberof positions in the comparison window, and multiplying the result by 100to yield the percentage of sequence identity.

Methods for aligning sequences for comparison are well-known in the art.Various programs and alignment algorithms are described in, for example:Smith and Waterman (1981) Adv. Appl. Math. 2:482; Needleman and Wunsch(1970) J. Mol. Biol. 48:443; Pearson and Lipman (1988) Proc. Natl. Acad.Sci. U.S.A. 85:2444; Higgins and Sharp (1988) Gene 73:237-44; Higginsand Sharp (1989) CABIOS 5:151-3; Corpet et al. (1988) Nucleic Acids Res.16:10881-90; Huang et al. (1992) Comp. Appl. Biosci. 8:155-65; Pearsonet al. (1994) Methods Mol. Biol. 24:307-31; Tatiana et al. (1999) FEMSMicrobiol. Lett. 174:247-50. A detailed consideration of sequencealignment methods and homology calculations can be found in Altschul etal. (1990) J. Mol. Biol. 215:403-10.

The National Center for Biotechnology Information (NCBI) Basic LocalAlignment Search Tool (BLAST™; Altschul et al. (1990)) may be used toalign sequences, and it is available from several sources, including theNational Center for Biotechnology Information (Bethesda, Md.), and onthe internet, for use in connection with several sequence analysisprograms. A description of how to determine sequence identity using thisprogram is available on the internet under the “help” section forBLAST™. For comparisons of nucleic acid sequences, the “Blast 2sequences” function of the BLAST™ (Blastn) program may be employed usingthe default parameters. Nucleic acid sequences with greater similarityto the reference sequences will show increasing percentage identity whenassessed by this method.

As used herein, the term “substantially identical” may refer tonucleotide sequences that are more than 80% identical. For example, asubstantially identical nucleotide sequence may be at least 85%, atleast 86%; at least 87%; at least 88%; at least 89%; at least 90%; atleast 91%; at least 92%; at least 93%; at least 94%; at least 95%; atleast 96%; at least 97%; at least 98%; at least 99%; or at least 99.5%identical to the reference sequence.

Locus: As used herein, the term “locus” refers to a position on a genomethat corresponds to a measurable characteristic (e.g., a trait). In someembodiments, a locus of particular interest is the genomic position of aFAD3 gene, where disruption of the gene reduces or eliminates expressionof the mRNA transcribed from the wild-type gene. A locus may be definedby a probe that hybridizes to a unique nucleotide sequence containedwithin the locus either during Southern hybridization or PCR.

Marker: As used herein, a “marker” refers to a gene or nucleotidesequence that can be used to identify plants that are likely to have aparticular allele and/or exhibit a particular trait or phenotype. Amarker may be described as a variation at a given genomic locus. Agenetic marker may be a short DNA sequence, such as a sequencesurrounding a single base-pair change (single nucleotide polymorphism,or “SNP”), or a long sequence, for example, a minisatellite/simplesequence repeat (“SSR”). A “marker allele” refers to the version of themarker that is present in a particular plant. The term marker as usedherein may refer to a cloned segment of plant chromosomal DNA (e.g., asegment comprising a FAD3 locus, or a modified and/or disrupted FAD3locus), and may also or alternatively refer to a DNA molecule that iscomplementary to a cloned segment of plant chromosomal DNA. As isrecognized by those of ordinary skill in the art, the process ofobtaining additional, contiguous nucleotide sequence for inclusion in amarker may be repeated nearly indefinitely (limited only by the lengthof the chromosome), thereby identifying additional markers along thechromosome. Any and all of the above-described varieties of markers maybe used in some embodiments of the present invention.

In some embodiments, the presence of a transgene or marker (which arecharacterized by a “target” sequence) in a germplasm may be detectedthrough the use of a nucleic acid probe; e.g., an oligonucleotide. Aprobe may be a DNA molecule or an RNA molecule. An oligonucleotide probemay be prepared synthetically or by cloning. Suitable cloning vectorsare well-known to those of skill in the art. RNA probes can besynthesized by means known in the art, for example, using a DNA moleculetemplate.

An oligonucleotide probe may be labeled or unlabeled. A wide variety oftechniques exist for labeling nucleic acid molecules, including, forexample and without limitation, radiolabeling by nick translation;random priming; and tailing with terminal deoxytransferase, where thenucleotides employed are labeled, for example, with radioactive ³²P.Other labels which may be used include, for example and withoutlimitation, fluorophores; enzymes; enzyme substrates; enzyme cofactors;and enzyme inhibitors. Alternatively, the use of a label that provides adetectable signal, by itself or in conjunction with other reactiveagents, may be replaced by ligands to which receptors bind, where thereceptors are labeled (for example, by the above-indicated labels) toprovide detectable signals, either by themselves, or in conjunction withother reagents. See, e.g., Leary et al. (1983) Proc. Natl. Acad. Sci.USA 80:4045-9.

A probe may be an exact copy of a transgene or marker to be detected. Aprobe may also be a nucleic acid molecule comprising, or consisting of,a nucleotide sequence that is substantially identical to a clonedsegment of chromosomal DNA comprising the transgene or marker to bedetected. A probe may further comprise additional nucleic acidsequences, for example, promoters; transcription signals; and/or vectorsequences.

A probe may contain all or a portion of the target nucleotide sequenceand additional, contiguous nucleotide sequence from the genome. This isreferred to herein as a “contiguous probe.” The additional, contiguousnucleotide sequence is referred to as “upstream” or “downstream” of theoriginal target, depending on whether the contiguous nucleotide sequencefrom the chromosome is on the 5′ or the 3′ side of the original marker,as conventionally understood. A probe may also contain a nucleotidesequence that is not contiguous to that of the original target; thisprobe is referred to herein as a “non-contiguous probe.” The sequence ofthe non-contiguous probe may be located sufficiently close to thesequence of the original target on the chromosome so that thenon-contiguous probe is linked to the original marker or transgene.

In some embodiments, a probe is a nucleic acid molecule that is“specifically hybridizable” or “specifically complementary” to an exactcopy of the target to be detected. “Specifically hybridizable” and“specifically complementary” are terms that indicate a sufficient degreeof complementarity, such that stable and specific binding occurs betweenthe nucleic acid molecule and the target. A nucleic acid molecule neednot be 100% complementary to its target sequence to be specificallyhybridizable. A nucleic acid molecule is specifically hybridizable whenthere is a sufficient degree of complementarity to avoid non-specificbinding of the nucleic acid to non-target sequences under conditionswhere specific binding is desired, for example, under stringenthybridization conditions.

Hybridization conditions resulting in particular degrees of stringencywill vary depending upon the nature of the hybridization method ofchoice and the composition and length of the hybridizing nucleic acidsequences. Generally, the temperature of hybridization and the ionicstrength (especially the Na⁺ and/or Mg⁺⁺ concentration) of thehybridization buffer will determine the stringency of hybridization,though wash times also influence stringency. Calculations regardinghybridization conditions required for attaining particular degrees ofstringency are known to those of ordinary skill in the art, and arediscussed, for example, in Sambrook et al. (ed.) Molecular Cloning: ALaboratory Manual, 2^(nd) ed., vol. 1-3, Cold Spring Harbor LaboratoryPress, Cold Spring Harbor, N.Y., 1989, chapters 9 and 11; and Hames andHiggins (eds.) Nucleic Acid Hybridization, IRL Press, Oxford, 1985.Further detailed instruction and guidance with regard to thehybridization of nucleic acids may be found, for example, in Tijssen,“Overview of principles of hybridization and the strategy of nucleicacid probe assays,” in Laboratory Techniques in Biochemistry andMolecular Biology-Hybridization with Nucleic Acid Probes, Part I,Chapter 2, Elsevier, N.Y., 1993; and Ausubel et al., Eds., CurrentProtocols in Molecular Biology, Chapter 2, Greene Publishing andWiley-Interscience, NY, 1995.

As used herein, “stringent conditions” encompass conditions under whichhybridization will only occur if there is less than 25% mismatch betweenthe hybridization molecule and the DNA target. “Stringent conditions”include further particular levels of stringency. Thus, as used herein,“moderate stringency” conditions are those under which molecules withmore than 25% sequence mismatch will not hybridize; conditions of“medium stringency” are those under which molecules with more than 15%mismatch will not hybridize; and conditions of “high stringency” arethose under which sequences with more than 10% mismatch will nothybridize. Conditions of “very high stringency” are those under whichsequences with more than 6% mismatch will not hybridize.

In particular embodiments, stringent conditions are hybridization at 65°C. in 6× saline-sodium citrate (SSC) buffer, 5×Denhardt's solution, 0.5%SDS, and 100 μg sheared salmon testes DNA, followed by 15-30 minutesequential washes at 65° C. in 2×SSC buffer and 0.5% SDS, followed by1×SSC buffer and 0.5% SDS, and finally 0.2×SSC buffer and 0.5% SDS.

Linkage (dis)equilibrium: As used herein, the term “linkage equilibrium”refers to the situation where a marker and a second nucleic acid (e.g.,transgene, PTU, and second marker) independently segregate; i.e., themarker and the second nucleic acid sort randomly among progeny. Nucleicacids that show linkage equilibrium are considered unlinked (whether ornot they lie on the same chromosome). As used herein, the term “linkagedisequilibrium” refers to the situation where a marker and a secondnucleic acid segregate in a non-random manner; i.e., the nucleic acidshave a recombination frequency of less than 50% (and thus by definition,are separated by less than 50 cM on the same linkage group). In someexamples, nucleic acids that show linkage disequilibrium are consideredlinked.

Linked, tightly linked, and extremely tightly linked: As used herein,linkage between a marker and a second nucleic acid (e.g., transgene,PTU, and second marker) may refer to the phenomenon in which nucleicacids on a chromosome show a measurable probability of being passed ontogether to individuals in the next generation. Thus, linkage of onemarker to a second nucleic acid may be measured and/or expressed as arecombination frequency. The closer two nucleic acids are to each other,the closer to “1” this probability becomes. Thus, the term “linked” mayrefer to one or more genes or markers that are passed together with asecond nucleic acid with a probability greater than 0.5 (which isexpected from independent assortment where markers/genes are located ondifferent chromosomes). When the presence of a gene (e.g., a transgene)contributes to a phenotype in an individual, markers that are linked tothe gene may be said to be linked to the phenotype. Thus, the term“linked” may refer to a relationship between a marker and a gene, orbetween a marker and a phenotype.

A relative genetic distance (determined by crossing over frequencies andmeasured in centimorgans (cM)) is generally proportional to the physicaldistance (measured in base pairs) that two linked markers or genes areseparated from each other on a chromosome. One centimorgan is defined asthe distance between two genetic markers that show a 1% recombinationfrequency (i.e., a crossing-over event occurs between the two markersonce in every 100 cell divisions). In general, the closer one marker isto another marker or gene (whether the distance between them is measuredin terms of genetic distance or physical distance,) the more tightlythey are linked. Because chromosomal distance is approximatelyproportional to the frequency of recombination events between traits,there is an approximate physical distance that correlates withrecombination frequency. This correlation is generally known or readilydeterminable across the major crop plants (Helentjaris and Burr (eds.)(1989) Development and Application of Molecular Markers to Problems inPlant Genetics. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.;Gresshoff (ed.) (1994) Plant Genome Analysis. CRC Press, Boca Raton,Fla.; Lander et al. (1987) Genomics 1:174-81; Tanksley et al. (1988)“Molecular mapping of plant chromosomes,” In Chromosome Structure andFunction. Gustafson and Appels (eds.) Plenum Press, NY, pp. 157-73) andmany other organisms. For example, 1 cM corresponds to about 2.5-3.0 kbin yeast, about 140 kb in Arabidopsis, about 400 kb in sunflower, andabout 350 kb in Eucalyptus.

The term “linked” may refer herein to one or more nucleic acids thatshow a recombination frequency of less than 50% (i.e., less than 50 cM).For example, “linked” nucleic acids may recombine with a frequency ofabout 45% or less, about 40% or less, about 35% or less, about 30% orless, about 25% or less, about 20% or less, about 15% or less, and about10% or less. The physical distances between such nucleic acids on thesame chromosome (nucleic acids on different chromosomes are expected tobe in linkage equilibrium) that correspond to the foregoingrecombination frequencies depend on the host genome, and may be easilycalculated as set forth, supra.

As used herein, the term “tightly-linked” may refer to one or morenucleic acids that show a recombination frequency of about 20% or less(i.e., about 20 cM or less). For example, “tightly linked” nucleic acidsmay recombine with a frequency of 22% or less, about 18% or less, about16% or less, about 14% or less, about 12% or less, about 10% or less,about 8% or less, about 6% or less, about 4% or less, and about 2% orless.

As used herein, the term “extremely tightly-linked” may refer to one ormore nucleic acids that show a recombination frequency of about 10% orless (i.e., about 10 cM or less). For example, “extremely tightlylinked” nucleic acids may recombine with a frequency of 11% or less,about 9% or less, about 8% or less, about 7% or less, about 6% or less,about 5% or less, about 4% or less, about 3% or less, about 2% or less,and about 1% or less.

The closer a particular nucleic acid is to a gene that encodes apolypeptide that contributes to a particular phenotype (whether measuredin terms of genetic or physical distance), the more tightly-linked isthe particular nucleic acid to the phenotype. In view of the foregoing,it will be appreciated that nucleic acids linked to a particular gene orphenotype include those nucleic acids that are tightly linked, and thosenucleic acids that are extremely tightly linked, to the gene orphenotype. In some embodiments, the closer a particular nucleic acid isto a FAD3 locus (e.g., a modified or disrupted FAD3 locus), whethermeasured in terms of genetic or physical distance, the moretightly-linked is the particular nucleic acid to any trait/phenotypeconferred by an exogenous nucleic acid integrated at the FAD3 locus (orto a wild-type FAD3 phenotype in the case of an unmodified locus). Thus,genetic markers that are linked, tightly linked, and/or extremelytightly linked to a FAD3 locus comprising an integrated exogenousnucleic acid may be useful in an MAS program to identify organisms(e.g., plants and plant varieties) comprising the integrated nucleicacid, to identify organisms comprising a phenotype conferred by theintegrated nucleic acid, and to breed such an integrated nucleic acidand/or a phenotype conferred by the integrated nucleic acid into othercompatible organisms.

Marker-assisted breeding: As used herein, the term “marker-assistedbreeding” may refer to an approach to breeding plants directly for oneor more trait(s) (e.g., a polygenic trait). In current practice, plantbreeders attempt to identify easily detectable traits, such as flowercolor, seed coat appearance, or isozyme variants that are linked to anagronomically desired trait. The plant breeders then follow theagronomic trait in the segregating, breeding populations by followingthe segregation of the easily detectable trait. However, there are veryfew of these linkage relationships between traits of interest and easilydetectable traits available for use in plant breeding. In someembodiments of the invention, marker-assisted breeding comprisesidentifying one or more genetic markers (e.g., SNP, isozyme, and/or SSRmarkers) that are linked to a FAD3 locus wherein an exogenous nucleicacid contributing to a trait of interest has been integrated, andfollowing the trait of interest in a segregating, breeding population byfollowing the segregation of the one or more genetic markers. In someexamples, the segregation of the one or more genetic markers may bedetermined utilizing a probe for the one or more genetic markers byassaying a genetic sample from a progeny plant for the presence of theone or more genetic markers. Marker-assisted breeding provides a time-and cost-efficient process for improvement of plant varieties.

Trait or phenotype: The terms “trait” and “phenotype” are usedinterchangeably herein. For the purposes of the present disclosure,traits of particular interest include agronomically important traits, asmay be expressed, for example, in a crop plant, and the production oftransgene expression products from a targeted integration event. Theterm “molecular phenotype” may refer to a phenotype that is detectableat the level of a population of (one or more) molecules. In someexamples, the molecular phenotype may only be detectable at themolecular level. The detectable molecules of the phenotype may benucleic acids (e.g., genomic DNA or RNA); proteins; and/or metabolites.For example, a molecular phenotype may be an expression profile for oneor more gene products (e.g., at a specific stage of plant development,or in response to an environmental condition or stress).

Quantitative Trait Locus: Traits that are continuously varying due togenetic (additive, dominant, and epistatic) and environmental influencesare commonly referred to as “quantitative traits.” Quantitative traitsmay be distinguished from “qualitative,” or “discrete,” traits on thebasis of two factors; environmental influences on gene expression thatproduce a continuous distribution of phenotypes, and the complexsegregation pattern produced by multigenic inheritance. Theidentification of one or more regions of the genome linked to theexpression of a quantitative trait defines such regions as QuantitativeTrait Loci (“QTL”).

Plant: As used herein, the term “plant” may refer to a whole plant, acell or tissue culture derived from a plant, and/or any part of any ofthe foregoing. Thus, the term “plant” encompasses, for example andwithout limitation, whole plants; plant components and/or organs (e.g.,leaves, stems, and roots); plant tissue; seed; and a plant cell. A plantcell may be, for example and without limitation, a cell in and/or of aplant, a cell isolated from a plant, and a cell obtained throughculturing of a cell isolated from a plant.

A “transgenic plant” is a plant comprising within at least one of itscells an exogenous polynucleotide. The term “transgenic” is used hereinto refer to any cell, cell line, callus, tissue, plant part, or plant,the genotype of which has been altered by the presence of a exogenousnucleic acid. Thus, this term encompasses transgenic organisms and cellsthat have been initially altered to comprise the exogenouspolynucleotide, and those organisms and cells created by crosses orasexual propagation of the initial transgenic organism or cell. The term“transgenic,” as used herein, does not encompass genome (chromosomal orextra-chromosomal) alternations introduced by conventional plantbreeding methods (e.g., crosses of only non-transgenic organisms) or bynaturally-occurring events (e.g., random cross-fertilization,non-recombinant viral infection, non-recombinant bacterialtransformation, non-recombinant transposition, and spontaneousmutation).

A plant “line,” “variety,” or “strain” is a group of individual plantshaving the same parentage. Plants of a line generally are inbred to somedegree, and are generally homozygous and homogeneous at most geneticloci (e.g., a FAD3 locus). A “subline” may refer to an inbred subset ofdescendents from a common progenitor that are genetically distinct fromother similarly inbred subsets descended from the same progenitor. Insome embodiments, a “subline” may be produced by inbreeding seed from anindividual transgenic plant selected at the F₃ to F₅ generation untilthe residual segregating loci are homozygous across most or all loci.

A “binding protein” is a protein that is able to bind to anothermolecule. A binding protein can bind to, for example, a DNA molecule (aDNA-binding protein), an RNA molecule (an RNA-binding protein) and/or aprotein molecule (a protein-binding protein). In the case of aprotein-binding protein, it can bind to itself (to form homodimers,homotrimers, etc.) and/or it can bind to one or more molecules of adifferent protein or proteins. A binding protein can have more than onetype of binding activity. For example, zinc finger proteins haveDNA-binding, RNA-binding and protein-binding activity.

A “zinc finger DNA binding protein” (or binding domain) is a protein, ora domain within a larger protein, that binds DNA in a sequence-specificmanner through one or more zinc fingers, which are regions of amino acidsequence within the binding domain whose structure is stabilized throughcoordination of a zinc ion. The term zinc finger DNA binding protein isoften abbreviated as zinc finger protein or ZFP.

A “TALE DNA binding domain” or “TALE” is a polypeptide comprising one ormore TALE repeat domains/units. The repeat domains are involved inbinding of the TALE to its cognate target DNA sequence. A single “repeatunit” (also referred to as a “repeat”) is typically 33-35 amino acids inlength and exhibits at least some sequence homology with other TALErepeat sequences within a naturally occurring TALE protein.

Zinc finger and TALE binding domains can be “engineered” to bind to apredetermined nucleotide sequence, for example via engineering (alteringone or more amino acids) of the recognition helix region of a naturallyoccurring zinc finger or TALE protein. Therefore, engineered DNA bindingproteins (zinc fingers or TALEs) are proteins that are non-naturallyoccurring. Non-limiting examples of methods for engineering DNA-bindingproteins are design and selection. A designed DNA binding protein is aprotein not occurring in nature whose design/composition resultsprincipally from rational criteria. Rational criteria for design includeapplication of substitution rules and computerized algorithms forprocessing information in a database storing information of existing ZFPand/or TALE designs and binding data. See, for example, U.S. Pat. Nos.6,140,081; 6,453,242; and 6,534,261; see also WO 98/53058; WO 98/53059;WO 98/53060; WO 02/016536 and WO 03/016496 and U.S. Publication No.20110301073.

A “selected” zinc finger protein or TALE is a protein not found innature whose production results primarily from an empirical process suchas phage display, interaction trap or hybrid selection. See e.g., U.S.Pat. No. 5,789,538; U.S. Pat. No. 5,925,523; U.S. Pat. No. 6,007,988;U.S. Pat. No. 6,013,453; U.S. Pat. No. 6,200,759; WO 95/19431; WO96/06166; WO 98/53057; WO 98/54311; WO 00/27878; WO 01/60970 WO01/88197, WO 02/099084 and U.S. Publication No. 20110301073.

“Cleavage” refers to the breakage of the covalent backbone of a DNAmolecule. Cleavage can be initiated by a variety of methods including,but not limited to, enzymatic or chemical hydrolysis of a phosphodiesterbond. Both single-stranded cleavage and double-stranded cleavage arepossible, and double-stranded cleavage can occur as a result of twodistinct single-stranded cleavage events. DNA cleavage can result in theproduction of either blunt ends or staggered ends. In certainembodiments, fusion polypeptides are used for targeted double-strandedDNA cleavage.

A “cleavage half-domain” is a polypeptide sequence which, in conjunctionwith a second polypeptide (either identical or different) forms acomplex having cleavage activity (preferably double-strand cleavageactivity). The terms “first and second cleavage half-domains;” “+ and −cleavage half-domains” and “right and left cleavage half-domains” areused interchangeably to refer to pairs of cleavage half-domains thatdimerize.

An “engineered cleavage half-domain” is a cleavage half-domain that hasbeen modified so as to form obligate heterodimers with another cleavagehalf-domain (e.g., another engineered cleavage half-domain). See, also,U.S. Patent Publication Nos. 2005/0064474, 20070218528, 2008/0131962 and2011/0201055, incorporated herein by reference in their entireties.

Means for generating a double strand DNA break: As used herein, the term“means for generating a double strand DNA break” is intended to invokethe special claiming provisions authorized by Congress in 35 U.S.C. §112, sixth paragraph. Specifically, a “means for generating a doublestrand DNA break” refers to a molecular structure that is capable ofcleaving both strands of a double-stranded DNA molecule. Such structuresinclude polypeptide domains comprised within many known nucleaseproteins, for example, the FokI nuclease domain, the catalytic domain isselected from the group consisting of proteins Mmel, Colicin-E7(CEA7_ECOLX), Colicin-E9, APFL, EndA, Endo I (END1_EC0LI), Human Endo G(NUCG_HUMAN), Bovine Endo G (NUCG_BOVIN), R.HinPll, 1-Basl, 1-Bmol,1-Hmul, 1-Tevl, 1-Tevll, 1-Tevlll, 1-Twol, R.Mspl, R.Mval, NucA, NucM,Vvn, Vvn CLS, Staphylococcal nuclease (NUC_STAAU), Staphylococcalnuclease (NUC_STAHY), Micrococcal nuclease (NUC_SHIFL), EndonucleaseyncB, Endodeoxyribonuclease I (ENRN_BPT7), Metnase, Nb.BsrDI, BsrDI A,Nt.BspD61 (R.BspD61 large subunit), ss.BspD61 (R.BspD61 small subunit),R.PIel, Mlyl, Alwl, Mval2691, Bsrl, Bsml, Nb.BtsCI, Nt.BtsCI, R1.Btsl,R2.Btsl, BbvCI subunit 1, BbvCI subunit 2, BpulOI alpha subunit, BpulOIbeta subunit, Bmrl, Bfil, 1-Crel, hExol (EX01JHUMAN), Yeast Exol(EX01_YEAST), E. coli Exol, Human TREX2, Mouse TREX1, Human TREX1,Bovine TREX1, Rat TREX1, Human DNA2, Yeast DNA2 (DNA2_YEAST).

Means for repairing a double strand DNA break: As used herein, the term“means for repairing a double strand DNA break” is also intended toinvoke the special claiming provisions authorized by Congress in 35U.S.C. § 112, sixth paragraph. Specifically, a “means for repairing adouble strand DNA break” refers to a molecular structure that is capableof facilitating/catalyzing the joining of the ends of double-strandedDNA molecules, for example, by joining ends generated by cleaving asingle double-stranded DNA molecule, or by joining one end generated bycleaving a single double-stranded DNA molecule with the end of anexogenous double-stranded DNA molecule. Such structures includepolypeptide domains comprised within many known ligase proteins, forexample, Cre recombinase. In some examples, the same molecular structuremay serve as both a means for generating a double strand DNA break and ameans for repairing a double strand DNA break, where the same structurefacilitates both the cleavage and repair of double-stranded DNAmolecules (e.g., Hin recombinase).

The induction of the site specific double stranded breaks in the genomeinduces the host plant cell DNA repair pathway which resolves the doublestranded break through homology-directed repair (HDR) or non-homologousend-joining (NHEJ) repair. In plants, the scientific literature reportsthat precise gene or donor DNA integration into native genomic or atpre-engineered locations have involved incoming donor DNA construct(s)that comprise varying amounts of sequence homologous to the sequencesflanking the targeted double stranded break. The integration of suchdonors into the specific target locus presumably has relied on the HDRpathway. Exclusively relying on the HDR approach for gene targeting inplants can have limitations due to reports that the HDR repair pathwayis not the dominate DNA repair pathway when compared to NHEJ. Thepublished plant scientific literature utilizing target specific DNAbreaks (ZFN, TALeNs, or Engineered Meganucleases, etc.) the NHEJ pathwayhas been reported as the method to introduce specific point mutations(insertions, or deletions) into the geneome. Here we report that sitespecific double stranded breaks (induced by ZFN, TALeNs, etc.) in thepresents of various donor DNA design with homology regions of 0 to <10bp can be specifically inserted at targeted break via the NHEJ repairpathway in plants. A variety of different DNA donor designs with zerohomology to small 1-10 bp of ranging from linear to circular, singlestranded to double stranded can be targeted to specific locations usingthe NHEJ pathway. NHEJ based donor DNA plant genome targeting can bebased on “sticky end capture”, where the targeted double stranded breakin the genome generated by Fok1 (or other Type II endonuclease domains)and the corresponding sticky ends are on the NHEJ donor DNA designs. Thesticky ends donor DNA can be delivered directly to the cell as lineardonor DNA with predefined overhangs. An alternative approach is toproduce the donor DNA sticky ends in vivo by co-delivering the hosttarget ZFN and a circular DNA donor molecule that contains at least oneZFN recognition site that is identical to the target recognition site.Expression of at least one ZFN cuts the host genomic DNA (native orpre-engineered) and the circular donor DNA to produce sticky ends thatare resolved using the hosts NHEJ repair pathway.

It is possible to have one or more ZFN cuts sites on the donor molecule(a single ZFN cut site to linearize the entire donor molecule, 2 of thesame ZFN sites to release a smaller donor DNA fragment or 2 differentZFN sites to release a fragment from the donor and a correspondingfragment from the host genomic DNA (DNA replacement).

Thus, the donor polynucleotide can be DNA or RNA, single-stranded and/ordouble-stranded and can be introduced into a cell in linear or circularform. See, e.g., U.S. Patent Publication Nos. 20100047805 and20110207221. In certain, embodiments of the present invention may alsoinclude linear exogenous (donor) nucleic acid(s), compositionscomprising these nucleic acids and methods of making and using theselinear donor molecules. In certain embodiments, the linear donormolecule stably persists in the cell into which it is introduced. Inother embodiments, the linear donor molecule is modified to resistexonucleolytic cleavage, for example by placing one or morephosphorothioate phosphodiester bonds between one or more base pairs onthe ends of the donor molecule. The linear exogenous nucleic acid mayalso include single stranded specific DNA.

IV. FAD3 Performance Loci

The loci designated FAD3 (fatty acid desaturase 3) are included in QTLsinvolved in the inheritance of the complex multigenic trait of fattyacid content in plants. FAD3 encodes the enzyme responsible for thedesaturation of linoleic acid (18:2) to linolenic acid (C18:3).Tanhuanpaa et al. (1998) Mol. Breed. 4:543-50; Schierholt et al. (2001)Crop Sci. 41:1444-9.

Within the plant oil biosynthetic pathway the fatty acid desaturases(FADs) play a key role in plant lipid biosynthesis and their activitysignificantly influences the fatty acid composition. FADs are abundantin plants, and expression analysis suggested that FAD mRNAs are producedin over-abundance. Furthermore, FAD genes are expressed in various,tissues, and cell types, as well as subcellular compartments includingthe plastid and endoplasmic reticulum.

The fatty acid composition of plants, and the performance of oilsproduced therefrom in many applications, is determined by the relativeconcentrations of the major fatty acid constituents; oleic, linoleic,and linolenic (C18:3). The concentrations of these fatty acids arepredominantly regulated by the function of the enzymes FAD2 and FAD3.Oleic acid is converted to linoleic acid and linolenic acid in plantsaccording to the scheme:

FAD3 genes have been identified in major plant and algal speciesincluding but not limited to maize, soybean, cotton, Arabidopsis, wheat,forage grasses, rice, sunflower and Brassica, and modification of FAD3expression leads to altered fatty acid profiles in such organisms.Furthermore, plants comprising modified FAD3 genes have beencommercialized, and disruption of a FAD3 gene has been shown to be ableto improve the nutritional and functional properties of oil produced bya host plant without an agronomic penalty to the host plant. Forexample, canola and sunflower varieties that have been commercializedunder the Nexera® brand (Dow AgroSciences, LLC) are characterized by ahigher oleic acid, lower linoleic aced, and lower linolenic acid (andlower saturated fatty acid) composition, when compared to wild-typecanola and sunflower profiles. The dominant canola species grown inEurope, North America, and Australia is Brassica napus, a polyploidBrassica species considered to have arisen from the hybridization of B.oleracea (having a diploid C genome) and B. rapa (having a diploid Agenome). Cytogenetic investigation revealed the AA and CC genomes show adegree of relatedness as being partially homologous to one another. Boththe A and C genomes contain a high percentage of homeologous and/orparalogous genes. Thus, it is thought that the AA and CC genomes arederived from a common ancestor genome. Prakash and Hinata (1980) OperaBotanica 55:1-57. Although the genomes of both progenitor species aretechnically classified as diploids, these genomes contain a highpercentage of regions that are duplicative of one another. Song et al.(1991) Theor. Appl. Genet. 82:296-304. A detailed organelle and nuclearRFLP analysis revealed that the AA genome of B. rapa contributed tenchromosomes to B. napus, while B. oleracea contributed nine chromosomesfrom its CC genome as the maternal donor. Song et al. (1992) Genome35:992-1001. Through the number of genome duplications in both ancestralgenomes, as well as the high percentage of similarity between the A, Band C genomes, there have arisen several copies of FAD2 and FAD3 genes.As a practical matter, this fact makes breeding canola with modifiedand/or disrupted copies of these genes challenging in order to produce aparticular fatty acid profile.

All of the known functional gene copies of FAD3 in canola are located onlinkage group N4 of the A genome. Scheffler et al. (1997) TAG94(5):583-91; Schierholt et al. (2000) TAG 101(5-6):897-901. Morerecently, a high oleic trait in canola has been associated with amodified and disrupted FAD3 gene that is located on the A genome. U.S.Patent Application Publication No. US 2006/0248611 A1; Hu et al. (2006)“Identification and Mapping of FAD2 and FAD3 Mutations and Developmentof Allele-specific Markers for High Oleic and Low Linolenic AcidContents in Canola (Brassica napus L.),” Plant & Animal Genomes XIVConference, Jan. 14-18, 2006, San Diego, Calif. An inactivating FAD3allele contributes to the control of oleic acid content by reducing thedesaturation of linoleic acid to linolenic acid. This high oleic acidand FAD3 trait was identified in a B. napus variety (DMS100) that has acharacteristic oleic acid content of about 77%. See, U.S. PublicationNo. 20060248611. Further, genetic markers have been developed to assistthe introgression of the Fad3 and high oleic acid trait into canola.

FAD3 loci may be modified and/or disrupted in a plant withoutdetrimentally affecting the value of the plant, and for many purposes,with an actual increase in its value, including alteration of FAD3expression, alteration of oil content/ratios and/or integration andexpression of desired transgenes. Furthermore, according to theubiquitous nature of FAD loci in plants, FAD3 loci may be modifiedand/or disrupted without detriment for at least some purposes in manyspecies, including, for example and without limitation: canola; soybean;maize; wheat; forage grasses; brassica sp.; rice, tomatoes, barley;oats; sorghum; cotton; and sunflower, as well as fungi and algae.Embodiments of the invention include FAD3 loci, and the use thereof asperformance loci for integration of exogenous nucleic acids. Inexamples, a FAD3 locus exhibits at least one of several features thathave been found to be desirable within the context of its use as aperformance locus, including, for example and without limitation: thatthere is an approximately consistent level of expression during the lifecycle of the host organism; and surprisingly, that insertion of donorDNA at a FAD3 locus does not induce a quality or fitness penalty on thehost.

In some embodiments of the present invention, at least one FAD3 locus(e.g., a FAD3A and/or FAD3C locus) is used as a target site for thesite-specific integration of an exogenous nucleic acid (e.g., a nucleicacid comprising a nucleotide sequence encoding a polypeptide ofinterest). In particular embodiments, integration of the exogenousnucleic acid results in a modified locus. For example, integration ofthe exogenous nucleic acid may modify the locus so as to produce adisrupted (i.e., inactivated) FAD3 gene.

In some embodiments, a FAD3 locus may comprise a nucleotide sequencethat is specifically hybridizable to the complement of a nucleotidesequence selected from the group consisting of SEQ ID NOs: 20-23, SEQ IDNOs: 25-38, SEQ ID NOs: 40-45, SEQ ID NO: 47 and SEQ ID NO: 49. Forexample, a FAD3 locus may comprise a nucleotide sequence selected fromthe group consisting of SEQ ID NOs: 20-23, SEQ ID NOs: 25-38, SEQ IDNOs: 40-45, SEQ ID NO: 47 and SEQ ID NO: 49. In some embodiments, a FAD3locus may comprise a nucleotide sequence that is substantially identicalto a nucleotide sequence selected from the group consisting of SEQ IDNOs: 20-23, SEQ ID NOs: 25-38, SEQ ID NOs: 40-45, SEQ ID NO: 47 and SEQID NO: 49. For example, in some embodiments, a FAD3 locus is a FAD3homologue (e.g., an ortholog or a paralog) that comprises a nucleotidesequence that is at least about 85% identical to a nucleotide sequenceselected from the group consisting of SEQ ID NOs: 20-23, SEQ ID NOs:25-38, SEQ ID NOs: 40-45, SEQ ID NO: 47 and SEQ ID NO: 49. A FAD3homologue may comprise a nucleotide sequence that is, for example andwithout limitation: at least 80%; at least 85%; at least about 90%; atleast about 91%; at least about 92%; at least about 93%; at least about94%; at least about 95%; at least about 96%; at least about 97%; atleast about 98%; at least about 99%; at least about 99.5%; 99.6%, 99.7%,99.8% and/or at least about 99.9% identical to a nucleotide sequenceselected from the group consisting of SEQ ID NOs: 20-23, SEQ ID NOs:25-38, SEQ ID NOs: 40-45, SEQ ID NO: 47 and SEQ ID NO: 49. Such a FAD3homologue may be readily identified and isolated from any complete orpartial genome readily available to those of skill in the art for avariety of organisms.

IV. Targeted Integration of a Nucleic Acid at a FAD3 Locus

Site-specific integration of an exogenous nucleic acid at a FAD3 locusmay be accomplished by any technique known to those of skill in the art.In some embodiments, integration of an exogenous nucleic acid at a FAD3locus comprises contacting a cell (e.g., an isolated cell or a cell in atissue or organism) with a nucleic acid molecule comprising theexogenous nucleic acid. In examples, such a nucleic acid molecule maycomprise nucleotide sequences flanking the exogenous nucleic acid thatfacilitate homologous recombination between the nucleic acid moleculeand at least one FAD3 locus. In particular examples, the nucleotidesequences flanking the exogenous nucleic acid that facilitate homologousrecombination may be complementary to endogenous nucleotides of the FAD3locus. In particular examples, the nucleotide sequences flanking theexogenous nucleic acid that facilitate homologous recombination may becomplementary to previously integrated exogenous nucleotides. In someembodiments, a plurality of exogenous nucleic acids may be integrated atone FAD3 locus, such as in gene stacking.

Integration of a nucleic acid at a FAD3 locus may be facilitated (e.g.,catalyzed) in some embodiments by endogenous cellular machinery of ahost cell, such as, for example and without limitation, endogenous DNAand endogenous recombinase enzymes. In some embodiments, integration ofa nucleic acid at a FAD3 locus may be facilitated by one or more factors(e.g., polypeptides) that are provided to a host cell. For example,nuclease(s), recombinase(s), and/or ligase polypeptides may be provided(either independently or as part of a chimeric polypeptide) bycontacting the polypeptides with the host cell, or by expressing thepolypeptides within the host cell. Accordingly, in some examples, anucleic acid comprising a nucleotide sequence encoding at least onenuclease, recombinase, and/or ligase polypeptide may be introduced intothe host cell, either concurrently or sequentially with a nucleic acidto be integrated site-specifically at a FAD3 locus, wherein the at leastone nuclease, recombinase, and/or ligase polypeptide is expressed fromthe nucleotide sequence in the host cell.

A. DNA-Binding Polypeptides

In some embodiments, site-specific integration may be accomplished byutilizing factors that are capable of recognizing and binding toparticular nucleotide sequences, for example, in the genome of a hostorganism. For instance, many proteins comprise polypeptide domains thatare capable of recognizing and binding to DNA in a site-specific manner.A DNA sequence that is recognized by a DNA-binding polypeptide may bereferred to as a “target” sequence. Polypeptide domains that are capableof recognizing and binding to DNA in a site-specific manner generallyfold correctly and function independently to bind DNA in a site-specificmanner, even when expressed in a polypeptide other than the protein fromwhich the domain was originally isolated. Similarly, target sequencesfor recognition and binding by DNA-binding polypeptides are generallyable to be recognized and bound by such polypeptides, even when presentin large DNA structures (e.g., a chromosome), particularly when the sitewhere the target sequence is located is one known to be accessible tosoluble cellular proteins (e.g., a gene).

While DNA-binding polypeptides identified from proteins that exist innature typically bind to a discrete nucleotide sequence or motif (e.g.,a consensus recognition sequence), methods exist and are known in theart for modifying many such DNA-binding polypeptides to recognize adifferent nucleotide sequence or motif. DNA-binding polypeptidesinclude, for example and without limitation: zinc finger DNA-bindingdomains; leucine zippers; UPA DNA-binding domains; GAL4; TAL; LexA; aTet repressor; LacR; and a steroid hormone receptor.

In some examples, a DNA-binding polypeptide is a zinc finger. Individualzinc finger motifs can be designed to target and bind specifically toany of a large range of DNA sites. Canonical Cys₂His₂ (as well asnon-canonical Cys₃His) zinc finger polypeptides bind DNA by inserting anα-helix into the major groove of the target DNA double helix.Recognition of DNA by a zinc finger is modular; each finger contactsprimarily three consecutive base pairs in the target, and a few keyresidues in the polypeptide mediate recognition. By including multiplezinc finger DNA-binding domains in a targeting endonuclease, theDNA-binding specificity of the targeting endonuclease may be furtherincreased (and hence the specificity of any gene regulatory effectsconferred thereby may also be increased). See, e.g., Urnov et al. (2005)Nature 435:646-51. Thus, one or more zinc finger DNA-bindingpolypeptides may be engineered and utilized such that a targetingendonuclease introduced into a host cell interacts with a DNA sequencethat is unique within the genome of the host cell.

Preferably, the zinc finger protein is non-naturally occurring in thatit is engineered to bind to a target site of choice. See, for example,See, for example, Beerli et al. (2002) Nature Biotechnol. 20:135-141;Pabo et al. (2001) Ann. Rev. Biochem. 70:313-340; Isalan et al. (2001)Nature Biotechnol. 19:656-660; Segal et al. (2001) Curr. Opin.Biotechnol. 12:632-637; Choo et al. (2000) Curr. Opin. Struct. Biol.10:411-416; U.S. Pat. Nos. 6,453,242; 6,534,261; 6,599,692; 6,503,717;6,689,558; 7,030,215; 6,794,136; 7,067,317; 7,262,054; 7,070,934;7,361,635; 7,253,273; and U.S. Patent Publication Nos. 2005/0064474;2007/0218528; 2005/0267061, all incorporated herein by reference intheir entireties.

An engineered zinc finger binding domain can have a novel bindingspecificity, compared to a naturally-occurring zinc finger protein.Engineering methods include, but are not limited to, rational design andvarious types of selection. Rational design includes, for example, usingdatabases comprising triplet (or quadruplet) nucleotide sequences andindividual zinc finger amino acid sequences, in which each triplet orquadruplet nucleotide sequence is associated with one or more amino acidsequences of zinc fingers which bind the particular triplet orquadruplet sequence. See, for example, co-owned U.S. Pat. Nos. 6,453,242and 6,534,261, incorporated by reference herein in their entireties.

Exemplary selection methods, including phage display and two-hybridsystems, are disclosed in U.S. Pat. Nos. 5,789,538; 5,925,523;6,007,988; 6,013,453; 6,410,248; 6,140,466; 6,200,759; and 6,242,568; aswell as WO 98/37186; WO 98/53057; WO 00/27878; WO 01/88197 and GB2,338,237. In addition, enhancement of binding specificity for zincfinger binding domains has been described, for example, in co-owned WO02/077227.

In addition, as disclosed in these and other references, zinc fingerdomains and/or multi-fingered zinc finger proteins may be linkedtogether using any suitable linker sequences, including for example,linkers of 5 or more amino acids in length. See, also, U.S. Pat. Nos.6,479,626; 6,903,185; and 7,153,949 for exemplary linker sequences 6 ormore amino acids in length. The proteins described herein may includeany combination of suitable linkers between the individual zinc fingersof the protein.

Selection of target sites; ZFPs and methods for design and constructionof fusion proteins (and polynucleotides encoding same) are known tothose of skill in the art and described in detail in U.S. Pat. Nos.6,140,0815; 789,538; 6,453,242; 6,534,261; 5,925,523; 6,007,988;6,013,453; 6,200,759; WO 95/19431; WO 96/06166; WO 98/53057; WO98/54311; WO 00/27878; WO 01/60970 WO 01/88197; WO 02/099084; WO98/53058; WO 98/53059; WO 98/53060; WO 02/016536 and WO 03/016496.

In addition, as disclosed in these and other references, zinc fingerdomains and/or multi-fingered zinc finger proteins may be linkedtogether using any suitable linker sequences, including for example,linkers of 5 or more amino acids in length. See, also, U.S. Pat. Nos.6,479,626; 6,903,185; and 7,153,949 for exemplary linker sequences 6 ormore amino acids in length. The proteins described herein may includeany combination of suitable linkers between the individual zinc fingersof the protein.

In some examples, a DNA-binding polypeptide is a DNA-binding domain fromGAL4. GAL4 is a modular transactivator in Saccharomyces cerevisiae, butit also operates as a transactivator in many other organisms. See, e.g.,Sadowski et al. (1988) Nature 335:563-4. In this regulatory system, theexpression of genes encoding enzymes of the galactose metabolic pathwayin S. cerevisiae is stringently regulated by the available carbonsource. Johnston (1987) Microbiol. Rev. 51:458-76. Transcriptionalcontrol of these metabolic enzymes is mediated by the interactionbetween the positive regulatory protein, GAL4, and a 17 bp symmetricalDNA sequence to which GAL4 specifically binds (the UAS).

Native GAL4 includes 881 amino acid residues, with a molecular weight of99 kDa. GAL4 comprises functionally autonomous domains, the combinedactivities of which account for activity of GAL4 in vivo. Ma and Ptashne(1987) Cell 48:847-53); Brent and Ptashne (1985) Cell 43(3 Pt 2):729-36.The N-terminal 65 amino acids of GAL4 comprise the GAL4 DNA-bindingdomain. Keegan et al. (1986) Science 231:699-704; Johnston (1987) Nature328:353-5. Sequence-specific binding requires the presence of a divalentcation coordinated by 6 Cys residues present in the DNA binding domain.The coordinated cation-containing domain interacts with and recognizes aconserved CCG triplet at each end of the 17 bp UAS via direct contactswith the major groove of the DNA helix. Marmorstein et al. (1992) Nature356:408-14. The DNA-binding function of the protein positions C-terminaltranscriptional activating domains in the vicinity of the promoter, suchthat the activating domains can direct transcription.

Additional DNA-binding polypeptides that may be utilized in certainembodiments include, for example and without limitation, a bindingsequence from a AVRBS3-inducible gene; a consensus binding sequence froma AVRBS3-inducible gene or synthetic binding sequence engineeredtherefrom (e.g., UPA DNA-binding domain); TAL; LexA (see, e.g., Brent &Ptashne (1985), supra); LacR (see, e.g., Labow et al. (1990) Mol. Cell.Biol. 10:3343-56; Baim et al. (1991) Proc. Natl. Acad. Sci. USA88(12):5072-6); a steroid hormone receptor (Ellliston et al. (1990) J.Biol. Chem. 265:11517-121); the Tet repressor (U.S. Pat. No. 6,271,341)and a mutated Tet repressor that binds to a tet operator sequence in thepresence, but not the absence, of tetracycline (Tc); the DNA-bindingdomain of NF-κB; and components of the regulatory system described inWang et al. (1994) Proc. Natl. Acad. Sci. USA 91(17):8180-4, whichutilizes a fusion of GAL4, a hormone receptor, and VP16.

In certain embodiments, the DNA-binding domain of one or more of thenucleases used in the methods and compositions described hereincomprises a naturally occurring or engineered (non-naturally occurring)TAL effector DNA binding domain. See, e.g., U.S. Patent Publication No.20110301073, incorporated by reference in its entirety herein. The plantpathogenic bacteria of the genus Xanthomonas are known to cause manydiseases in important crop plants. Pathogenicity of Xanthomonas dependson a conserved type III secretion (T3S) system which injects more than25 different effector proteins into the plant cell. Among these injectedproteins are transcription activator-like (TAL) effectors which mimicplant transcriptional activators and manipulate the plant transcriptome(see Kay et al (2007) Science 318:648-651). These proteins contain a DNAbinding domain and a transcriptional activation domain. One of the mostwell characterized TAL-effectors is AvrBs3 from Xanthomonas campestgrispv. Vesicatoria (see Bonas et al (1989) Mol Gen Genet 218: 127-136 andWO2010079430). TAL-effectors contain a centralized domain of tandemrepeats, each repeat containing approximately 34 amino acids, which arekey to the DNA binding specificity of these proteins. In addition, theycontain a nuclear localization sequence and an acidic transcriptionalactivation domain (for a review see Schornack S, et al (2006) J PlantPhysiol 163(3): 256-272). In addition, in the phytopathogenic bacteriaRalstonia solanacearum two genes, designated brg11 and hpx17 have beenfound that are homologous to the AvrBs3 family of Xanthomonas in the R.solanacearum biovar 1 strain GMI1000 and in the biovar 4 strain RS1000(See Heuer et al (2007) Appl and Envir Micro 73(13): 4379-4384). Thesegenes are 98.9% identical in nucleotide sequence to each other butdiffer by a deletion of 1,575 bp in the repeat domain of hpx17. However,both gene products have less than 40% sequence identity with AvrBs3family proteins of Xanthomonas. See, e.g., U.S. Pat. Nos. 8,420,782 and8,440,431 and U.S. Patent Publication No. 20110301073.

In other embodiments, the nuclease comprises a CRISPR/Cas system. TheCRISPR (clustered regularly interspaced short palindromic repeats)locus, which encodes RNA components of the system, and the cas(CRISPR-associated) locus, which encodes proteins (Jansen et al., 2002.Mol. Microbiol. 43: 1565-1575; Makarova et al., 2002. Nucleic Acids Res.30: 482-496; Makarova et al., 2006. Biol. Direct 1: 7; Haft et al.,2005. PLoS Comput. Biol. 1: e60) make up the gene sequences of theCRISPR/Cas nuclease system. CRISPR loci in microbial hosts contain acombination of CRISPR-associated (Cas) genes as well as non-coding RNAelements capable of programming the specificity of the CRISPR-mediatednucleic acid cleavage.

The Type II CRISPR is one of the most well characterized systems andcarries out targeted DNA double-strand break in four sequential steps.First, two non-coding RNA, the pre-crRNA array and tracrRNA, aretranscribed from the CRISPR locus. Second, tracrRNA hybridizes to therepeat regions of the pre-crRNA and mediates the processing of pre-crRNAinto mature crRNAs containing individual spacer sequences. Third, themature crRNA:tracrRNA complex directs Cas9 to the target DNA viaWastson-Crick base-pairing between the spacer on the crRNA and theprotospacer on the target DNA next to the protospacer adjacent motif(PAM), an additional requirement for target recognition. Finally, Cas9mediates cleavage of target DNA to create a double-stranded break withinthe protospacer. Activity of the CRISPR/Cas system comprises of threesteps: (i) insertion of alien DNA sequences into the CRISPR array toprevent future attacks, in a process called ‘adaptation’, (ii)expression of the relevant proteins, as well as expression andprocessing of the array, followed by (iii) RNA-mediated interferencewith the alien nucleic acid. Thus, in the bacterial cell, several of theso-called ‘Os’ proteins are involved with the natural function of theCRISPR/Cas system and serve roles in functions such as insertion of thealien DNA etc.

In certain embodiments, Cas protein may be a “functional derivative” ofa naturally occurring Cas protein. A “functional derivative” of a nativesequence polypeptide is a compound having a qualitative biologicalproperty in common with a native sequence polypeptide. “Functionalderivatives” include, but are not limited to, fragments of a nativesequence and derivatives of a native sequence polypeptide and itsfragments, provided that they have a biological activity in common witha corresponding native sequence polypeptide. A biological activitycontemplated herein is the ability of the functional derivative tohydrolyze a DNA substrate into fragments. The term “derivative”encompasses both amino acid sequence variants of polypeptide, covalentmodifications, and fusions thereof. Suitable derivatives of a Caspolypeptide or a fragment thereof include but are not limited tomutants, fusions, covalent modifications of Cas protein or a fragmentthereof. Cas protein, which includes Cas protein or a fragment thereof,as well as derivatives of Cas protein or a fragment thereof, may beobtainable from a cell or synthesized chemically or by a combination ofthese two procedures. The cell may be a cell that naturally produces Casprotein, or a cell that naturally produces Cas protein and isgenetically engineered to produce the endogenous Cas protein at a higherexpression level or to produce a Cas protein from an exogenouslyintroduced nucleic acid, which nucleic acid encodes a Cas that is sameor different from the endogenous Cas. In some case, the cell does notnaturally produce Cas protein and is genetically engineered to produce aCas protein.

In particular embodiments, a DNA-binding polypeptide specificallyrecognizes and binds to a target nucleotide sequence comprised within agenomic nucleic acid of a host organism. Any number of discreteinstances of the target nucleotide sequence may be found in the hostgenome in some examples. The target nucleotide sequence may be rarewithin the genome of the organism (e.g., fewer than about 10, about 9,about 8, about 7, about 6, about 5, about 4, about 3, about 2, or about1 copy(ies) of the target sequence may exist in the genome). Forexample, the target nucleotide sequence may be located at a unique sitewithin the genome of the organism. Target nucleotide sequences may be,for example and without limitation, randomly dispersed throughout thegenome with respect to one another; located in different linkage groupsin the genome; located in the same linkage group; located on differentchromosomes; located on the same chromosome; located in the genome atsites that are expressed under similar conditions in the organism (e.g.,under the control of the same, or substantially functionally identical,regulatory factors); and located closely to one another in the genome(e.g., target sequences may be comprised within nucleic acids integratedas concatemers at genomic loci).

B. Targeting Endonucleases

In particular embodiments, a DNA-binding polypeptide that specificallyrecognizes and binds to a target nucleotide sequence may be comprisedwithin a chimeric polypeptide, so as to confer specific binding to thetarget sequence upon the chimeric polypeptide. In examples, such achimeric polypeptide may comprise, for example and without limitation,nuclease, recombinase, and/or ligase polypeptides, as these polypeptidesare described above. Chimeric polypeptides comprising a DNA-bindingpolypeptide and a nuclease, recombinase, and/or ligase polypeptide mayalso comprise other functional polypeptide motifs and/or domains, suchas for example and without limitation: a spacer sequence positionedbetween the functional polypeptides in the chimeric protein; a leaderpeptide; a peptide that targets the fusion protein to an organelle(e.g., the nucleus); polypeptides that are cleaved by a cellular enzyme;peptide tags (e.g., Myc, His, etc.); and other amino acid sequences thatdo not interfere with the function of the chimeric polypeptide.

Functional polypeptides (e.g., DNA-binding polypeptides and nucleasepolypeptides) in a chimeric polypeptide may be operatively linked. Insome embodiments, functional polypeptides of a chimeric polypeptide maybe operatively linked by their expression from a single polynucleotideencoding at least the functional polypeptides ligated to each otherin-frame, so as to create a chimeric gene encoding a chimeric protein.In alternative embodiments, the functional polypeptides of a chimericpolypeptide may be operatively linked by other means, such as bycross-linkage of independently expressed polyp eptides.

In some embodiments, a DNA-binding polypeptide that specificallyrecognizes and binds to a target nucleotide sequence may be comprisedwithin a natural isolated protein (or mutant thereof), wherein thenatural isolated protein or mutant thereof also comprises a nucleasepolypeptide (and may also comprise a recombinase and/or ligasepolypeptide). Examples of such isolated proteins include TALENs,recombinases (e.g., Cre, Hin, Tre, and FLP recombinase), RNA-guidedCRISPR-Cas9, and meganucleases.

As used herein, the term “targeting endonuclease” refers to natural orengineered isolated proteins and mutants thereof that comprise aDNA-binding polypeptide and a nuclease polypeptide, as well as tochimeric polypeptides comprising a DNA-binding polypeptide and anuclease. Any targeting endonuclease comprising a DNA-bindingpolypeptide that specifically recognizes and binds to a targetnucleotide sequence comprised within a FAD3 locus (e.g., either becausethe target sequence is comprised within the native sequence at thelocus, or because the target sequence has been introduced into thelocus, for example, by recombination) may be utilized in certainembodiments.

Some examples of chimeric polypeptides that may be useful in particularembodiments of the invention include, without limitation, combinationsof the following polypeptides: zinc finger DNA-binding polypeptides; aFold nuclease polypeptide; TALE domains; leucine zippers; transcriptionfactor DNA-binding motifs; and DNA recognition and/or cleavage domainsisolated from, for example and without limitation, a TALEN, arecombinase (e.g., Cre, Hin, RecA, Tre, and FLP recombinases),RNA-guided CRISPR-Cas9, a meganuclease; and others known to those in theart. Particular examples include a chimeric protein comprising asite-specific DNA binding polypeptide and a nuclease polypeptide.Chimeric polypeptides may be engineered by methods known to those ofskill in the art to alter the recognition sequence of a DNA-bindingpolypeptide comprised within the chimeric polypeptide, so as to targetthe chimeric polypeptide to a particular nucleotide sequence ofinterest.

In certain embodiments, the chimeric polypeptide comprises a DNA-bindingdomain (e.g., zinc finger, TAL-effector domain, etc.) and a nuclease(cleavage) domain. The cleavage domain may be heterologous to theDNA-binding domain, for example a zinc finger DNA-binding domain and acleavage domain from a nuclease or a TALEN DNA-binding domain and acleavage domain, or meganuclease DNA-binding domain and cleavage domainfrom a different nuclease. Heterologous cleavage domains can be obtainedfrom any endonuclease or exonuclease. Exemplary endonucleases from whicha cleavage domain can be derived include, but are not limited to,restriction endonucleases and homing endonucleases. See, for example,2002-2003 Catalogue, New England Biolabs, Beverly, Mass.; and Belfort etal. (1997) Nucleic Acids Res. 25:3379-3388. Additional enzymes whichcleave DNA are known (e.g., S1 Nuclease; mung bean nuclease; pancreaticDNase I; micrococcal nuclease; yeast HO endonuclease; see also Linn etal. (eds.) Nucleases, Cold Spring Harbor Laboratory Press, 1993). One ormore of these enzymes (or functional fragments thereof) can be used as asource of cleavage domains and cleavage half-domains.

Similarly, a cleavage half-domain can be derived from any nuclease orportion thereof, as set forth above, that requires dimerization forcleavage activity. In general, two fusion proteins are required forcleavage if the fusion proteins comprise cleavage half-domains.Alternatively, a single protein comprising two cleavage half-domains canbe used. The two cleavage half-domains can be derived from the sameendonuclease (or functional fragments thereof), or each cleavagehalf-domain can be derived from a different endonuclease (or functionalfragments thereof). In addition, the target sites for the two fusionproteins are preferably disposed, with respect to each other, such thatbinding of the two fusion proteins to their respective target sitesplaces the cleavage half-domains in a spatial orientation to each otherthat allows the cleavage half-domains to form a functional cleavagedomain, e.g., by dimerizing. Thus, in certain embodiments, the nearedges of the target sites are separated by 5-8 nucleotides or by 15-18nucleotides. However any integral number of nucleotides or nucleotidepairs can intervene between two target sites (e.g., from 2 to 50nucleotide pairs or more). In general, the site of cleavage lies betweenthe target sites.

Restriction endonucleases (restriction enzymes) are present in manyspecies and are capable of sequence-specific binding to DNA (at arecognition site), and cleaving DNA at or near the site of binding, forexample, such that one or more exogenous sequences (donors/trangsenes)are integrated at or near the binding (target) sites. Certainrestriction enzymes (e.g., Type IIS) cleave DNA at sites removed fromthe recognition site and have separable binding and cleavage domains.For example, the Type IIS enzyme Fok I catalyzes double-strandedcleavage of DNA, at 9 nucleotides from its recognition site on onestrand and 13 nucleotides from its recognition site on the other. See,for example, U.S. Pat. Nos. 5,356,802; 5,436,150 and 5,487,994; as wellas Li et al. (1992) Proc. Natl. Acad. Sci. USA 89:4275-4279; Li et al.(1993) Proc. Natl. Acad. Sci. USA 90:2764-2768; Kim et al. (1994a) Proc.Natl. Acad. Sci. USA 91:883-887; Kim et al. (1994b) J. Biol. Chem.269:31,978-31,982. Thus, in one embodiment, fusion proteins comprise thecleavage domain (or cleavage half-domain) from at least one Type IISrestriction enzyme and one or more zinc finger binding domains, whichmay or may not be engineered.

An exemplary Type IIS restriction enzyme, whose cleavage domain isseparable from the binding domain, is Fok I. This particular enzyme isactive as a dimer. Bitinaite et al. (1998) Proc. Natl. Acad. Sci. USA95: 10,570-10,575. Accordingly, for the purposes of the presentdisclosure, the portion of the Fok I enzyme used in the disclosed fusionproteins is considered a cleavage half-domain. Thus, for targeteddouble-stranded cleavage and/or targeted replacement of cellularsequences using zinc finger-Fok I fusions, two fusion proteins, eachcomprising a FokI cleavage half-domain, can be used to reconstitute acatalytically active cleavage domain. Alternatively, a singlepolypeptide molecule containing a DNA binding domain and two Fok Icleavage half-domains can also be used.

A cleavage domain or cleavage half-domain can be any portion of aprotein that retains cleavage activity, or that retains the ability tomultimerize (e.g., dimerize) to form a functional cleavage domain.

Exemplary Type IIS restriction enzymes are described in U.S. PatentPublication No. 20070134796, incorporated herein in its entirety.Additional restriction enzymes also contain separable binding andcleavage domains, and these are contemplated by the present disclosure.See, for example, Roberts et al. (2003) Nucleic Acids Res. 31:418-420.

In certain embodiments, the cleavage domain comprises one or moreengineered cleavage half-domain (also referred to as dimerization domainmutants) that minimize or prevent homodimerization, as described, forexample, in U.S. Patent Publication Nos. 20050064474; 20060188987 and20080131962, the disclosures of all of which are incorporated byreference in their entireties herein. Amino acid residues at positions446, 447, 479, 483, 484, 486, 487, 490, 491, 496, 498, 499, 500, 531,534, 537, and 538 of Fok I are all targets for influencing dimerizationof the Fok I cleavage half-domains.

Exemplary engineered cleavage half-domains of Fok I that form obligateheterodimers include a pair in which a first cleavage half-domainincludes mutations at amino acid residues at positions 490 and 538 ofFok I and a second cleavage half-domain includes mutations at amino acidresidues 486 and 499.

Thus, in one embodiment, a mutation at 490 replaces Glu (E) with Lys(K); the mutation at 538 replaces Iso (I) with Lys (K); the mutation at486 replaced Gln (Q) with Glu (E); and the mutation at position 499replaces Iso (I) with Lys (K). Specifically, the engineered cleavagehalf-domains described herein were prepared by mutating positions 490(E→K) and 538 (I→K) in one cleavage half-domain to produce an engineeredcleavage half-domain designated “E490K:1538K” and by mutating positions486 (Q→E) and 499 (I→L) in another cleavage half-domain to produce anengineered cleavage half-domain designated “Q486E:I499L”. The engineeredcleavage half-domains described herein are obligate heterodimer mutantsin which aberrant cleavage is minimized or abolished. See, e.g., U.S.Patent Publication No. 2008/0131962, the disclosure of which isincorporated by reference in its entirety for all purposes.

In certain embodiments, the engineered cleavage half-domain comprisesmutations at positions 486, 499 and 496 (numbered relative to wild-typeFokI), for instance mutations that replace the wild type Gln (Q) residueat position 486 with a Glu (E) residue, the wild type Iso (I) residue atposition 499 with a Leu (L) residue and the wild-type Asn (N) residue atposition 496 with an Asp (D) or Glu (E) residue (also referred to as a“ELD” and “ELE” domains, respectively). In other embodiments, theengineered cleavage half-domain comprises mutations at positions 490,538 and 537 (numbered relative to wild-type FokI), for instancemutations that replace the wild type Glu (E) residue at position 490with a Lys (K) residue, the wild type Iso (I) residue at position 538with a Lys (K) residue, and the wild-type His (H) residue at position537 with a Lys (K) residue or a Arg (R) residue (also referred to as“KKK” and “KKR” domains, respectively). In other embodiments, theengineered cleavage half-domain comprises mutations at positions 490 and537 (numbered relative to wild-type FokI), for instance mutations thatreplace the wild type Glu (E) residue at position 490 with a Lys (K)residue and the wild-type His (H) residue at position 537 with a Lys (K)residue or a Arg (R) residue (also referred to as “KIK” and “KIR”domains, respectively). (See US Patent Publication No. 20110201055).Engineered cleavage half-domains described herein can be prepared usingany suitable method, for example, by site-directed mutagenesis ofwild-type cleavage half-domains (Fok I) as described in U.S. PatentPublication Nos. 20050064474; 20080131962; and 20110201055.

Alternatively, nucleases may be assembled in vivo at the nucleic acidtarget site using so-called “split-enzyme” technology (see e.g. U.S.Patent Publication No. 20090068164). Components of such split enzymesmay be expressed either on separate expression constructs, or can belinked in one open reading frame where the individual components areseparated, for example, by a self-cleaving 2A peptide or IRES sequence.Components may be individual zinc finger binding domains or domains of ameganuclease nucleic acid binding domain.

C. Zinc Finger Nucleases

In specific embodiments, a chimeric polypeptide is a custom-designedzinc finger nuclease (ZFN) that may be designed to deliver a targetedsite-specific double-strand DNA break into which an exogenous nucleicacid, or donor DNA, may be integrated (See co-owned US Patentpublication 20100257638, incorporated by reference herein). ZFNs arechimeric polypeptides containing a non-specific cleavage domain from arestriction endonuclease (for example, FokI) and a zinc fingerDNA-binding domain polypeptide. See, e.g., Huang et al. (1996) J.Protein Chem. 15:481-9; Kim et al. (1997a) Proc. Natl. Acad. Sci. USA94:3616-20; Kim et al. (1996) Proc. Natl. Acad. Sci. USA 93:1156-60; Kimet al. (1994) Proc Natl. Acad. Sci. USA 91:883-7; Kim et al. (1997b)Proc. Natl. Acad. Sci. USA 94:12875-9; Kim et al. (1997c) Gene 203:43-9;Kim et al. (1998) Biol. Chem. 379:489-95; Nahon and Raveh (1998) NucleicAcids Res. 26:1233-9; Smith et al. (1999) Nucleic Acids Res. 27:674-81.In some embodiments, the ZFNs comprise non-canonical zinc finger DNAbinding domains (see co-owned US Patent publication 20080182332,incorporated by reference herein). The FokI restriction endonucleasemust dimerize via the nuclease domain in order to cleave DNA andintroduce a double-strand break. Consequently, ZFNs containing anuclease domain from such an endonuclease also require dimerization ofthe nuclease domain in order to cleave target DNA. Mani et al. (2005)Biochem. Biophys. Res. Commun. 334:1191-7; Smith et al. (2000) NucleicAcids Res. 28:3361-9. Dimerization of the ZFN can be facilitated by twoadjacent, oppositely oriented DNA-binding sites. Id.

The flexibility and specificity of the ZFN system provides a level ofcontrol previously unachievable by known recombinase-mediated geneediting strategies. As one example, ZFNs can be easily engineered, forexample, to recognize specific nucleic acid sequences. Wu et al. (2007)Cell. Mol. Life Sci. 64:2933-44 (See, US Patent Publications20090205083, 20110189775, 20110167521 and 20100199389, incorporated byreference in their entireties herein). Randomization of the codons forzinc finger recognition residues allows the selection of new fingersthat have high affinity for arbitrarily chosen DNA sequences.Furthermore, zinc fingers are natural DNA-binding molecules, andengineered zinc fingers have been shown to act on their designed targetsin living cells. Thus, nucleases based on zinc fingers are targetable tospecific but arbitrary recognition sites.

In particular examples, a method for the site-specific integration of anexogenous nucleic acid into at least one FAD3 performance locus of ahost comprises introducing into a cell of the host a ZFN, wherein theZFN recognizes and binds to a target nucleotide sequence, wherein thetarget nucleotide sequence is comprised within at least one FAD3 locusof the host. In certain examples, the target nucleotide sequence is notcomprised within the genome of the host at any other position than theat least one FAD3 locus. For example, a DNA-binding polypeptide of theZFN may be engineered to recognize and bind to a target nucleotidesequence identified within the at least one FAD3 locus (e.g., bysequencing the FAD3 locus). A method for the site-specific integrationof an exogenous nucleic acid into at least one FAD3 performance locus ofa host that comprises introducing into a cell of the host a ZFN may alsocomprise introducing into the cell an exogenous nucleic acid, whereinrecombination of the exogenous nucleic acid into a nucleic acid of thehost comprising the at least one FAD3 locus is facilitated bysite-specific recognition and binding of the ZFN to the target sequence(and subsequent cleavage of the nucleic acid comprising the FAD3 locus).

VI. Exogenous Nucleic Acids for Integration at a FAD3 Locus

Embodiments of the invention may include one or more nucleic acidsselected from the group consisting of: an exogenous nucleic acid forsite-specific integration in at least one FAD3 locus, for example andwithout limitation, a PTU, ELP, ETIP or an ORF; a nucleic acidcomprising a nucleotide sequence encoding a targeting endonuclease; anda vector comprising at least one of either or both of the foregoing.Thus, particular nucleic acids for use in some embodiments includenucleotide sequences encoding a polypeptide, structural nucleotidesequences, and/or DNA-binding polypeptide recognition and binding sites.

A. Exogenous Nucleic Acid Molecules for Site-Specific Integration

As noted above, insertion of an exogenous sequence (also called a “donorsequence” or “donor” or “transgene”) is provided, for example forexpression of a polypeptide, correction of a mutant gene or forincreased expression of a wild-type gene. It will be readily apparentthat the donor sequence is typically not identical to the genomicsequence where it is placed. A donor sequence can contain anon-homologous sequence flanked by two regions of homology to allow forefficient HDR at the location of interest. Additionally, donor sequencescan comprise a vector molecule containing sequences that are nothomologous to the region of interest in cellular chromatin. A donormolecule can contain several, discontinuous regions of homology tocellular chromatin. For example, for targeted insertion of sequences notnormally present in a region of interest, said sequences can be presentin a donor nucleic acid molecule and flanked by regions of homology tosequence in the region of interest.

The donor polynucleotide can be DNA or RNA, single-stranded ordouble-stranded and can be introduced into a cell in linear or circularform. See, e.g., U.S. Patent Publication Nos. 20100047805, 20110281361,20110207221 and U.S. application Ser. No. 13/889,162. If introduced inlinear form, the ends of the donor sequence can be protected (e.g., fromexonucleolytic degradation) by methods known to those of skill in theart. For example, one or more dideoxynucleotide residues are added tothe 3′ terminus of a linear molecule and/or self-complementaryoligonucleotides are ligated to one or both ends. See, for example,Chang et al. (1987) Proc. Natl. Acad. Sci. USA 84:4959-4963; Nehls etal. (1996) Science 272:886-889. Additional methods for protectingexogenous polynucleotides from degradation include, but are not limitedto, addition of terminal amino group(s) and the use of modifiedinternucleotide linkages such as, for example, phosphorothioates,phosphoramidates, and O-methyl ribose or deoxyribose residues.

A polynucleotide can be introduced into a cell as part of a vectormolecule having additional sequences such as, for example, replicationorigins, promoters and genes encoding antibiotic resistance. Moreover,donor polynucleotides can be introduced as naked nucleic acid, asnucleic acid complexed with an agent such as a liposome or poloxamer, orcan be delivered by viruses (e.g., adenovirus, AAV, herpesvirus,retrovirus, lentivirus and integrase defective lentivirus (IDLV)).

The donor is generally integrated so that its expression is driven bythe endogenous promoter at the integration site, namely the promoterthat drives expression of the endogenous gene into which the donor isintegrated (e.g., FAD3). However, it will be apparent that the donor maycomprise a promoter and/or enhancer, for example a constitutive promoteror an inducible or tissue specific promoter.

Furthermore, although not required for expression, exogenous sequencesmay also include transcriptional or translational regulatory sequences,for example, promoters, enhancers, insulators, internal ribosome entrysites, sequences encoding 2A peptides and/or polyadenylation signals.

Exogenous nucleic acids that may be integrated in a site-specific mannerinto at least one FAD3 locus, so as to modify the FAD3 locus, inembodiments include, for example and without limitation, nucleic acidscomprising a nucleotide sequence encoding a polypeptide of interest;nucleic acids comprising an agronomic gene; nucleic acids comprising anucleotide sequence encoding an RNAi molecule; or nucleic acids thatdisrupt the FAD3 gene.

In some embodiments, an exogenous nucleic acid is integrated at a FAD3locus, so as to modify the FAD3 locus, wherein the nucleic acidcomprises an agronomic gene or nucleotide sequence encoding apolypeptide of interest, such that the agronomic gene or nucleotidesequence is expressed in the host from the FAD3 locus. In some examples,the polypeptide of interest (e.g., a foreign protein) is expressed froma nucleotide sequence encoding the polypeptide of interest in commercialquantities. In such examples, the polypeptide of interest may beextracted from the host cell, tissue, or biomass. In some embodiments,the host is a plant, and plant material provided for commercialproduction of a polypeptide of interest may be a plant, plant part,plant tissue, or plant cell. In some examples, the plant part may beplant seed. Protein extraction from a plant biomass may be accomplishedby known methods which are discussed, for example, in Heney and Orr(1981) Anal. Biochem. 114:92-6.

Likewise, agronomic genes may be expressed in transformed plant cells,plants, and/or their progeny. For example, a plant may be geneticallyengineered via methods of particular embodiments to express variousphenotypes of agronomic interest from at least one FAD3 locus.

In some embodiments, nucleic acids comprising an agronomic gene ornucleotide sequence encoding a polypeptide of interest may include, forexample and without limitation: a gene that confers resistance to apests or disease (See, e.g., Jones et al. (1994) Science 266:789(cloning of the tomato Cf-9 gene for resistance to Cladosporium fulvum);Martin et al. (1993) Science 262:1432; Mindrinos et al. (1994) Cell78:1089 (RSP2 gene for resistance to Pseudomonas syringae); PCTInternational Patent Publication No. WO 96/30517 (resistance to soybeancyst nematode); PCT International Patent Publication No. WO 93/19181); agene that encodes a Bacillus thuringiensis protein, a derivativethereof, or a synthetic polypeptide modeled thereon (See, e.g., Geiseret al. (1986) Gene 48:109 (cloning and nucleotide sequence of a Btδ-endotoxin gene; moreover, DNA molecules encoding δ-endotoxin genes canbe purchased from American Type Culture Collection (Manassas, Va.), forexample, under ATCC Accession Nos. 40098; 67136; 31995; and 31998)); agene that encodes a lectin (See, e.g., Van Damme et al. (1994) PlantMolec. Biol. 24:25 (nucleotide sequences of several Clivia miniatamannose-binding lectin genes)); a gene that encodes a vitamin-bindingprotein, e.g., avidin (See PCT International Patent Publication No.US93/06487 (use of avidin and avidin homologues as larvicides againstinsect pests)); a gene that encodes an enzyme inhibitor, e.g., aprotease, proteinase inhibitor, or amylase inhibitor (See, e.g., Abe etal. (1987) J. Biol. Chem. 262:16793 (nucleotide sequence of ricecysteine proteinase inhibitor); Huub et al. (1993) Plant Molec. Biol.21:985 (nucleotide sequence of cDNA encoding tobacco proteinaseinhibitor I); Sumitani et al. (1993) Biosci. Biotech. Biochem. 57:1243(nucleotide sequence of Streptomyces nitrosporeus alpha-amylaseinhibitor) and U.S. Pat. No. 5,494,813); a gene encoding aninsect-specific hormone or pheromone, e.g., an ecdysteroid or juvenilehormone, a variant thereof, a mimetic based thereon, or an antagonist oragonist thereof (See, e.g., Hammock et al. (1990) Nature 344:458(baculovirus expression of cloned juvenile hormone esterase, aninactivator of juvenile hormone)); a gene encoding an insect-specificpeptide or neuropeptide that, upon expression, disrupts the physiologyof the affected pest (See, e.g., Regan (1994) J. Biol. Chem. 269:9(expression cloning yields DNA coding for insect diuretic hormonereceptor); Pratt et al. (1989) Biochem. Biophys. Res. Comm. 163:1243 (anallostatin in Diploptera puntata); and U.S. Pat. No. 5,266,317 (genesencoding insect-specific, paralytic neurotoxins)); a gene encoding aninsect-specific venom produced in nature by a snake, a wasp, or otherorganism (See, e.g., Pang et al. (1992) Gene 116:165 (heterologousexpression in plants of a gene coding for a scorpion insectotoxicpeptide)); a gene encoding an enzyme responsible for a hyperaccumulationof a monoterpene, a sesquiterpene, a steroid, hydroxamic acid, aphenylpropanoid derivative or other molecule with insecticidal activity;a gene encoding an enzyme involved in the modification, including thepost-translational modification, of a biologically active molecule,e.g., a glycolytic enzyme, a proteolytic enzyme, a lipolytic enzyme, anuclease, a cyclase, a transaminase, an esterase, a hydrolase, aphosphatase, a kinase, a phosphorylase, a polymerase, an elastase, achitinase, or a glucanase, whether natural or synthetic (See, e.g., PCTInternational Patent Publication No. WO 93/02197 (nucleotide sequence ofa callase gene); moreover, DNA molecules containing chitinase-encodingsequences can be obtained, for example, from the ATCC, under AccessionNos. 39637 and 67152; Kramer et al. (1993) Insect Biochem. Molec. Biol.23:691 (nucleotide sequence of a cDNA encoding tobacco hornwormchitinase); and Kawalleck et al. (1993) Plant Molec. Biol. 21:673(nucleotide sequence of the parsley ubi4-2 polyubiquitin gene)); a geneencoding a molecule that stimulates signal transduction (See, e.g.,Botella et al. (1994) Plant Molec. Biol. 24:757 (nucleotide sequencesfor mung bean calmodulin cDNA clones); and Griess et al. (1994) PlantPhysiol. 104:1467 (nucleotide sequence of a maize calmodulin cDNAclone)); a gene that encodes a hydrophobic moment peptide (See, e.g.,PCT International Patent Publication No. WO 95/16776 (peptidederivatives of Tachyplesin which inhibit fungal plant pathogens); andPCT International Patent Publication No. WO 95/18855 (syntheticantimicrobial peptides that confer disease resistance)); a gene thatencodes a membrane permease, a channel former, or a channel blocker(See, e.g., Jaynes et al. (1993) Plant Sci 89:43 (heterologousexpression of a cecropin-β lytic peptide analog to render transgenictobacco plants resistant to Pseudomonas solanacearum)); a gene thatencodes a viral-invasive protein or complex toxin derived therefrom(See, e.g., Beachy et al. (1990) Ann. rev. Phytopathol. 28:451); a genethat encodes an insect-specific antibody or immunotoxin derivedtherefrom (See, e.g., Taylor et al., Abstract #497, Seventh IntlSymposium on Molecular Plant-Microbe Interactions (Edinburgh, Scotland)(1994) (enzymatic inactivation in transgenic tobacco via production ofsingle-chain antibody fragments)); a gene encoding a virus-specificantibody (See, e.g., Tavladoraki et al. (1993) Nature 366:469(transgenic plants expressing recombinant antibody genes are protectedfrom virus attack)); a gene encoding a developmental-arrestive proteinproduced in nature by a pathogen or a parasite (See, e.g., Lamb et al.(1992) Bio/Technology 10:1436 (fungal endo α-1,4-D-polygalacturonasesfacilitate fungal colonization and plant nutrient release bysolubilizing plant cell wall homo-α-1,4-D-galacturonase); Toubart et al.(1992) Plant J. 2:367 (cloning and characterization of a gene whichencodes a bean endopolygalacturonase-inhibiting protein)); a geneencoding a developmental-arrestive protein produced in nature by a plant(See, e.g., Logemann et al. (1992) Bio/Technology 10:305 (transgenicplants expressing the barley ribosome-inactivating gene have anincreased resistance to fungal disease)).

In some embodiments, nucleic acids comprising an agronomic gene ornucleotide sequence encoding a polypeptide of interest may also and/oralternatively include, for example and without limitation: genes thatconfer resistance to an herbicide, such as an herbicide that inhibitsthe growing point or meristem, for example, an imidazolinone or asulfonylurea (exemplary genes in this category encode mutant ALS andAHAS enzymes, as described, for example, by Lee et al. (1988) EMBO J.7:1241, and Miki et al. (1990) Theor. Appl. Genet. 80:449,respectively); glyphosate resistance as conferred by, e.g., mutant5-enolpyruvylshikimate-3-phosphate synthase (EPSPs) genes (via theintroduction of recombinant nucleic acids and/or various forms of invivo mutagenesis of native EPSPs genes (including but not limited toCP4, DMMG, and DGT-28); aroA genes and glyphosate acetyl transferase(GAT) genes, respectively); other phosphono compounds, such asglufosinate phosphinothricin acetyl transferase (PAT) genes fromStreptomyces species, including Streptomyces hygroscopicus andStreptomyces viridichromogenes); and pyridinoxy or phenoxy proprionicacids and cyclohexones (ACCase inhibitor-encoding genes). See, e.g.,U.S. Pat. Nos. 4,940,835 and 6,248,876 (nucleotide sequences of forms ofEPSPs which can confer glyphosate resistance to a plant). A DNA moleculeencoding a mutant aroA gene can be obtained under ATCC accession number39256. See also U.S. Pat. No. 4,769,061 (nucleotide sequence of a mutantaroA gene). European patent application No. 0 333 033 and U.S. Pat. No.4,975,374 disclose nucleotide sequences of glutamine synthetase genes,which may confer resistance to herbicides such as L-phosphinothricin.Nucleotide sequences of exemplary PAT genes are provided in Europeanapplication No. 0 242 246, and DeGreef et al. (1989) Bio/Technology 7:61(production of transgenic plants that express chimeric bar genes codingfor PAT activity). Exemplary of genes conferring resistance to phenoxyproprionic acids and cyclohexones, such as sethoxydim and haloxyfop,include the Acc1-S1, Acc1-S2 and Acc1-S3 genes described by Marshall etal. (1992) Theor. Appl. Genet. 83:435. GAT genes capable of conferringglyphosate resistance are described, for example, in WO 2005012515.Genes conferring resistance to 2,4-D, phenoxyproprionic acid andpyridyloxy auxin herbicides are described, for example, in WO 2005107437and WO 2007053482.

Nucleic acids comprising an agronomic gene or nucleotide sequenceencoding a polypeptide of interest may also include, for example andwithout limitation: a gene conferring resistance to an herbicide thatinhibits photosynthesis, such as a triazine (psbA and gs+ genes) or abenzonitrile (nitrilase gene). See, e.g., Przibila et al. (1991) PlantCell 3:169 (transformation of Chlamydomonas with plasmids encodingmutant psbA genes). Nucleotide sequences for nitrilase genes aredisclosed in U.S. Pat. No. 4,810,648, and DNA molecules containing thesegenes are available under ATCC Accession Nos. 53435; 67441; and 67442.See also Hayes et al. (1992) Biochem. J. 285:173 (cloning and expressionof DNA coding for a glutathione S-transferase).

In some embodiments, nucleic acids comprising an agronomic gene ornucleotide sequence encoding a polypeptide of interest may also and/oralternatively include, genes that confer or contribute to a value-addedtrait, for example and without limitation: modified fatty acidmetabolism, e.g., by transforming a plant with an antisense gene ofstearyl-ACP desaturase to increase stearic acid content of the plant(See, e.g., Knultzon et al. (1992) Proc. Natl. Acad. Sci. U.S.A.89:2624); decreased phytate content, e.g., introduction of aphytase-encoding gene may enhance breakdown of phytate, adding more freephosphate to the transformed plant (See, e.g., Van Hartingsveldt et al.(1993) Gene 127:87 (nucleotide sequence of an Aspergillus niger phytasegene); a gene may be introduced to reduce phytate content—in maize, forexample, this may be accomplished by cloning and then reintroducing DNAassociated with the single allele which may be responsible for maizemutants characterized by low levels of phytic acid (See Raboy et al.(1990) Maydica 35:383)); and modified carbohydrate composition effected,e.g., by transforming plants with a gene encoding an enzyme that altersthe branching pattern of starch (See, e.g., Shiroza et al. (1988) J.Bacteol. 170:810 (nucleotide sequence of Streptococcus mutantfructosyltransferase gene); Steinmetz et al. (1985) Mol. Gen. Genet.20:220 (levansucrase gene); Pen et al. (1992) Bio/Technology 10:292(α-amylase); Elliot et al. (1993) Plant Molec. Biol. 21:515 (nucleotidesequences of tomato invertase genes); Sogaard et al. (1993) J. Biol.Chem. 268:22480 (barley α-amylase gene); and Fisher et al. (1993) PlantPhysiol. 102:1045 (maize endosperm starch branching enzyme II)).

In some embodiments, an exogenous nucleic acid is integrated at a FAD3locus, so as to modify the FAD3 locus, wherein the nucleic acidcomprises a PTU or ELP, such that, for example, the subsequentsite-specific integration of a second exogenous nucleic acid at the siteof the PTU or ELP is facilitated. See, also, U.S. application Ser. No.13/889,162.

Targeting endonuclease-mediated integration of a nucleic acid moleculeof interest into a plant genome via targeted integration requiresdelivery of targeting endonucleases or targeting endonuclease-encodingnucleic acid molecules, followed by expression of a functional targetingendonuclease protein in the host. An exogenous nucleic acid ispreferably also be present in the host cell at the same time as thetargeting endonuclease is delivered or expressed therein, such thatfunctional targeting endonuclease protein induces double-stranded breaksat the target site(s) in the at least one FAD3 locus, which are thenrepaired, for example via homology-driven integration of the exogenousnucleic acid into the locus. One skilled in the art may envision thatexpression of a functional targeting endonuclease protein may beachieved by several methods, including, but not limited to, transgenesisof a targeting endonuclease-encoding construct, and transient expressionof a targeting endonuclease-encoding construct. In both these cases,expression of a functional targeting endonuclease protein and deliveryof an exogenous nucleic acid in the host cell may be simultaneouslyachieved in order to drive targeted integration at a FAD3 locus.

A particular advantage obtained in embodiments utilizing ZFNs astargeting endonucleases, is that the requirement for dimerization ofcleavage domains of chimeric zinc finger nucleases imparts a high levelof sequence, and hence cleavage, specificity. Since each set of threefingers binds nine consecutive base pairs, two chimeric nucleaseseffectively demand an 18 bp target if each zinc finger domain hasperfect specificity. Any given sequence of this length is predicted tobe unique within a single genome (assuming approximately 10⁹ bp).Bibikova et al. (2001) Mol. Cell. Biol. 21(1):289-97; Wu et al. (2007),supra. Furthermore, additional fingers can provide enhanced specificity,Beerli et al. (1998) Proc. Natl. Acad. Sci. USA 95:14628-33; Kim andPabo (1998) Proc. Natl. Acad. Sci. USA 95:2812-7; Liu et al. (1997)Proc. Natl. Acad. Sci. USA 94:5525-30, so the number of zinc fingers ineach DNA-binding domain may be increased to provide even furtherspecificity. For example, specificity may be further increased by usinga pair of 4-, 5-, 6- or more finger ZFNs that recognize a 24 bpsequence. Urnov et al. (2005) Nature 435:646-51. Thus, ZFNs may be usedsuch that a recognition sequence is introduced into the host plantgenome is unique within the genome.

B. Nucleic Acid Molecules Comprising a Nucleotide Sequence Encoding aTargeting Endonuclease

In some embodiments, a nucleotide sequence encoding a targetingendonuclease may be engineered by manipulation (e.g., ligation) ofnative nucleotide sequences encoding polypeptides comprised within thetargeting endonuclease. For example, the nucleotide sequence of a geneencoding a protein comprising a DNA-binding polypeptide may be inspectedto identify the nucleotide sequence of the gene that corresponds to theDNA-binding polypeptide, and that nucleotide sequence may be used as anelement of a nucleotide sequence encoding a targeting endonucleasecomprising the DNA-binding polypeptide. Alternatively, the amino acidsequence of a targeting endonuclease may be used to deduce a nucleotidesequence encoding the targeting endonuclease, for example, according tothe degeneracy of the genetic code.

In exemplary nucleic acid molecules comprising a nucleotide sequenceencoding a targeting endonuclease, the last codon of a firstpolynucleotide sequence encoding a nuclease polypeptide, and the firstcodon of a second polynucleotide sequence encoding a DNA-bindingpolypeptide, may be separated by any number of nucleotide triplets,e.g., without coding for an intron or a “STOP.” Likewise, the last codonof a nucleotide sequence encoding a first polynucleotide sequenceencoding a DNA-binding polypeptide, and the first codon of a secondpolynucleotide sequence encoding a nuclease polypeptide, may beseparated by any number of nucleotide triplets. In these and furtherembodiments, the last codon of the last (i.e., most 3′ in the nucleicacid sequence) of a first polynucleotide sequence encoding a nucleasepolypeptide, and a second polynucleotide sequence encoding a DNA-bindingpolypeptide, may be fused in phase-register with the first codon of afurther polynucleotide coding sequence directly contiguous thereto, orseparated therefrom by no more than a short peptide sequence, such asthat encoded by a synthetic nucleotide linker (e.g., a nucleotide linkerthat may have been used to achieve the fusion). Examples of such furtherpolynucleotide sequences include, for example and without limitation,tags, targeting peptides, and enzymatic cleavage sites. Likewise, thefirst codon of the most 5′ (in the nucleic acid sequence) of the firstand second polynucleotide sequences may be fused in phase-register withthe last codon of a further polynucleotide coding sequence directlycontiguous thereto, or separated therefrom by no more than a shortpeptide sequence.

A sequence separating polynucleotide sequences encoding functionalpolypeptides in a targeting endonuclease (e.g., a DNA-bindingpolypeptide and a nuclease polypeptide) may, for example, consist of anysequence, such that the amino acid sequence encoded is not likely tosignificantly alter the translation of the targeting endonuclease. Dueto the autonomous nature of known nuclease polypeptides and knownDNA-binding polypeptides, intervening sequences will not in examplesinterfere with the respective functions of these structures.

C. Vectors and Expression Constructs

In some embodiments, at least one nucleic acid molecule(s) comprising atleast one exogenous polynucleotide sequence encoding a polypeptide ofinterest, and/or a targeting endonuclease, may be introduced into acell, tissue, or organism for expression therein. For example, a nucleicacid molecule comprising a polynucleotide sequence encoding a targetingendonuclease that specifically recognizes a nucleotide sequencecomprised within at least one FAD3 locus may be introduced into a cellfor expression of the targeting endonuclease, and a nucleic acidmolecule comprising a polynucleotide sequence encoding a polypeptide ofinterest may be introduced into the cell, such that the polynucleotidesequence encoding the polypeptide of interest is integrated into the atleast one FAD3 locus, e.g., by homologous recombination followingintroduction of a double strand break at the locus by the expressedtargeting endonuclease, and the polypeptide of interest is expressedfrom the integrated polynucleotide sequence.

In some embodiments, a nucleic acid molecule such as one of theforegoing may, for example, be a vector system including, for exampleand without limitation, a linear plasmid, or a closed circular plasmid.In particular examples, the vector may be an expression vector. Nucleicacid sequences according to particular embodiments may, for example, beintegrated into a vector, such that the nucleic acid sequence isoperably linked to one or more regulatory sequences. Many vectors areavailable for this purpose, and selection of the particular vector maydepend, for example, on the size of the nucleic acid to be inserted intothe vector, the particular host cell to be transformed with the vector,and/or the amount of any encoded polypeptide that is desired to beexpressed. A vector typically contains various components, the identityof which depend on a function of the vector (e.g., amplification of DNAor expression of DNA), and the particular host cell(s) with which thevector is compatible.

In some embodiments, a regulatory sequence operably linked to one ormore coding sequence(s) may be a promoter sequence that functions in ahost cell, such as a bacterial cell, algal cell, fungal cell, or plantcell, wherein the nucleic acid molecule is to be amplified or expressed.Some embodiments may include a plant transformation vector thatcomprises a nucleotide sequence comprising at least one regulatorysequence operably linked to one or more nucleotide sequence(s) encodinga polypeptide of interest or a targeting endonuclease, wherein the oneor more nucleotide sequence(s) may be expressed, under the control ofthe regulatory sequence(s), in a plant cell, tissue, or organism toproduce the polypeptide of interest or the targeting endonuclease.

Promoters suitable for use in nucleic acid molecules according to someembodiments include those that are inducible, tissue-specific, viral,synthetic, or constitutive, all of which are well known in the art.Non-limiting examples of promoters that may be useful in embodiments ofthe invention are provided by: U.S. Pat. No. 6,437,217 (maize RS81promoter); U.S. Pat. No. 5,641,876 (rice actin promoter); U.S. Pat. No.6,426,446 (maize RS324 promoter); U.S. Pat. No. 6,429,362 (maize PR-1promoter); U.S. Pat. No. 6,232,526 (maize A3 promoter); U.S. Pat. No.6,177,611 (constitutive maize promoters); U.S. Pat. Nos. 5,322,938,5,352,605, 5,359,142, and 5,530,196 (35S promoter); U.S. Pat. No.6,433,252 (maize L3 oleosin promoter); U.S. Pat. No. 6,429,357 (riceactin 2 promoter, and rice actin 2 intron); U.S. Pat. No. 6,294,714(light-inducible promoters); U.S. Pat. No. 6,140,078 (salt-induciblepromoters); U.S. Pat. No. 6,252,138 (pathogen-inducible promoters); U.S.Pat. No. 6,175,060 (phosphorous deficiency-inducible promoters); U.S.Pat. No. 6,388,170 (bidirectional promoters); U.S. Pat. No. 6,635,806(gamma-coixin promoter); U.S. Pat. No. 5,447,858 (soybean heat shockpromoter); and U.S. patent application Ser. No. 09/757,089 (maizechloroplast aldolase promoter).

Additional exemplary promoters include the nopaline synthase (NOS)promoter (Ebert et al. (1987) Proc. Natl. Acad. Sci. USA 84(16):5745-9);the octopine synthase (OCS) promoter (which is carried on tumor-inducingplasmids of Agrobacterium tumefaciens); the caulimovirus promoters suchas the cauliflower mosaic virus (CaMV) 19S promoter (Lawton et al.(1987) Plant Mol. Biol. 9:315-24); the CaMV 35S promoter (Odell et al.(1985) Nature 313:810-2; the figwort mosaic virus 35S-promoter (Walkeret al. (1987) Proc. Natl. Acad. Sci. USA 84(19):6624-8); the sucrosesynthase promoter (Yang and Russell (1990) Proc. Natl. Acad. Sci. USA87:4144-8); the R gene complex promoter (Chandler et al. (1989) PlantCell 1:1175-83); the chlorophyll alb binding protein gene promoter;CaMV35S (U.S. Pat. Nos. 5,322,938, 5,352,605, 5,359,142, and 5,530,196);FMV35S (U.S. Pat. Nos. 6,051,753, and 5,378,619); a PC1SV promoter (U.S.Pat. No. 5,850,019); the SCP1 promoter (U.S. Pat. No. 6,677,503); andAGRtu.nos promoters (GenBank Accession No. V00087; Depicker et al.(1982) J. Mol. Appl. Genet. 1:561-73; Bevan et al. (1983) Nature304:184-7).

In particular embodiments, nucleic acid molecules may comprise atissue-specific promoter. A tissue-specific promoter is a nucleotidesequence that directs a higher level of transcription of an operablylinked nucleotide sequence in the tissue for which the promoter isspecific, relative to the other tissues of the organism. Examples oftissue-specific promoters include, without limitation: tapetum-specificpromoters; anther-specific promoters; pollen-specific promoters (See,e.g., U.S. Pat. No. 7,141,424, and International PCT Publication No. WO99/042587); ovule-specific promoters; (See, e.g., U.S. PatentApplication No. 2001/047525 A1); fruit-specific promoters (See, e.g.,U.S. Pat. Nos. 4,943,674, and 5,753,475); and seed-specific promoters(See, e.g., U.S. Pat. Nos. 5,420,034, and 5,608,152). In someembodiments, a developmental stage-specific promoter (e.g., a promoteractive at a later stage in development) may be used.

Additional regulatory sequences that may in some embodiments be operablylinked to a nucleic acid molecule include 5′ UTRs located between apromoter sequence and a coding sequence that function as a translationleader sequence. The translation leader sequence is present in thefully-processed mRNA, and it may affect processing of the primarytranscript, and/or RNA stability. Examples of translation leadersequences include maize and petunia heat shock protein leaders (U.S.Pat. No. 5,362,865), plant virus coat protein leaders, plant rubiscoleaders, and others. See, e.g., Turner and Foster (1995) MolecularBiotech. 3(3):225-36. Non-limiting examples of 5′ UTRs are provided by:GmHsp (U.S. Pat. No. 5,659,122); PhDnaK (U.S. Pat. No. 5,362,865);AtAntl; TEV (Carrington and Freed (1990) J. Virol. 64:1590-7); andAGRtunos (GenBank Accession No. V00087; and Bevan et al. (1983), supra).

Additional regulatory sequences that may in some embodiments be operablylinked to a nucleic acid molecule also include 3′ non-translatedsequences, 3′ transcription termination regions, or poly-adenylationregions. These are genetic elements located downstream of a nucleotidesequence, and include polynucleotides that provide polyadenylationsignal, and/or other regulatory signals capable of affectingtranscription or mRNA processing. The polyadenylation signal functionsin plants to cause the addition of polyadenylate nucleotides to the 3′end of the mRNA precursor. The polyadenylation sequence can be derivedfrom a variety of plant genes, or from T-DNA genes. A non-limitingexample of a 3′ transcription termination region is the nopalinesynthase 3′ region (nos 3′; Fraley et al. (1983) Proc. Natl. Acad. Sci.USA 80:4803-7). An example of the use of different 3′ nontranslatedregions is provided in Ingelbrecht et al. (1989) Plant Cell 1:671-80.Non-limiting examples of polyadenylation signals include one from aPisum sativum RbcS2 gene (Ps.RbcS2-E9; Coruzzi et al. (1984) EMBO J.3:1671-9) and AGRtu.nos (GenBank Accession No. E01312).

Additional information regarding regulatory sequences that may be usefulin particular embodiments is described, for example, in Goeddel (1990)“Gene Expression Technology,” Methods Enzymol. 185, Academic Press, SanDiego, Calif.

A recombinant nucleic acid molecule or vector may comprise a selectablemarker that confers a selectable phenotype on a transformed cell, suchas a plant cell. Selectable markers may also be used to select for cellsor organisms that comprise a nucleic acid molecule comprising theselectable marker. A marker may encode biocide resistance, antibioticresistance (e.g., kanamycin, Geneticin (G418), bleomycin, andhygromycin), or herbicide resistance (e.g., glyphosate). Examples ofselectable markers include, but are not limited to: a neo gene thatconfers kanamycin resistance and can be selected for using, e.g.,kanamycin and G418; a bar gene that confers bialaphos resistance; amutant EPSP synthase gene that confers glyphosate resistance; anitrilase gene that confers resistance to bromoxynil; a mutantacetolactate synthase gene (ALS) that confers imidazolinone orsulfonylurea resistance; and a methotrexate-resistant DHFR gene.Multiple selectable markers are available that confer resistance tochemical agents including, for example and without limitation,ampicillin; bleomycin; chloramphenicol; gentamycin; hygromycin;kanamycin; lincomycin; methotrexate; phosphinothricin; puromycin;spectinomycin; rifampicin; streptomycin; and tetracycline. Examples ofsuch selectable markers are illustrated in, e.g., U.S. Pat. Nos.5,550,318; 5,633,435; 5,780,708 and 6,118,047.

A nucleic acid molecule or vector may also or alternatively include ascreenable marker. Screenable markers may be used to monitor expression.Exemplary screenable markers include a β-glucuronidase or uidA gene(GUS) which encodes an enzyme for which various chromogenic substratesare known (Jefferson et al. (1987) Plant Mol. Biol. Rep. 5:387-405); anR-locus gene, which encodes a product that regulates the production ofanthocyanin pigments (red color) in plant tissues (Dellaporta et al.(1988) “Molecular cloning of the maize R-nj allele by transposon taggingwith Ac.” In 18th Stadler Genetics Symposium, P. Gustafson and R.Appels, eds., Plenum, N.Y. (pp. 263-82); a β-lactamase gene (Sutcliffeet al. (1978) Proc. Natl. Acad. Sci. USA 75:3737-41); a gene whichencodes an enzyme for which various chromogenic substrates are known(e.g., PADAC, a chromogenic cephalosporin); a luciferase gene (Ow et al.(1986) Science 234:856-9); a xylE gene that encodes a catecholdioxygenase that converts chromogenic catechols (Zukowski et al. (1983)Gene 46(2-3):247-55); an amylase gene (Ikatu et al. (1990) Bio/Technol.8:241-2); a tyrosinase gene which encodes an enzyme capable of oxidizingtyrosine to DOPA and dopaquinone, which in turn condenses to melanin(Katz et al. (1983) J. Gen. Microbiol. 129:2703-14); and anα-galactosidase.

All of the nucleotide sequences that encode, for example, a particularpolypeptide of interest or a particular targeting endonuclease, will beimmediately recognizable by those of skill in the art. The degeneracy ofthe genetic code provides a finite number of coding sequences for aparticular amino acid sequence. The selection of a particular sequenceto encode a polypeptide according to embodiments of the invention iswithin the discretion of the practitioner. Different coding sequencesmay be desirable in different applications.

In some embodiments, it may be desirable to modify the nucleotides of anucleic acid, for example, to enhance expression of a polynucleotidesequence comprised within the nucleic acid in a particular host. Thegenetic code is redundant with 64 possible codons, but most organismspreferentially use a subset of these codons. The codons that areutilized most often in a species are called optimal codons, and thosenot utilized very often are classified as rare or low-usage codons.Zhang et al. (1991) Gene 105:61-72. Codons may be substituted to reflectthe preferred codon usage of a particular host in a process sometimesreferred to as “codon optimization.” Optimized coding sequencescontaining codons preferred by a particular prokaryotic or eukaryotichost may be prepared, for example, to increase the rate of translationor to produce recombinant RNA transcripts having desirable properties(e.g., a longer half-life, as compared with transcripts produced from anon-optimized sequence).

Nucleic acids may be introduced into a host cell in embodiments of theinvention by any method known to those of skill in the art, including,for example and without limitation: by transformation of protoplasts(See, e.g., U.S. Pat. No. 5,508,184); by desiccation/inhibition-mediatedDNA uptake (See, e.g., Potrykus et al. (1985) Mol. Gen. Genet.199:183-8); by electroporation (See, e.g., U.S. Pat. No. 5,384,253); byagitation with silicon carbide fibers (See, e.g., U.S. Pat. Nos.5,302,523 and 5,464,765); by Agrobacterium-mediated transformation (See,e.g., U.S. Pat. Nos. 5,563,055, 5,591,616, 5,693,512, 5,824,877,5,981,840, and 6,384,301); and by acceleration of DNA-coated particles(See, e.g., U.S. Pat. Nos. 5,015,580, 5,550,318, 5,538,880, 6,160,208,6,399,861, and 6,403,865). Through the application of techniques such asthese, the cells of virtually any species may be stably transformed. Insome embodiments, transforming DNA is integrated into the genome of thehost cell. In the case of multicellular species, transgenic cells may beregenerated into a transgenic organism. Any of these techniques may beused to produce a transgenic plant, for example, comprising one or morenucleic acid sequences of the invention in the genome of the transgenicplant.

The most widely-utilized method for introducing an expression vectorinto plants is based on the natural transformation system ofAgrobacterium. A. tumefaciens and A. rhizogenes are plant pathogenicsoil bacteria that genetically transform plant cells. The T_(i) andR_(i) plasmids of A. tumefaciens and A. rhizogenes, respectively, carrygenes responsible for genetic transformation of the plant. The T_(i)(tumor-inducing)-plasmids contain a large segment, known as T-DNA, whichis transferred to transformed plants. Another segment of the T_(i)plasmid, the vir region, is responsible for T-DNA transfer. The T-DNAregion is bordered by left-hand and right-hand borders that are eachcomposed of terminal repeated nucleotide sequences. In some modifiedbinary vectors, the tumor-inducing genes have been deleted, and thefunctions of the vir region are utilized to transfer foreign DNAbordered by the T-DNA border sequences. The T-region may also contain,for example, a selectable marker for efficient recovery of transgenicplants and cells, and a multiple cloning site for inserting sequencesfor transfer such as a nucleic acid encoding a fusion protein of theinvention.

Thus, in some embodiments, a plant transformation vector is derived froma T_(i) plasmid of A. tumefaciens (See, e.g., U.S. Pat. Nos. 4,536,475,4,693,977, 4,886,937, and 5,501,967; and European Patent EP 0 122 791)or a R_(i) plasmid of A. rhizogenes. Additional plant transformationvectors include, for example and without limitation, those described byHerrera-Estrella et al. (1983) Nature 303:209-13; Bevan et al. (1983),supra; Klee et al. (1985) Bio/Technol. 3:637-42; and in European PatentEP 0 120 516, and those derived from any of the foregoing. Otherbacteria, such as Sinorhizobium, Rhizobium, and Mesorhizobium, thatnaturally interact with plants can be modified to mediate gene transferto a number of diverse plants. These plant-associated symbiotic bacteriacan be made competent for gene transfer by acquisition of both adisarmed T_(i) plasmid and a suitable binary vector.

After providing exogenous DNA to recipient cells, transformed cells aregenerally identified for further culturing and plant regeneration. Inorder to improve the ability to identify transformed cells, one maydesire to employ a selectable or screenable marker gene, as previouslyset forth, with the vector used to generate the transformant. In thecase where a selectable marker is used, transformed cells are identifiedwithin the potentially transformed cell population by exposing the cellsto a selective agent or agents. In the case where a screenable marker isused, cells may be screened for the desired marker gene trait.

Cells that survive the exposure to the selective agent, or cells thathave been scored positive in a screening assay, may be cultured in mediathat supports regeneration of plants. In some embodiments, any suitableplant tissue culture media (e.g., MS and N6 media) may be modified byincluding further substances, such as growth regulators. Tissue may bemaintained on a basic media with growth regulators until sufficienttissue is available to begin plant regeneration efforts, or followingrepeated rounds of manual selection, until the morphology of the tissueis suitable for regeneration (e.g., at least 2 weeks), then transferredto media conducive to shoot formation. Cultures are transferredperiodically until sufficient shoot formation has occurred. Once shootsare formed, they are transferred to media conducive to root formation.Once sufficient roots are formed, plants can be transferred to soil forfurther growth and maturity.

To confirm the presence of a nucleic acid molecule of interest (forexample, a nucleotide sequence encoding a polypeptide comprising atleast one fusion protein of the invention) in a regenerating plant, avariety of assays may be performed. Such assays include, for example:molecular biological assays, such as Southern and Northern blotting,PCR, and nucleic acid sequencing; biochemical assays, such as detectingthe presence of a protein product, e.g., by immunological means (ELISAand/or Western blots) or by enzymatic function; plant part assays, suchas leaf or root assays; and analysis of the phenotype of the wholeregenerated plant.

Integration events may be analyzed, for example, by PCR amplificationusing, e.g., oligonucleotide primers that are specific for a nucleotidesequence of interest. PCR genotyping is understood to include, but notbe limited to, polymerase-chain reaction (PCR) amplification of genomicDNA derived from isolated host plant tissue predicted to contain anucleic acid molecule of interest integrated into the genome, followedby standard cloning and sequence analysis of PCR amplification products.Methods of PCR genotyping have been well described (see, e.g., Rios, G.et al. (2002) Plant J. 32:243-53), and may be applied to genomic DNAderived from any plant species or tissue type, including cell cultures.

A transgenic plant formed using Agrobacterium-dependent transformationmethods typically contains a single to multiple copies of recombinantDNA. The single recombinant DNA sequence is referred to as a “transgenicevent” or “integration event.” Such transgenic plants are heterozygousfor the inserted DNA sequence. In some embodiments, a transgenic planthomozygous with respect to a transgene may be obtained by sexuallymating (selfing) an independent segregant transgenic plant that containsa single exogenous gene sequence to itself, for example, an F₀ plant, toproduce F₁ seed. One fourth of the F₁ seed produced will be homozygouswith respect to the transgene. Germinating F₁ seed results in plantsthat can be tested for heterozygosity, typically using a SNP assay or athermal amplification assay that allows for the distinction betweenheterozygotes and homozygotes (i.e., a zygosity assay).

In addition to direct transformation of a plant or plant cell with anucleic acid molecule in some embodiments, transgenic plants may beprepared in particular embodiments by crossing a first plant having atleast one transgenic event with a second plant lacking such an event.For example, a nucleic acid comprising at least one modified FAD3 locus,wherein an exogenous nucleic acid has been integrated in a site-specificmanner, may be introduced into a first plant line that is amenable totransformation, to produce a transgenic plant, which transgenic plantmay be crossed with a second plant line to introgress the at least onemodified FAD3 locus (and therefore the exogenous nucleic acid) into thesecond plant line.

To confirm the presence of a nucleic acid molecule of interest inregenerating plants, a variety of assays may be performed. Such assaysinclude, for example: molecular biological assays, such as Southern andNorthern blotting and PCR; biochemical assays, such as detecting thepresence of a protein product, e.g., by immunological means (ELISAand/or Western blots) or by enzymatic function; plant part assays, suchas leaf or root assays; and analysis of the phenotype of the wholeregenerated plant.

Targeted integration events may be screened, for example, by PCRamplification using, e.g., oligonucleotide primers specific for nucleicacid molecules of interest. PCR genotyping is understood to include, butnot be limited to, polymerase-chain reaction (PCR) amplification ofgenomic DNA derived from isolated host plant callus tissue predicted tocontain a nucleic acid molecule of interest integrated into the genome,followed by standard cloning and sequence analysis of PCR amplificationproducts. Methods of PCR genotyping have been well described (forexample, Rios, G. et al. (2002) Plant J. 32:243-53) and may be appliedto genomic DNA derived from any plant species or tissue type, includingcell cultures. Combinations of oligonucleotide primers that bind to bothtarget sequence and introduced sequence may be used sequentially ormultiplexed in PCR amplification reactions. Oligonucleotide primersdesigned to anneal to the target site, introduced nucleic acidsequences, and/or combinations of the two are feasible. Thus, PCRgenotyping strategies may include (but are not limited to) amplificationof specific sequences in the plant genome, amplification of multiplespecific sequences in the plant genome, amplification of non-specificsequences in the plant genome, or combinations thereof. One skilled inthe art may devise additional combinations of primers and amplificationreactions to interrogate the genome. For example, a set of forward andreverse oligonucleotide primers may be designed to anneal to nucleicacid sequence(s) specific for the target outside the boundaries of theintroduced nucleic acid sequence.

Forward and reverse oligonucleotide primers may be designed to annealspecifically to an introduced nucleic acid molecule of interest, forexample, at a sequence corresponding to a coding region within thenucleic acid molecule of interest, or other parts of the nucleic acidmolecule of interest. These primers may be used in conjunction with theprimers described above. Oligonucleotide primers may be synthesizedaccording to a desired sequence, and are commercially available (e.g.,from Integrated DNA Technologies, Inc., Coralville, Iowa). Amplificationmay be followed by cloning and sequencing, or by direct sequenceanalysis of amplification products. One skilled in the art mightenvision alternative methods for analysis of amplification productsgenerated during PCR genotyping. In one embodiment, oligonucleotideprimers specific for the gene target are employed in PCR amplifications.

VI. Transgenic Plants and Plant Materials Comprising a Nucleic AcidIntegrated at a FAD3 Performance Locus

In some embodiments, a transgenic plant is provided, wherein the plantcomprises a plant cell comprising at least one modified (e.g., FAD3locus, disrupted and/or targeted integration of an exogenous sequence)FAD3 locus. In particular embodiments, such a plant may be produced bytransformation of a plant tissue or plant cell, and regeneration of awhole plant. In further embodiments, such a plant may be obtainedthrough introduction of an exogenous nucleic acid at the at least oneFAD3 locus in a site-specific manner, or through introgression of themodified FAD3 locus into a germplasm. Plant materials comprising such aplant cell are also provided. Such a plant material may be obtained froma plant comprising the plant cell.

A transgenic plant or plant material comprising a plant cell comprisingat least one modified FAD3 locus may in some embodiments exhibit one ormore of the following characteristics: expression of a targetingendonuclease in a cell of the plant; expression of a polypeptide ofinterest in a cell of the plant (or in a plastid therein); expression ofa targeting endonuclease in the nucleus of a cell of the plant;localization of a targeting endonuclease in a cell of the plant;integration at a FAD3 locus in the genome of a cell of the plant;integration of a nucleotide sequence encoding a polypeptide of interestor an agronomic gene at a FAD3 locus in the genome of a cell of theplant; and/or the presence of an RNA transcript corresponding to acoding sequence integrated at a FAD3 locus in the genome of a cell ofthe plant. Such a plant may additionally have one or more desirabletraits, including, for example and without limitation, those resultingfrom the expression of an endogenous or transgenic nucleotide sequence,the expression of which is regulated by a polypeptide of interest or anagronomic gene integrated at a FAD3 locus in the genome of a cell of theplant; resistance to insects, other pests, and disease-causing agents;tolerances to herbicides; enhanced stability, yield, or shelf-life;environmental tolerances; pharmaceutical production; industrial productproduction; and nutritional enhancements.

A transgenic plant according to the invention may be any plant capableof being transformed with a nucleic acid that is subsequently integratedin at least one FAD3 locus according to methods described herein.Accordingly, the plant may be a dicot or monocot. Non-limiting examplesof dicotyledonous plants usable in the present methods includeArabidopsis, alfalfa, beans, broccoli, cabbage, canola, carrot,cauliflower, celery, Chinese cabbage, cotton, cucumber, eggplant,lettuce, melon, pea, pepper, peanut, potato, pumpkin, radish, rapeseed,spinach, soybean, squash, sugarbeet, sunflower, tobacco, tomato, andwatermelon. Non-limiting examples of monocotyledonous plants usable inthe present methods include corn, barley, onion, rice, sorghum, wheat,rye, millet, sugarcane, oat, triticale, switchgrass, and turfgrass.Transgenic plants according to the invention may be used or cultivatedin any manner.

Some embodiments also provide commodity products produced fromtransgenic plants of the invention. Commodity products include, forexample and without limitation: food products, meals, oils, or crushedor whole grains or seeds of a plant comprising one or more nucleotidesequences integrated in at least one FAD3 locus. The detection of one ormore such nucleotide sequences in one or more commodity or commodityproducts is de facto evidence that the commodity or commodity productwas at least in part produced from a transgenic plant produced accordingto an embodiment of the invention. In some embodiments, a transgenicplant or seed comprising a plant cell comprising at least one modifiedFAD3 locus may comprise at least one other transgenic event in itsgenome, including without limitation: a transgenic event from which istranscribed an RNAi molecule; a gene encoding an insecticidal protein(e.g., a Bacillus thuringiensis insecticidal protein); an herbicidetolerance gene (e.g., a gene providing tolerance to glyphosate); and agene contributing to a desirable phenotype in the transgenic plant(e.g., increased yield, altered fatty acid metabolism, or restoration ofcytoplasmic male sterility).

A transgenic plant comprising a plant cell comprising at least onemodified FAD3 locus may have one or more desirable traits. Such traitscan include, for example: resistance to insects, other pests, anddisease-causing agents; tolerances to herbicides; enhanced stability,yield, or shelf-life; environmental tolerances; pharmaceuticalproduction; industrial product production; and nutritional enhancements.The desirable traits may be conferred by one or more nucleic acidmolecules integrated by targeted recombination at the FAD3 locus thatare expressed in the plant exhibiting the desirable traits. Thus, insome embodiments, the desired trait can be due to the presence of atransgene(s) in the plant, which is introduced into the genome of theplant at the site of at least one modified FAD3 locus. In an additionalembodiment, the desirable trait can be obtained through conventionalbreeding, which trait may be conferred by one or more nucleic acidmolecules integrated by targeted recombination at the at least onemodified FAD3 locus.

Transgenic plants according to the invention may be used or cultivatedin any manner, wherein presence of at least one modified FAD3 locus isdesirable. Accordingly, a plant may be engineered to, inter alia, haveone or more desired traits, by being transformed with nucleic acidmolecules that are subsequently integrated in a site-specific manner inat least one FAD3 locus according to the invention, and cropped andcultivated by any method known to those of skill in the art.

VII. Marker-Assisted Breeding of Transgenic Plants Comprising a NucleicAcid Integrated at a FAD3 Performance Locus

Molecular markers that are linked (e.g., tightly-linked) to Fad2 andFad3, in Brasicca spp. are provided. For example, DNA segmentscontaining sequences involved in the HO trait (FAD3) are identified.These segments are located around and between markers that are linked(e.g., tightly-linked) to the mutant alleles in a genomic linkage group.Thus, nucleic acid molecules comprising a mutant FAD3 gene having aninactivating mutation are also provided. The segments identified, andthe markers thereof, are included in the present subject matter, inpart, by their position in linkage groups in the B. napus genome.

All references, including publications, patents, and patentapplications, cited herein are hereby incorporated by reference to theextent they are not inconsistent with the explicit details of thisdisclosure, and are so incorporated to the same extent as if eachreference were individually and specifically indicated to beincorporated by reference and were set forth in its entirety herein. Thereferences discussed herein are provided solely for their disclosureprior to the filing date of the present application. Nothing herein isto be construed as an admission that the inventors are not entitled toantedate such disclosure by virtue of prior invention. The followingexamples are provided to illustrate certain particular features and/orembodiments. The examples should not be construed to limit thedisclosure to the particular features or embodiments exemplified.

EXAMPLES Example 1: Identification of FAD3 Target Sequences from aBacterial Artificial Chromosome Library

BAC Library Construction

A Bacterial Artificial Chromosome (BAC) library was sourced from acommercial vendor (Amplicon Express, Pullman, Wash.). The BAC libraryincluded 110,592 BAC clones containing high molecular weight genomic DNA(gDNA) fragments isolated from Brassica napus L. var. DH10275. The gDNAwas digested with either the BamHI or HindIII restriction enzyme.Isolated gDNA fragments of about 135 Kbp were ligated into the pCC1BACvector (Epicentre, Madison, Wis.) and transformed into Escherichia colistr. DH10B (Invitrogen). The BAC library was made up of an even numberof BAC clones that were constructed using the two different restrictionenzymes. As such, the Hind III constructed BAC library was contained in144 individual 384-well plates. Likewise, the BamHI constructed BAClibrary was contained in 144 individual 384-well plates. A total of110,592 BAC clones were isolated and arrayed into 288 individual384-well plates. Each of the 288 individual 384 well plates wereprovided by the vendor as a single DNA extraction for rapid PCR basedscreening. The resulting BAC library covers approximately 15 Gbp ofgDNA, which corresponds to a 12-fold genome coverage of Brassica napusL. var. DH10275genome (estimate of the Brassica napus L. genome is ca.1.132 Gbp as described in Johnston et al. (2005) Annals of Botany95:229-235).

Sequence Analysis of FAD3 Coding Sequences Isolated from the BAC Library

The constructed BAC library was used to isolate FAD3 gene codingsequences. Sequencing experiments were conducted to identify thespecific gene sequences of six FAD3 gene homeologous and paralogs fromBrassica napus L. var. DH10275.

The FAD3 gene sequence was initially identified within the model speciesArabidopsis thaliana. The gene sequence is listed in Genbank as LocusTag: At2g29980. Comparative genomic relationships between the modelplant species Arabidopsis thaliana and the diploid Brassica rapa, one ofthe progenitors of the tetraploid Brassica napus, have been previouslydescribed. (Schranz et al. (2006) Trends in Plant Science11(11):535-542). With specific relation to the FAD gene the comparativeanalysis predicted that 3-4 copies of the gene may occur within thediploid Brassica genome. Additional genetic mapping studies werecompleted by Scheffler et al. (1997) Theoretical and Applied Genetics94; 583-591. The results of these genetic mapping studies indicated thatsix copies of the FAD3 gene were present in Brassica napus.

Previous sequencing efforts focused on the FAD3 genes from Brassicanapus had identified and genetically mapped both A and C genome specificcopies (Hu et al., (2006) Theoretical and Applied Genetics, 113(3):497-507). A collection of EST sequences from seed specific cDNAlibraries had previously been constructed and sequenced from the plantline DH12075 by Andrew Sharpe of Agriculture and Agri-food Canada, 107Science Place, Saskatoon, Saskatchewan. As a collection of ESTs from thedoubled haploid canola plant DH12075 full length gene sequences were notavailable, moreover the indications of sequence quality and confidenceof correctly called nucleotides was also not available. Consequently,sequence variation between different FAD gene sequence reads could notbe unequivocally attributed to different gene copies of the varioushomeologues and paralogs of the FAD3 gene family, nor was the genomicsequence available. However, when a combined sequence analysis wasperformed with the ESTs as well as the two FAD3A and FAD3C full lengthgene sequences described in Hu et al., (2006), ESTs that matched both ofthe genes were identified along with an additional 4 haplotypes. As aresult, a total of six unique haplotypes of FAD3 were identified.Following the assembly of all available data for the various FAD3haplotypes, high levels of exon sequence divergence in exon 1 wasidentified. The divergence of the FAD3 sequence in exon 1 was identifiedas an opportunity which could be utilized for the design of gene/allelespecific PCR primers. In addition, exons were identified that wereeither minimally differentiated between haplotypes (e.g., exons 5, 6, 7and 8 had 1-3 bp that varied between FAD3A and FAD3C) or that weredevoid of sequence variation (e.g., exons 2 and 3).

Sequencing analysis of the BAC library which was constructed from B.napus L. var. DH12075 resulted in the isolation of six BAC sequences(SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, andSEQ ID NO:6) from which the coding sequences for the FAD3A (SEQ IDNO:7), FAD3A′ (SEQ ID NO:8), FAD3A″ (SEQ ID NO:9), FAD3C (SEQ ID NO:10),FAD3C″ (SEQ ID NO:11), and FAD3C′ (SEQ ID NO:12) genes were determined.The FAD3A, FAD3A′, FAD3A″, FAD3C, FAD3C″, and FAD3C′ gene sequences wereidentified and genetically mapped.

Sequence analysis of the six FAD3 genes was conducted using a sequencealignment program and a neighbor-joining tree using percentage ofidentity. The sequence alignment was made via the AlignX® program fromthe Vector NTI Advance 11.0 computer program (Life Technologies,Carlsbad, Calif.) and is shown in FIG. 1. AlignX® uses a modifiedClustal W algorithm to generate multiple sequence alignments of eitherprotein or nucleic acid sequences for similarity comparisons and forannotation. The neighbour-joining tree was created with Jalview v2.3®software and is shown in FIG. 2. (Waterhouse et al. (2009)Bioinformatics 25 (9) 1189-1191). The contigs identified as containingFAD3 genes were used as BLASTn queries against a database of Arabidopsisthaliana genes. The region of each of the 6 contigs containing the FAD3gene was identified through comparison to the Arabidopsis thaliana FAD3gene (Genbank Accession No: At2g29980). The FAD3 contigs were thenorientated such that all FAD3 genes were in the 5′ to 3′ orientation.FAD3 contigs were trimmed to contain as many as 2 upstream (5′) and 1downstream (3′) Arabidopsis thaliana genes where possible. Onceorientated the complete coding region of the FAD3 genes were extractedfrom each contig and used to generate a Neighbour joining tree todisplay the relationship between the different FAD3 gene family members.The 6 FAD3 family members were aligned into 3 pairs of FAD3 genes (FIG.2).

PCR Based Screening

A cohort of PCR primers were designed to screen the aforementioned BAClibrary. The primers were designed as either universal primers, whichwould amplify all members of the gene family, or as gene specificprimers for targeted allele amplification. The PCR primers were designedto be 20 bp long (+/−1 bp) and contain a G/C content of 50% (+/−8%).Table 1 lists the primers which were designed and synthesized. Theclones of the BAC library were pooled and screened via the PolymeraseChain Reaction (PCR).

TABLE 1 Primer sequences used for PCR amplification of FAD3 sequencesSEQ ID Primer Name: NO: Sequence: D_uni_F3_F1 SEQ IDGAATAAGCCATCGGACACAC NO: 13 D_spec_F3_F2 SEQ ID ATGCGAACGGAGACGAAAGGNO: 14 D_spec_F3_F3 SEQ ID TGTTAACGGAGATTCCGGTG NO: 15 D_spec_F3_F4SEQ ID GTAGCAATGTGAACGGAGAT NO: 16 D_uni_F3_R1 SEQ IDCAGTGTATCTGAGCATCCG NO: 17 D_spec_F3_R2 SEQ ID GTGGCCGAGTACGAAGATAGNO: 18 D_spec_F3_R3 SEQ ID CAGTAGAGTGGCCAGAGGA NO: 19

Two different sets of conditions were used for the polymerase chainreactions (PCR). The first series of PCR reactions contained: 1×PCRbuffer (containing dNTPs); 1.5 mM MgCl₂; 200 μM of 0.25 U Immolase® DNApolymerase (Bioline, London, UK); 250 nM of each primer; and, about 5-10ng template DNA. A second series of PCR reactions were developed for theamplification of genomic DNA and contained: 5-10 ng of genomic DNA,1×PCR buffer, 2 mM dNTPs, 0.4 μM forward and reverse primer, and 0.25 UImmolase® DNA polymerase (Bioline, London, UK). Reagents were pooledinto a final volume of 13 μL and amplified using an MJ PTC200®thermocycler (BioRad, Hercules, Calif.) or an ABI 9700 Gene Amp System®(Life Technologies, Carlsbad, Calif.). PCR based screening of specificplates was conducted using a 4 dimension screening approach based on thescreening system described by Bryan et at (Scottish Crops ResearchInstitute annual report: 2001-2002) with the above described PCRconditions. Following PCR based screening of pooled BAC libraries; theamplified PCR product was sequenced using a direct Sanger sequencingmethod. The amplified products were purified with ethanol, sodiumacetate and EDTA following the BigDye® v3.1 protocol (AppliedBiosystems) and electrophoresis was performed on an ABI3730x1® automatedcapillary electrophoresis platform.

Following PCR based screening and confirmational Sanger sequencing, acollection of plates were identified that contained the variousdifferent FAD3 gene family members. A total of six unique FAD3homeologous and paralogous gene sequences were identified (Table 2). Atotal of two plates per each FAD3 gene sequence were chosen to undergoplate screening to identify the specific well and clone within the platethat contained the FAD3 gene (Table 2). The specific wells wereidentified for both of the plates and an individual clone was selectedfor each of the FAD3 gene family members (Table 2).

TABLE 2 Identification of the BAC clone plates that provided positivereaction with the detailed PCR primer combinations, along with two plateidentities that were taken forward for clone identification within theplate Primer Chosen Gene Name Sets Positive Plate Pools Plates FAD3AF2 + R2 16, 231 Plate 16 (FAD3A-1) Plate 231 FAD3C F4 + R2 18, 27, 136,178, 211, Plate 18 232 Plate 27 FAD3C″ F4 + R2, 23, 44, 53, 56, 77, 116,Plate 44 (Haplotype1) F4 + R3, 158, 199, 209, 278, 280, Plate 199 F3 +R3 282, 283, 284, 286 FAD3A′ F4 + R2 52, 121, 139 Plate 121(FAD3A′/FAD3A″) Plate 139 FAD3C′ F4 + R2 144, 188, 235 Plate 144(Haplotype2) Plate 188 FAD3A″ F4 + R3 69, 105, 106, 229, 242, Plate 69(Haplotype3) and 247, 248 Plate 106 F3 + R3

The single BAC clone, for each identified FAD gene family member, wasfurther analysed via sequencing. The DNA was isolated for the BAC cloneand was prepared for sequencing using a Large Construct Kit® (Qiagen,Valencia, Calif.) following the manufacturer's instructions. Theextracted BAC DNA was prepared for sequencing using GS-FLX TitaniumTechnology® (Roche, Indianapolis, Ind.) following manufacturer'sinstructions. Sequencing reactions were performed using a physicallysectored GS-FLX TI Pico-titer Plate® with the BACs pooled in pairs foroptimal data output. The BACs were combined in pairs where the FAD2 genewas paired with a FAD3 gene. All generated sequence data was assembledby Newbler v2.0.01.14® (454 Life Sciences, Branford, Conn.). Theassembled contigs were manually assessed for the presence of thecorresponding FAD gene using Sequencher v3.7® (GeneCodes, Ann Arbor,Mich.).

After the full genomic sequence of all six FAD3 genes had beenidentified and fully characterized, zinc finger nucleases were designedto bind to the sequences for each specific gene family member.

Example 2: Design of Zinc Finger Binding Domains Specific to FAD3 Genes

Zinc finger proteins directed against DNA sequences encoding variousfunctional sequences of the FAD3 gene locus were designed as previouslydescribed. See, e.g., Urnov et al. (2005) Nature 435:646-651. Exemplarytarget sequence and recognition helices are shown in Table 3(recognition helix regions designs) and Table 4 (target sites). In Table4, nucleotides in the target site that are contacted by the ZFPrecognition helices are indicated in uppercase letters; non-contactednucleotides indicated in lowercase. Zinc finger nuclease (ZFN) targetsites were designed to bind seven target sites of FAD3. The FAD3 zincfinger designs were incorporated into zinc finger expression vectorsencoding a protein having at least one finger with a CCHC structure.See, U.S. Patent Publication No. 2008/0182332. In particular, the lastfinger in each protein had a CCHC backbone for the recognition helix.The non-canonical zinc finger-encoding sequences were fused to thenuclease domain of the type IIS restriction enzyme FokI (amino acids384-579 of the sequence of Wah et al., (1998) Proc. Natl. Acad. Sci. USA95:10564-10569) via a four amino acid ZC linker and an opaque-2 nuclearlocalization signal derived from Zea mays to form FAD3 zinc-fingernucleases (ZFNs). Expression of the fusion proteins was driven by arelatively strong constitutive promoter such as a promoter derived fromthe Cassava Vein Mosaic Virus (CsVMV) promoter and flanked by theAgrobacterium tumefaciens ORF23 3′UnTranslated Region (AtuORF23 3′UTRv1). The self-hydrolyzing 2A encoding nucleotide sequence from Thoseaasigna virus (Szymczak et al., 2004) was added between the two ZFNs thatwere cloned into the construct. Exemplary vectors are described below.

The optimal zinc fingers were verified for cleavage activity using abudding yeast based system previously shown to identify activenucleases. See, e.g., U.S. Patent Publication No. 20090111119; Doyon etal. (2008) Nat Biotechnol. 26:702-708; Geurts et al. (2009) Science325:433. Zinc fingers for the various functional domains were selectedfor in-vivo use. Of the numerous ZFNs that were designed, produced andtested to bind to the putative FAD genomic polynucleotide target sites,fifteen ZFNs were identified as having in vivo activity at high levels,and selected for further experimentation. These ZFNs were characterizedas being capable of efficiently binding and cleaving the unique FAD3genomic polynucleotide target sites in planta.

TABLE 3 FAD3 Zinc Finger Designs ZFP sF1 F2 F3 F4 F5 F6 27961 RSDNLARQKKDRSY RSDNLAR QRGNRNT RSDHLSR RNQDRTN (SEQ ID (SEQ ID (SEQ ID (SEQ ID(SEQ ID (SEQ ID NO: 116) NO: 117) NO: 116) NO: 119) NO: 120) NO: 121)27962 DRSNLSR RQDSRSQ QSSDLSR DRSALAR TSGSLTR N/A (SEQ ID (SEQ ID(SEQ ID (SEQ ID (SEQ ID NO: 122) NO: 123) NO: 124) NO: 125) NO: 126)27973 QSSDLSR AASNRSK TSGSLSR RSDALAR RSDVLST WGRLRKL (SEQ ID (SEQ ID(SEQ ID (SEQ ID (SEQ ID (SEQ ID NO: 124) NO: 128) NO: 129) NO: 130)NO: 131) NO: 132) 27974 ERGTLAR RSDDLTR RSDHLSA QHGALQT TSGNLTR QSGHLSR(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID NO: 133) NO: 134)NO: 135) NO: 136) NO: 137) NO: 138) 27987 TSGSLTR RSDHLSQ CTRNRWRRSDNLSE ASKTRKN N/A (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID NO: 126)NO: 140) NO: 141) NO: 142) NO: 143) 27990 TSGSLSR TSSNRAV TSGNLTRDRSALAR RSDVLSE RNFSLTM (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ IDNO: 129) NO: 145) NO: 137) NO: 125) NO: 148) NO: 149) 27991 QSGDLTRTSGSLSR QSGNLAR TSGSLSR QSGSLTR N/A (SEQ ID (SEQ ID (SEQ ID (SEQ ID(SEQ ID NO: 150) NO: 129) NO: 152) NO: 129) NO: 154) 27992 DRSHLARTSGSLSR TSSNRAV TSGNLTR DRSALAR N/A (SEQ ID (SEQ ID (SEQ ID (SEQ ID(SEQ ID NO: 155) NO: 129) NO: 145) NO: 137) NO: 125) 28004 QSGNLARHLGNLKT RSDHLSQ TARLLKL QSGNLAR QTSHLPQ (SEQ ID (SEQ ID (SEQ ID (SEQ ID(SEQ ID (SEQ ID NO: 152) NO: 161) NO: 140) NO: 163) NO: 152) NO: 165)28005 RSDNLSV TSGHLSR TSGSLTR RSDALST DRSTRTK N/A (SEQ ID (SEQ ID(SEQ ID (SEQ ID (SEQ ID NO: 166) NO: 167) NO: 126) NO: 169) NO: 170)28021 QNAHRKT TSGNLTR LKQMLAV RSDNLSR DNSNRKT N/A (SEQ ID (SEQ ID(SEQ ID (SEQ ID (SEQ ID NO: 171) NO: 137) NO: 173) NO: 174) NO: 175)28022 RSDNLSV QNANRIT TSGSLSR QSSVRNS DRSALAR N/A (SEQ ID (SEQ ID(SEQ ID (SEQ ID (SEQ ID NO: 166) NO: 177) NO: 129) NO: 179) NO: 125)28023 RSDNLSR DNSNRKT DRSNLTR RSDVLSE TRNGLKY N/A (SEQ ID (SEQ ID(SEQ ID (SEQ ID (SEQ ID NO: 174) NO: 175) NO: 183) NO: 148) NO: 185)28024 RSDALAR RSDVLSE RSSDRTK RSDNLSV QNANRIT N/A (SEQ ID (SEQ ID(SEQ ID (SEQ ID (SEQ ID NO: 130) NO: 148) NO: 188) NO: 166) NO: 177)28025 QSSDLSR QSTHRNA RSDNLAR QRGNRNT RSDHLSR RNQDRTN (SEQ ID (SEQ ID(SEQ ID (SEQ ID (SEQ ID (SEQ ID NO: 124) NO: 192) NO: 116) NO: 119)NO: 120) NO: 121) 28026 DRSNLSR RQDSRSQ QSSDLSR DRSALAR TSGSLTR N/A(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID NO: 122) NO: 123) NO: 124)NO: 125) NO: 126) 28035 QSSDLSR AASNRSK TSGSLSR RSDALAR RSDTLSQ QRDHRIK(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID NO: 124) NO: 128)NO: 129) NO: 130) NO: 206) NO: 207) 28036 RSDDLTR QSSDLRR RSDHLSAQHGALQT TSGNLTR QSGHLSR (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ IDNO: 134) NO: 209) NO: 135) NO: 136) NO: 137) NO: 138) 28039 TSGSLSRRSDALAR RSDTLSQ QRDHRIK TSGNLTR DRGDLRK (SEQ ID (SEQ ID (SEQ ID (SEQ ID(SEQ ID (SEQ ID NO: 129) NO: 130) NO: 206) NO: 207) NO: 137) NO: 219)28040 DSSDRKK TSGNLTR DNYNRAK DRSHLTR RSDNLTT N/A (SEQ ID (SEQ ID(SEQ ID (SEQ ID (SEQ ID NO: 220) NO: 137) NO: 222) NO: 223) NO: 224)28051 RSDNLSN TSSSRIN RSDNLSE ASKTRKN RSDALTQ N/A (SEQ ID (SEQ ID(SEQ ID (SEQ ID (SEQ ID NO: 225) NO: 226) NO: 142) NO: 143) NO: 229)28052 RSDTLST DRSSRIK RSDDLSK DNSNRIK N/A N/A (SEQ ID (SEQ ID (SEQ ID(SEQ ID NO: 230) NO: 231) NO: 232) NO: 233) 28053 QSSDLSR QAGNLSKQSGDLTR TSGSLSR QSGNLAR N/A (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ IDNO: 124) NO: 235) NO: 150) NO: 129) NO: 152) 28054 TSGSLSR LRQTLRDTSGNLTR DRSALAR RSDVLSE RNFSLTM (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID(SEQ ID NO: 129) NO: 240) NO: 137) NO: 125) NO: 148) NO: 149) 28055QSGDLTR TSGSLSR QSGNLAR TSGSLSR QSGSLTR N/A (SEQ ID (SEQ ID (SEQ ID(SEQ ID (SEQ ID NO: 150) NO: 129) NO: 152) NO: 129) NO: 154) 28056DRSHLAR TSGSLSR LRQTLRD TSGNLTR DRSALAR N/A (SEQ ID (SEQ ID (SEQ ID(SEQ ID (SEQ ID NO: 155) NO: 129) NO: 240) NO: 137) NO: 125)

TABLE 4 Target Sites of FAD3 Zinc Fingers ZFP Target Site (5′ to 3′)SEQ ID NO: 27961 cgCCGGAGAAAGAGAGAGAGctttgagg SEQ ID NO: 20 27962tgGTTGTCGCTATGGACcagcgtagcaa SEQ ID NO: 21 27969tcTCCGTTcGCATTGcTACGCTggtcca SEQ ID NO: 22 27970gaAAGGTTtGATCCGAGCGCAcaaccac SEQ ID NO: 23 27973tcTCCGTTcGCATTGcTACGCTggtcca SEQ ID NO: 22 27974tcGGAGATATAAGGGCGGCCattcctaa SEQ ID NO: 25 27987taGCCCAGAACAGGGTTccttgggcggc SEQ ID NO: 26 27988ctTCGTACTCGGCCACGactggtaattt SEQ ID NO: 27 27989ttGAAGTTGCAaTAAGCTttctctcgct SEQ ID NO: 28 27990acTTGCTGGTCGATCATGTTggccactc SEQ ID NO: 29 27991aaGTAGTTGAAGTTGCAataagctttct SEQ ID NO: 30 27992tgGTCGATCATGTTGGCcactcttgttt SEQ ID NO: 31 28004aaCGAGAATGAAGGAATGAAgaatatga SEQ ID NO: 32 28005atACCATGGTTGGTAAGtcatttatttt SEQ ID NO: 33 28021ccAACGAGgAATGATAGAtaaacaagag SEQ ID NO: 34 28022caGTCACAGTTcTAAAAGtctatggtgt SEQ ID NO: 35 28023tgTGACTGGACcAACGAGgaatgataga SEQ ID NO: 36 28024tcTAAAAGTCTATGGTGttccttacatt SEQ ID NO: 37 28025cgCCGGAGAAAGAGAGAGCTttgaggga SEQ ID NO: 38 28026tgGTTGTCGCTATGGACcagcgtagcaa SEQ ID NO: 21 28035ctTAAACGGTGGTTgTGCGCTcggatca SEQ ID NO: 40 28036tcGGAGATATAAGGGCTGCGattcctaa SEQ ID NO: 41 28039tcTCCGATctTAAACGGTGGTTgtgcgc SEQ ID NO: 42 28040atAAGGGCTGCGATTCCtaagcattgtt SEQ ID NO: 43 28051agATGGCCCAGAAAAGGgttccttgggc SEQ ID NO: 44 28052cgTACTCGGCCACGactggtaatttaat SEQ ID NO: 45 28053ttGAAGTTGCAaTAAGCTttctctcgct SEQ ID NO: 28 28054acTTGCTGGTCGATCGTGTTggccactc SEQ ID NO: 47 28055aaGTAGTTGAAGTTGCAataagctttct SEQ ID NO: 30 28056tgGTCGATCGTGTTGGCcactcttgttt SEQ ID NO: 49

Example 3: Evaluation of Zinc Finger Nuclease Cleavage of FAD3 Genes

Construct Assembly

Plasmid vectors containing ZFN expression constructs of the exemplaryzinc finger nucleases, which were identified using the yeast assay, asdescribed in Example 2, were designed and completed using skills andtechniques commonly known in the art. Each zinc finger-encoding sequencewas fused to a sequence encoding an opaque-2 nuclear localization signal(Maddaloni et al. (1989) Nuc. Acids Res. 17(18):7532), that waspositioned upstream of the zinc finger nuclease.

Next, the opaque-2 nuclear localization signal::zinc finger nucleasefusion sequence was paired with the complementary opaque-2 nuclearlocalization signal::zinc finger nuclease fusion sequence. As such, eachconstruct included a single open reading frame comprised of two opaque-2nuclear localization signal::zinc finger nuclease fusion sequencesseparated by the 2A sequence from Thosea asigna virus (Mattion et al.(1996) J. Virol. 70:8124-8127). Expression of the fusion proteins wasdriven by a relatively strong constitutive promoter such as a promoterderived from the Cassava Vein Mosaic Virus (CsVMV) promoter and flankedby the Agrobacterium tumefaciens ORF23 3′UnTranslated Region (AtuORF233′UTR).

The vectors were assembled using the IN-FUSION™ Advantage Technology(Clontech, Mountain View, Calif.). Restriction endonucleases wereobtained from New England BioLabs (NEB; Ipswich, Mass.) and T4 DNALigase (Invitrogen) was used for DNA ligation. Plasmid preparations wereperformed using NUCLEOSPIN® Plasmid Kit (Macherey-Nagel Inc., Bethlehem,Pa.) or the Plasmid Midi Kit (Qiagen) following the instructions of thesuppliers. DNA fragments were isolated using QIAquick Gel ExtractionKit™ (Qiagen) after agarose Tris-acetate gel electrophoresis. Coloniesof all assembled plasmids were initially screened by restrictiondigestion of miniprep DNA. Plasmid DNA of selected clones was sequencedby a commercial sequencing vendor (Eurofins MWG Operon, Huntsville,Ala.). Sequence data were assembled and analyzed using the SEQUENCHER™software (Gene Codes Corp., Ann Arbor, Mich.). Before delivery to B.napus protoplasts, Plasmid DNA was prepared from cultures of E. coliusing the Pure Yield Plasmid Maxiprep System® (Promega Corporation,Madison, Wis.) or Plasmid Maxi Kit® (Qiagen, Valencia, Calif.) followingthe instructions of the suppliers.

The resulting eleven plasmid constructs; pDAB107824 (ZFNs28025-2A-28026), pDAB107815 (ZFNs 27961-2A-27962), pDAB107816 (ZFNs27969-2A-27970), pDAB107817 (ZFNs 27973-2A-27974), pDAB107825 (ZFNs28035-2A-28036), pDAB107826 (ZFNs 28039-2A-28040), pDAB107818 (ZFNs27987-2A-27988), pDAB107827 (ZFNs 28051-2A-28052), pDAB107821 (ZFNs28004-2A-28005), pDAB107819 (ZFNs 27989-2A-27990), pDAB107828 (ZFNs28053-2A-28054) (FIG. 3), pDAB107829 (ZFNs 28055-2A-28056) (FIG. 4),pDAB107820 (ZFNs 27991-2A-27992), pDAB107822 (ZFNs 28021-2A-28022) andpDAB107823 (ZFNs 28023-2A-28024) were confirmed via restriction enzymedigestion and via DNA sequencing.

Preparation of DNA for Transfection

Plasmid DNA of the above described vectors was sterilized byprecipitation, washed in 100% (v/v) ethanol, and dried in a laminar flowhood. The DNA pellet was suspended in 30 μL of sterile double-distilledwater at a final concentration of 0.7 μg/μl for transfection intoprotoplast cells as described below. The preparation of the plasmid DNAwas undertaken to result in supercoiled plasmid DNA for transienttransfection and linearized plasmid DNA for stable transfection. Theaddition of carrier DNA (e.g. fish-sperm DNA) to the transformingplasmid was not required for the transient transfection of protoplastcells. For transient studies about 30 μg of plasmid DNA per 10⁶protoplasts was used per transformation.

Transfection

Transfection of Brassica napus L. var. DH10275 was completed asdescribed in Spangenberg et al., (1986) Plant Physiology 66: 1-8, themedia formulations are described in Spangenberg G. and Protrykus I.(1995) Polyethylene Glycol-Mediated Direct Gene Transfer in TobaccoProtoplasts. In: Gene Transfer to Plants. (Protrykus I. and SpangenbergG. Eds.) Springer-Verlag, Berlin. Brassica napus seeds were surfacesterilized in 70% ethanol. The seeds were immersed in 12 mL of the 70%ethanol solution and mixed by gently rocking the cocktail for 10minutes. The 70% ethanol solution was removed by decanting the solutionand exchanged with a seed sterilization solution of 1% w/v calciumhypochlorite and 0.1% v/v Tween-20. The seeds were immersed in the seedsterilization solution and mixed by gently rocking the cocktail for 25minutes. The seed sterilization solution was decanted and the sterilizedseeds were rinsed three times in 50 mL of sterile water. Finally, theseeds were transferred to a sterile 80 mm Whatman filter paper Disc®(Fisher-Scientific, St. Louis, Mo.) that had been laid within a Petridish and the seeds were lightly saturated with sterile water. The Petridish was sealed with Parafilm® (Fisher-Scientific, St. Louis, Mo.) andthe plates were incubated at 25° C. under complete darkness for one totwo days. After signs of seedling emergence were observed from theseeds, the seedlings were transferred to Petri dish containingsolidified GEM medium to encourage further seed germination. Theseedlings were incubated on the GEM medium at 25° C. for four to fivedays.

A volume of liquid PS medium (about 10 mL) was decanted into a sterilePetri dish. Using sterile forceps and a scalpel, an aerial portion ofthe four to five day old seedling in the 4-leaf stage of growth anddevelopment, was removed and discarded. Hypocotyl segments in lengths of20-40 mm were determined to produce the highest population of small,cytoplasmic-rich protoplasts. The hypocotyl segments were asepticallyexcised and transferred to liquid PS medium. The excised hypocotylsegments were grouped together and cut transversely into 5-10 mmsegments. Next, the hypocotyl segments were transferred to fresh PSmedium and incubated at room temperature for 1 hour. The plasmolysedhypocotyls were transferred to a Petri dish containing enzyme solution.Care was taken to immerse all of the hypocotyl segments into thesolution. The Petri dishes were sealed with Parafilm® and incubatedovernight for sixteen to eighteen hours at 20-22° C. with gentlerocking.

Protoplast cells were released from the hypocotyl segments. Theovernight hypocotyl digests were gently agitated to release protoplastsinto the enzyme solution. The Petri dish was angled slightly to aid thetransfer of the digesting suspension of enzyme solution and plantdebris. Using a 10 mL pipette the digesting suspension was transferredto a sterilized protoplast filtration (a filter of 100 micron mesh) unitto further separate the protoplasts from the plant debris. Thefiltration unit was tapped gently to release the excess liquid that hadbeen caught in the sieve. The protoplast suspension, about 8 to 9 mL,was gently mixed and distributed into 14 mL sterile plasticround-bottomed centrifuge tubes. Each suspension was overlaid with 1.5mL of W5 solution. The W5 solution was carefully dispensed over theprotoplast suspension at an angle and dispensed drop-by-drop withminimal agitation. The addition of the W5 solution to the protoplastsuspension resulted in the production of a protoplast rich interface.This interface was collected using a pipette. Next, the collectedprotoplasts were transferred into a new 14 mL centrifuge tube, andgently mixed. The yield or obtained protoplasts were determined using ahaemocytometer to determine the number of protoplasts per milliliter.The method was repeated, wherein leaf tissue was digested to producemesophyll protoplasts.

Next, W5 solution was added to a volume of 10 mL and the protoplastswere pelleted at 70 g, before removing the W5 solution. The remainingprotoplast suspension was resuspended by gentle shaking. Each tubecontaining the protoplast suspension was filled with 5 mL of W5 solutionand incubated at room temperature from one to four hours. The protoplastsuspensions were pelleted at 70 g, and all of the W5 solution wasremoved. Next, 300 μL of transformation buffer was added to each of thepelleted protoplast suspensions which contained the isolatedprotoplasts. To each of the tubes, 10 μg of plasmid DNA was added to theprotoplast suspensions. The plasmid DNA included the zinc fingernuclease constructs described above. Next, 300 μL of pre-warmed PEG 4000solution was added to the protoplast suspension and the tubes weregently tapped. The protoplast suspensions and transformation mixture wasallowed to incubate at room temperature for fifteen minutes without anyagitation. An additional 10 mL of W5 solution was added to each tube insequential aliquots of 1 mL, 1 mL, 1 mL, 2 mL, 2 mL, and 3 mL withgentle inversion of the tubes between each addition of W5 solution. Theprotoplasts were pelleted by spinning in a centrifuge at 70 g. All ofthe W5 solution was removed leaving a pure protoplast suspension.

Next, 0.5 mL of K3 medium was added to the pelleted protoplast cells andthe cells were resuspended. The resuspended protoplast cells were placedin the center of a Petri dish and 5 mL of K3 and 0.6 mL Sea Plaque™agarose (Cambrex, East Rutherford, N.J.) in a 1:1 concentration. ThePetri dishes were shaken in a single gentle swirling motion and left toincubate for 20-30 minutes at room temperature. The Petri dishes weresealed with Parafilm® and the protoplasts were cultured for twenty-fourhours in complete darkness. After the incubation in darkness, the Petridishes were cultured for six days in dim light (5 μMol m⁻² s⁻¹ of OsramL36 W/21 Lumilux white tubes). After the culture step, a sterile spatulawas used to divide the agarose containing the protoplasts intoquadrants. The separated quadrants were placed into a 250 mL plasticculture vessel containing 20 mL of A medium and incubated on a rotaryshaker at 80 rpm and 1.25 cm throw at 24° C. in continuous dim light for14 days and then analyzed to determine the level of activity of each ZFNconstruct.

Genomic DNA Isolation from Canola Protoplasts

Transfected protoplasts were supplied in individual 1.5 or 2.0 mLmicrofuge tubes. The cells were pelleted at the base of the tube in abuffer solution. DNA extraction was carried out by snap freezing thecells in liquid nitrogen followed by freeze drying the cells, for about48 hours in a Labconco Freezone 4.5® (Labconco, Kansas City, Mo.) at−40° C. and about 133×10⁻³ mBar pressure. The lyophilized cells weresubjected to DNA extraction using the DNeasy® (QIAGEN, Carlsbad, Calif.)plant kit following manufactures instructions, with the exception thattissue disruption was not required and the protoplast cells were addeddirectly to the lysis buffer.

Testing of FAD3A and FAD3C ZFN's for Genomic DNA Sequence Cleavage inCanola Protoplasts

The design of the ZFN target sites within the FAD3A and FAD3C gene locuswere clustered, so that multiple pairs of ZFN were design to overlappingtarget sites. The clustering of ZFN target sites enabled PCR primers tobe designed that would amplify the flanking genomic sequence from allFAD3A and FAD3C gene family members within a 100 bp window so as toencompass all of the overlapping ZFN target sites. As such, the Illuminashort read sequence technology could be used to assess the integrity ofthe target ZFN site of the transfected protoplasts. In addition, the PCRprimers designed needed to include specific nucleotide bases that wouldattribute sequence reads to the specific gene member of the FAD3A andFAD3C gene family. Therefore, all of the PCR primers would be requiredto bind 5-10 nucleotides away from any ZFN target cut site asnon-homologous end joining (NHEJ) activity is known to cause smalldeletions that could remove a priming site to inhibit amplification andtherefore distort the assessment of NHEJ activity.

Primers were designed to bind to all of the ZFN target loci for theFAD3A and FAD3C gene families (Table 5) and were empirically tested foramplification of all gene family members through Sanger based sequencingof PCR amplification products. In several instances primers could not bedeveloped that would distinguish all gene family members (Table 6),however in all instances the target gene sequences of FAD3A or FAD3C,could be distinguished. Following PCR primer design custom DNA barcodesequences were incorporated into the PCR primers that were used todistinguish the different ZFN target loci and identify specific sequencereads to a transfection and ZFN (Tables 5 and 6).

TABLE 5 Amplification performance of the designed PCR primers on theFAD3 gene families. An “X” indicates gene copy detection specificity,“+” indicates that at the specific locus in question the sequence readsdesigned by the two primers were unable to be distinguished and an “N/A”indicates that the locus was unable to be amplified from those specificgene copies ZFN FAD Gene Copy Locus FAD3A FAD3C FAD3A′ FAD3C′ FAD3A″FAD3C″ Locus 1 X X X X X X Locus 2 X X X X N/A X Locus 3 X X + + X XLocus 4 X X X X + + Locus 5 X X N/A N/A N/A N/A Locus 6 X X X X X XLocus 7 X X X X X X

TABLE 6 Primer sequences designed for FAD3 ZFN assessment of activity.Primers include custom barcodes, along with both requisite illuminaadaptor sequences for construction of illumina library forsequencing-by-synthesis analysis. Purchased primer was the sumof all three columns presented SEQ Locus ID ID NO:Illumina Adaptor Primer Sequence Barcode Locus PrimerFAD3_ZFN_Locus1A_F3 50 ACACTCTTTCCCTACACGACGCTCTTCCGATCTACGTACCTTTCTTCACCACATTYCA FAD3_ZFN_Locus1B_F3 51ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGTAC CCTTTCTTCACCACATTYCAFAD3_ZFN_Locus2C_F1 52 ACACTCTTTCCCTACACGACGCTCTTCCGATCTCTGAC GATGGTTGTCGCTATGGACC FAD3_ZFN_Locus3D_F1 53ACACTCTTTCCCTACACGACGCTCTTCCGATCTTGACT CG AAAGGTTTGATCCRAGCGFAD3_ZFN_Locus3E_F1 54 ACACTCTTTCCCTACACGACGCTCTTCCGATCTGACTG CGAAAGGTTTGATCCRAGCG FAD3_ZFN_Locus3F_F1 55ACACTCTTTCCCTACACGACGCTCTTCCGATCTACTGA CG AAAGGTTTGATCCRAGCGFAD3_ZFN_Locus4G_F1 56 ACACTCTTTCCCTACACGACGCTCTTCCGATCTGCTAG CCGTGTATTTTGATAGCTGGTTC FAD3_ZFN_Locus4H_F1 57ACACTCTTTCCCTACACGACGCTCTTCCGATCTCTAGC CC GTGTATTTTGATAGCTGGTTCFAD3_ZFN_Locus5J_F1 58 ACACTCTTTCCCTACACGACGCTCTTCCGATCTTAGCT GGAGCTTCTCAGACATTCCTCT FAD3_ZFN_Locus6K_F1 59ACACTCTTTCCCTACACGACGCTCTTCCGATCTTCAGT GT TTATTTGCCCCAAGCGAGAGFAD3_ZFN_Locus6L_F1 60 ACACTCTTTCCCTACACGACGCTCTTCCGATCTCAGTC GTTTATTTGCCCCAAGCGAGAG FAD3_ZFN_Locus6M_F1 61ACACTCTTTCCCTACACGACGCTCTTCCGATCTAGTCA GT TTATTTGCCCCAAGCGAGAGFAD3_ZFN_Locus6N_F1 62 ACACTCTTTCCCTACACGACGCTCTTCCGATCTGTCAG GTTTATTTGCCCCAAGCGAGAG FAD3_ZFN_Locus7P_F3 63ACACTCTTTCCCTACACGACGCTCTTCCGATCTGTACG AC TTCAACTACTTGCTGGTCSATFAD3_ZFN_Locus7Q_F3 64 ACACTCTTTCCCTACACGACGCTCTTCCGATCTTACGT ACTTCAACTACTTGCTGGTCSAT FAD3_ZFN_Locus1A_R1 65CGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCTACG TA CGTTCACATTGSTRCGYTGGFAD3_ZFN_Locus1B_R1 66 CGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCTCGT ACCGTTCACATTGSTRCGYTGG FAD3_ZFN_Locus2C_R1 67CGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCTCTG AC CCGATCTTAAACGGYGGTTGTFAD3_ZFN_Locus3D_R1 68 CGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCTTGA CTTAGCTCATGGATCTCAAAGGACT FAD3_ZFN_Locus3E_R1 69CGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCTGAC TG TAGCTCATGGATCTCAAAGGACTFAD3_ZFN_Locus3F_R1 70 CGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCTACT GATAGCTCATGGATCTCAAAGGACT FAD3_ZFN_Locus4G_R_uni 71CGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCTGCT AG TTAAATTACCAGTCGTGGCCFAD3_ZFN_Locus4H_R_uni 72 CGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCTCTA GCTTAAATTACCAGTCGTGGCC FAD3_ZFN_Locus5J_R2 73CGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCTTAG CT CTTTTTTCTTCGATKCTAAAGATTFAD3_ZFN_Locus6K_R1 74 CGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCTTCA GTCTGTGACTGGACCAACGAGG FAD3_ZFN_Locus6L_R1 75CGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCTCAG TC CTGTGACTGGACCAACGAGGFAD3_ZFN_Locus6M_R1 76 CGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCTAGT CACTGTGACTGGACCAACGAGG FAD3_ZFN_Locus6N_R1 77CGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCTGTC AG CTGTGACTGGACCAACGAGGFAD3_ZFN_Locus7P_R1 78 CGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCTGTA CGACTTACAATGTAAGGAACRCCRTA FAD3_ZFN_Locus7Q_R1 79CGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCTTACGT ACTTACAATGTAAGGAACRCCRTA

Following DNA extraction of canola protoplasts transfected with the ZFN,PCR amplification of the target ZFN loci was performed to generate therequisite loci specific DNA molecules in the correct format for Illuminabased sequencing by synthesis technology. Each assay was optimised towork on 25 ng starting DNA (about 12,500 cell equivalents of theBrassica napus genome). Multiple reactions were performed, per sample toprovide the coverage required to assess NHEJ efficiency and specificityat the appropriate level, about sixteen PCR reactions equivalent to200,000 copies of the Brassica napus genome taken from individualprotoplasts. PCR amplification master-mixes were made for all samples tobe tested with the same assay and one reaction, performed in triplicate,was assayed using a quantitative PCR method that was used to determinethe optimal number of cycles to perform on the target tissue, to ensurethat PCR amplification had not become reagent limited and was still inan exponential amplification stage. The experimentation with thenecessary negative control reactions was performed in 96 well formatusing a MX3000P Thermocycler® (Stratagene, LaJolla, Calif.).

From the output gathered from the quantitative PCR platform, therelative increase in fluorescence was plotted from cycle-to-cycle andthe cycle number was determined per assay that would deliver sufficientamplification, while not allowing the reaction to become reagentlimited, in an attempt to reduce over cycling and the amplification ofcommon transcripts or molecules. The unused master mix, remained on iceuntil the quantitative PCR analysis was concluded and the cycle numberdetermined and was then aliquoted into the desired number of reactiontubes (about 16 per ZFN assay) and the PCR reaction was performed.

Following amplification, samples for a single ZFN locus were pooledtogether and 200 μL of pooled product per ZFN was cleaned using theMinElute PCR purification Kit® (Qiagen) following manufacturer'sinstructions. To enable the sample to be sequenced using the Illuminashort read technology additional paired end primers were required to beattached by amplification onto the generated fragments. This wasachieved by PCR amplification using primers that would be, in partcomplementary to the sequence added in the first round of amplification,but also contain the paired end sequence required. The optimal number ofPCR cycles to perform, that would add the paired end sequences withoutover amplifying common fragments to the template was again determinedusing a sample pass through a quantitative PCR cycle analysis, asdescribed previously.

Following PCR amplification, the generated product was cleaned using aMinElute Column® (Qiagen) following manufacturer's instructions and wasresolved on a 2.5% agarose gel. DNA fragments visualised using Syber®Safe (Life Technologies, Carlsbad, Calif.) as bands of the correct sizewere gel extracted to remove any residual PCR generated primer-dimer orother spurious fragments, the DNA was extracted from the gel slice usinga MinElute gel extraction Kit® (Qiagen) following manufacturer'sinstructions. After completion of the gel extraction an additional cleanup of the DNA was performed using AMPure magnetic Beads®(Beckman-Coulter, Brea, Calif.) with a DNA to bead ratio of 1:1.7. TheDNA was then assessed for concentration using a quantitative PCR basedlibrary quantification kit for Illumina sequencing (KAPA) with a1/40,000 and a 1/80,000 dilution and with the reaction being performedin triplicate. Based on the quantitative PCR results the DNA was dilutedto a standard concentration of 2 nM and all libraries were combined forDNA sequencing. The samples were prepared for sequencing using a cBotcluster generation Kit® (Illumina, San Diego, Calif.) and were sequencedon an Illumina GA2x® with 100 bp paired-end sequencing reads followingmanufacturer's instructions.

Method of Data Analysis for Detection of Non-Homologous End Joining atTarget Zinc Finger Sites

Following completion of the sequencing reaction and primary data callingperformed using the Illumina bioinformatic pipeline for base calling,full analysis was performed to identify deleted bases at the target ZFNsite in each instance. A custom PERL script was designed to extract andsort barcodes from DNA sequences computationally following a list ofinput sequences. The barcode had to match the reference sequence at aPhred score of greater than 30 to be accepted, to reduce misattributingsequence reads. After the sequence reads had been binned into thedifferent barcode groups that had been used, a quality filter was passedacross all sequences. The quality filter was a second custom developedPERL script. Sequence reads were excluded if there were more than threebases called as “N”, or if the median Phred score was less than 20, orif there were 3 consecutive bases with a Phred score of less than 20, orif the sequence read was shorter than 40 bp in length. The remainingsequences were merged where both of the paired sequence reads wereavailable using the NextGENe® (SoftGenetics, State College, Pa.)package. The remaining merged sequence reads were then reduced to acollection of unique sequence reads using a third custom PERL scriptwith a count of the number of redundant sequences that had beenidentified recorded on the end of the remaining sequence identifier. Theunique sequence reads were then aligned to the FAD3 reference sequenceusing the NextGENe® software that created a gapped FASTA aligned file.

Using the gapped FASTA file a conversion of the gapped base positionnumber to the input reference was performed using a fourth custom PERLscript. This enabled bases that discriminate the different gene familymembers (either homoeologous or paralogous sequence variation betweenthe different gene family members) to be identified in the assembleddata. Once the conversion of base numbering had been performed it waspossible to generate haplotype reports for each unique sequence readsand assign the reads to specific gene family members. Once the reads hadbeen grouped by gene a 10 bp window was identified and assessed thatsurrounded the ZFN target site. The number of sequences with deletionswas recorded per gene along with the number of missing bases.

The data was then graphically displayed as a multiple line graph, withthe number of sequences with 1 through 10 bases deleted at the targetZFN site per 10,000 sequence reads. This analysis was performed for allZFN transfections along with control transfections. In severalinstances, repeats in the native DNA sequence lead to an increase insequencing error in the target ZFN site, such an error can be commonlyseen as an increase in the prevalence of single base deletions that werereported in all samples, both transfected with ZFN or controls.

From these results highest level of ZFN activity at a FAD3A and FAD3Ctarget site was observed as determined by the greater activity of NHEJ.The ZFNs which were encoded on plasmid pDAB107828 (i.e., ZFN28053 and28054) and pDAB107829 (i.e., ZFN28055 and 28056) were selected for inplanta targeting of an Engineered Transgene Integration Platform (ETIP)given its characteristics of significant genomic DNA cleavage activityand minimal non-target activity.

Example 4: DNA Constructs for Engineered Transgene Integration Platform(ETIP) Canola Plant Lines

The plasmid vector constructs described below were built using methodsand techniques commonly known by one with skill in the art. Theapplication of specific reagents and techniques described within thisparagraph are readily known by those with skill in the art, and could bereadily interchanged with other reagents and techniques to achieve thedesired purpose of building plasmid vector constructs. The restrictionendonucleases were obtained from New England BioLabs (NEB; Ipswich,Mass.). Ligations were completed with T4 DNA Ligase (Invitrogen,Carlsbad, Calif.). Gateway reactions were performed using GATEWAY® LRCLONASE® enzyme mix (Invitrogen) for assembling one entry vector into asingle destination vector. IN-FUSION™ reactions were performed usingIN-FUSION™ Advantage Technology (Clontech, Mountain View, Calif.) forassembling one entry vector into a single destination vector Plasmidpreparations were performed using NUCLEOSPIN® Plasmid Kit(Macherey-Nagel Inc., Bethlehem, Pa.) or the Plasmid Midi Kit® (Qiagen)following the instructions of the suppliers. DNA fragments were isolatedusing QIAquick Gel Extraction Kit™ (Qiagen) after agarose Tris-acetategel electrophoresis. Colonies of all assembled plasmids were initiallyscreened by restriction digestion of miniprep DNA. Plasmid DNA ofselected clones was sequenced by a commercial sequencing vendor(Eurofins MWG Operon, Huntsville, Ala.). Sequence data were assembledand analyzed using the SEQUENCHER™ software (Gene Codes Corp., AnnArbor, Mich.).

Control Vectors

A control vector was used to develop a Fluorescence Activated CellSorting (FACS) cell based sorting method. Standard cloning methods wereused in the construction of a control vector, pDAS000031 (FIG. 10:T-strand insert as SEQ ID NO:85) including two gene expressioncassettes. The first gene expression cassette contained the Cauliflowermosaic virus 19s promoter (CaMV 19S promoter; Shillito, et al., (1985)Bio/Technology 3; 1099-1103):: hygromycin resistance gene (hph(HygR);U.S. Pat. No. 4,727,028):: and the Agrobacterium tumefaciens OpenReading Frame 1 3′UnTranslated Region (AtORF1 terminator; Huang et al.,(1990) J. Bacteriol. 1990172:1814-1822). The second gene expressioncassette contained the Arabidopsis thaliana Ubiquitin 10 promoter(AtUbi10 promoter; Callis, et al., (1990) J. Biol. Chem., 265:12486-12493):: dsRED (dsRED(D); U.S. Pat. No. 6,852,849) and an intronfrom Arabidopsis (intron #1; GenBank: AB025639.1):: Agrobacteriumtumefaciens Open Reading Frame 23 3′UnTranslated Region (AtORF23terminator; U.S. Pat. No. 5,428,147) as an in-frame fusion with a transorientation (e.g., head to head orientation). The plasmid vector wasassembled using the IN-FUSION™ Advantage Technology (Clontech, MountainView, Calif.).

Example 5: Generation of ETIP Canola Plant Lines Transformation ofBrassica napus

The ETIP constructs for the FAD3A and FAD3C site specific construct(pDAS000271-pDAS000275) and accompanying ZFN (pDAB107828 and 107829) andthe control the DS-Red control construct (pDAS000031) are previouslydescribed in Example 4. These binary vectors are transformed intoAgrobacterium tumefaciens strain GV3101: PM90. Transformation ofBrassica napus protoplast cells is completed using the transfectionprotocol described in Example 3 with some modification.

The modifications to the protocol include the use of sodium alginateinstead of Sea Plaque™ agarose. The transfection experiments in whichboth the ZFN construct and the ETIP construct are co-delivered intoBrassica napus protoplast cells are completed at DNA concentrationscomprising a 5:1 molar ratio of plasmid DNA. The other ETIP and controlplasmid constructs are transformed at concentrations of 30 μg of plasmidDNA.

Additional modifications to the protocol include the propagation ofwhole plants from the transformed protoplast cells in medium containing1.5 mg/mL of hygromycin. The propagation of whole plants requires thatthe A medium is replaced every two weeks and the growth of theprotoplast-derived colonies is monitored. After the protoplast-derivedcolonies grow to approximately 2-3 mm in diameter, the colonies aretransferred into individual wells of a 12-well Costar® plate (FisherScientific, St. Louis, Mo.) containing solidified MS morpho medium. Theplates are incubated for one to two weeks at 24° C. under continuous dimlight until the calli proliferate to a size of 8-10 mm in diameter.After the protoplast cells reach a diameter of 1-2 cm in diameter, theprotoplast cells are transferred to individual 250 mL culture vesselscontaining MS morpho medium. The vessels are incubated at 24° C. under16 h light (20 μMol m⁻² s⁻¹ of Osram L36 W/21 Lumilux white tubes) and 8h dark conditions. Within one to two weeks, multiple shoots are visible.The shoots are transferred into 250 mL culture vessels containing MSmedium after they reach a length of 3-4 cm. The 250 mL culture vesselsare incubated at 24° C. under 16 h light (20 μMol m⁻² s⁻¹ of Osram L36W/21 Lumilux white tubes) and 8 h dark conditions. The shoots aremaintained in the culture vessels until they develop into plantlets atwhich time they are transferred to a greenhouse to grow to maturity.

Example 6: Molecular Confirmation of Integration of T-DNAS ContainingETIPS in Canola

Genomic DNA is extracted from leaf tissue of all putative transgenicplants using a DNeasy 96 Plant DNA extraction Kit™ or a DNeasy PlantMini Kit™ (Qiagen). The genomic DNA from each plant is analyzed by PCRusing primers designed to amplify virC from pTiC58 Forward (SEQ ID NO:88CGAGAACTTGGCAATTCC) and pTiC58 Reverse (SEQ ID NO:89 TGGCGATTCTGAGATTCC)to test for persistence of A. tumfaciens, primers designed to amplifyactin from B. napus; Actin Forward (SEQ ID NO:90 GACTCATCGTACTCTCCCTTCG)and Actin Reverse (SEQ ID NO:91 GACTCATCGTACTCTCCCTTCG) to check thequality of the genomic DNA. Primers are designed to amplify the hphgene; HPH Forward (SEQ ID NO:92 TGTTGGTGGAAGAGGATACG) and HPH Reverse(SEQ ID NO:93 ATCAGCAGCAGCGATAGC) encoded by the ETIP. Plants that donot give a product from virC primers, and that produce amplicons of thecorrect size when amplified with primers to actin and hph are confirmedas transgenic.

A second screen is completed, where gDNA from each transgenic plant isanalysed by PCR using five sets of primers designed to amplify thebinary vector outside of the T-DNA region [(1F SEQ ID NO:94ATGTCCACTGGGTTCGTGCC; 1R SEQ ID NO:95 GAAGGGAACTTATCCGGTCC) (2F SEQ IDNO:96 TGCGCTGCCATTCTCCAAAT; 2R SE ID NO:97 ACCGAGCTCGAATTCAATTC) (3F SEQID NO:98 CCTGCATTCGGTTAAACACC; 3R SEQ ID NO:99 CCATCTGGCTTCTGCCTTGC) (4FSEQ ID NO:100 ATTCCGATCCCCAGGGCAGT; 4R SEQ ID NO:101GCCAACGTTGCAGCCTTGCT) (5F SEQ ID NO:102 GCCCTGGGATGTTGTTAAGT; 5R SEQ IDNO:103 GTAACTTAGGACTTGTGCGA)]. Plants from which PCR products of thecorrect and expected size are amplified with primer sets 3 and 4 areconsidered to have backbone integration.

DNA from plants with no backbone integration is purified from 20 g ofleaf tissue using a modified CTAB method (Maguire et al. (1994) PlantMolecular Biology Reporter, 12(2): 106-109). The isolated gDNA isdigested with several restriction enzymes and 10 μg of gDNA is separatedby electrophoresis on an agarose gel and transferred to membrane using astandard Southern blotting protocol. Membranes are probed using the DIGEasy Hyb System™ (Roche, South San Francisco, Calif.) following themanufacturer's instructions. Probes to each expression cassette to theELP and to an endogenous control gene, actin, are amplified from theETIP construct using the following primers: (IPT-F SEQ ID NO:104TCTCTACCTTGATGATCGG; IPT-R SEQ ID NO:105 AACATCTGCTTAACTCTGGC; dsRED-FSEQ ID NO:106 ATGGCTTCATCTGAGAACG; dsRED-R SEQ ID NO:107TTCCGTATTGGAATTGAGG; PAT-F SEQ ID NO:108 TTGCTTAAGTCTATGGAGGCG; PAT-RSEQ ID NO:109 TGGGTAACTGGCCTAACTGG; ELP-F SEQ ID NO:110ATGATATGTAGACATAGTGGG; ELP-R SEQ ID NO:111 AGGGTGTAAGGTACTAGCC; Hph-FSEQ ID NO:112 TGTTGGTGGAAGAGGATACG; Hph-R SEQ ID NO:113,ATCAGCAGCAGCGATAGC; actin-F SEQ ID NO:114 GTGGAGAAGAACTACGAGCTACCC;actin-R SEQ ID NO:115 GACTCATCGTACTCTCCCTTCG).

The ETIP sequence is amplified and sequenced from all plants containingonly a single copy of the ETIP. The sequence of each T-DNA insert isanalyzed by direct sequencing of PCR products using the ABI3730xI™(Applied Biosystems, Life Teachnologies). The T-DNA insert was amplifiedfrom genomic DNA, using Phusion Hot Start II Polymerase™ (Finnzymes,Thermo Fisher Scientific). The amplification reactions of the T-DNA arecompleted with multiple primer pairs to amplify overlapping sequences ofapproximately 2 Kbp in length. Each PCR product is sequenced withmultiple primers to ensure complete coverage. The PCR reactions aretreated with shrimp alkaline phosphatase and exonuclease I (AppliedBiosystems, Life Technologies) to inactivate excess primer prior to thesequencing PCR reaction. The sequences flanking the T-DNA insert of eachsingle copy ETIP line are identified by digestion of purified genomicDNA with eight restriction endonucleases separately followed by ligationof double-stranded adapters specific for the overhangs created by therestriction endonucleases. Following this ligation step a PCR isperformed with a biotinylated primer to either the 3′ or 5′ end of theETIP and a primer to each adapter. The PCR products are captures andcleaned on Ampure Solid Phase Reversible Immobilization (SPRI) Beads™(Agencourt Bioscience Corporation, Beckman Coulter Company). A nestedPCR is performed and all products are sequenced using ABI SangerSequencing and Big Dye Terminator v3.1 Cycle™ sequencing protocol(Applied Biosystems, Life Technologies). Sequence data are assembled andanalyzed using the SEQUENCHER™ software (Gene Codes Corp., Ann Arbor,Mich.).

Results of ETIP Transgenic Canola Transformed with Zinc Finger Nucleaseand PDAS000271-PDAS000275 ETIP Constructs

The transgenic Brassica napus events which are produced viatransformation of ETIP and ZFN constructs result in the integration of asingle copy, full length T-strand insertion of the ETIP polynucleotidesequence from pDAS000273 or pDAS275 within the FAD3A locus, and frompDAS000271, pDAS000272 or pDAS000274 into the FAD3C locus. Three to fourevents are fully characterized and confirmed to contain the integratedETIP. The confirmation is completed using an in-out PCR amplificationmethod, and further validated via Southern blot. The selected T₀ eventsare grown to the T₁ stage of development. The T₁ plants are rescreenedto determine the zygosity of the integrated T-strand. Screened eventsare categorized as homozygous, hemizygous, or null.

The homozygous events are used to produce protoplasts via the previouslydescribed method. The protoplasts are subsequently co-transformed with aZFN that is designed to target a zinc finger binding site which isincorporated within the ETIP sequence and a donor plasmid which shareshomology with specific regions of the ETIP. The ZFN cleaves the ETIPlocus and the donor plasmid is integrated within the genome of Brassicanapus cells via homology directed repair. As a result of the integrationof the donor plasmid, the partial DS-red transgene is repaired to a fulllength DS-red transgene. The expression of the now fully operationalDS-red transgene is used to sort protoplast cells with a FACS method.Putative transgenic plants are sorted using the FACS method described inExample 7 and the isolated protoplasts are regenerated into matureplants. The integration of the donor plasmid is confirmed within theETIP-targeted plants using molecular confirmation methods. As such, theETIP locus serves as a site-specific locus for gene targeted integrationof a donor polynucleotide sequence.

Example 7: FACS Based Sorting of Protoplast Cells

Brassica napus protoplasts that were transfected with the DS-Red controlconstruct, pDAS000031, were sorted via FACS-mediated cell sorting usinga BD Biosciences Influx-Cell Sorter™ (San Jose, Calif.). The protoplastcells were isolated and transfected as described in Example 3. After thecells had been transfected with pDAS000031, the cells were sorted usingthe FACS sorter with the conditions described in Table 7.

TABLE 7 Conditions used for sorting protoplast cells transfected withpDAS000031 Parameters Drop frequency 6.1 KHz Nozzle diameter 200 μmSheath pressure 4 psi Recovery media W5 media Culture conditions Beadtype culture using sea-plaque agarose and sodium alginate Sort criteriaSorting based on chlorophyll autofluorescence, reporter gene expression(Ds-Red) Sort recovery (%) 50-75 Viability post sorting (%) >95

The protoplasts which expressed the DS-red transgene were sorted andisolated. The FACS isolated protoplasts were counted using the sorter.About 1×10⁵ to 1.8×10⁵ of cells were placed in a well of a 24-well microtiter plate on the first day after the FACS isolation. The cells weretransferred to a bead culture for 5 to 20 days. Similar conditions weretested, wherein about 1×10⁴ of cells were placed in a well of a 2 or4-well micro titer plate on the second day after the FACS isolation. Thevarious conditions that were tested resulted in the recovery of cells ata viability or 95-98% of the total isolated protoplast cells. The FACSsorted protoplast cells were transferred to a bead culture for 3-20days. The FACS sorted protoplast cells were regenerated into plants onmedia which contained 1.5 mg/mL of hygromycin using the above describedprotocol. The putative transgenic plants were confirmed to contain anintact T-strand insert from pDAS000031 via molecular confirmationprotocols.

The FACS sorting method is directly applicable to screen any fluorescenttransgene sequence and is used to isolate a proportion of Brassica napusprotoplast cells that are targeted with a fluorescent transgene viahomology mediated repair within a specific site in the ETIP regionwithin a genomic locus.

Example 8: Targeted Integration into and Disruption of Brassica napusOMEGA-3 Fatty Acid Desaturase (FAD3) Via NHEJ

Selection of Zinc Finger Binding Domains Specific to Fad3C and Fad3A

The transcribed regions for homoeologous Fad3 genes were identified andcharacterized, zinc finger nucleases that were designed to bind andcleave these sites for NHEJ-mediated targeting of a donor sequence. Zincfinger proteins (ZFPs) directed against DNA sequences from homeologuesof Fad3 sequences were designed and tested as described above. From theZFNs showing on-target activity, two zinc finger proteins were selectedthat cut the Fad3 target at high efficiency: ZFP 28051-2A-28052recognizes SEQ ID NO:2555′-gcccaaggaacCCTTTTCTGGGCCATcttcgTACTCGGCCACGactggtaatttaat-3′ and wasshown to specifically bind and cleave the Fad3C genomic locus. LikewiseZinc finger protein 28053-2A-28054 recognizes SEQ ID NO:2565′-agcgagagaaAGCTTAtTGCAACTTCaactacTTGCTGGTCGATCGTGTTggccactc-3′ and wasshown to specifically bind and cleave the Fad3A and Fad3C genomic locus.Exemplary target sites are shown in Table 8; nucleotides in the targetsite that are contacted by the ZFP recognition helices are indicated inuppercase letters; non-contact nucleotides are indicated in lowercase.Nucleotides in copies of Fad3 that differ from Fad3C are identified byunderlining. Nucleotides in the target sites that are contacted by theZFP recognition helices are shown in Table 8.

TABLE 8 Zinc Finger Protein Binding Sites specific to Fad3C(28051-2A-28052) or Fad3A and Fad3C (28053-2A-28054) 28051-SEQ ID NO: 257 

2A-28052 SEQ ID NO: SEQ ID NO: 45  

Fad3C 259 GCCCAAGGAACCCTTTTCTGGGCCATCTTCGTACTCGGC CACGACTGGTAATTTAATFad3A 260 GCCCAAGGAACCCTGTTCTGGGCTATCTTCGTACTCGGC CACGACTGGTAATTTAATFad3C′ 261 GCCCAAGGAACCCTTTTCTGGGCCATCTTCGTCCTCGGC CACGACTGGTAAAGTTTCFad3A′ 261 GCCCAAGGAACCCTTTTCTGGGCCATCTTCGTCCTCGGC CACGACTGGTAAAGTTTCFad3A″ 263 GCCCAAGGAACCCTTTTCTGGGCCATCTTCGTTCTTGGCC ACGACTGGTAAATTAAAFad3C″ 263 GCCCAAGGAACCCTTTTCTGGGCCATCTTCGTTCTTGGCC ACGACTGGTAAATTAAA28053- SEQ ID NO: 265 

2A-28054 SEQ ID NO: SEQ ID NO: 47  

Fad3C 256 AGCGAGAGAAAGCTTATTGCAACTTCAACTACTTGCTGG TCGATCGTGTTGGCCACTCFad3A 268 AGCGAGAGAAAGCTTATTGCAACTTCAACTACTTGCTGG TCGATCATGTTGGCCACTCFad3C′ 269 AGCGAGAGAAAGCTTATTGCAACTTCAACTACTTGCTGG TCCATAATGTTGGCCATTCFad3A′ 270 AGCGAGAGAAAGCTTATTGCAACTTCGACTACTTGCTGG TCCATAATGTTGGCAATTCFad3A″ 271 AGCGAGAGGAAGCTTATTGCAACTTCAACAACTTGCTGG TCCATAATGTTGGCCACTCFad3C″ 272 AGCGAGAGGAAGCTTATTGCAACTTCAACTACTTGCTGG TCCATAATGTTGGCCACTCDesign and Construction of Expression Vectors Encoding Zinc FingerNucleases Specific to Fad3C and Fad3A

The Fad3 zinc finger designs were incorporated into zinc fingerexpression vectors encoding a protein having at least one finger with aCCHC structure (U.S. Patent Publication No. 2008/0182332). Inparticular, the last finger in each protein had a CCHC backbone for therecognition helix. The non-canonical, zinc finger-encoding-sequenceswere fused to the nuclease domain of the type IIS restriction enzymeFokI (amino acids 384-579 of the sequence of Wah et al., (1998) Proc.Natl. Acad. Sci. USA 95:10564-10569) via a four amino acid ZC linker anda sop2 nuclear localization signal. The self-hydrolyzing 2A encodingnucleotide sequence from Thosea asigna virus (Szymczak et al., 2004) wasadded between the two ZFN fusion proteins. Expression of the ZFNs wasdriven by the strong constitutive promoter and 5′ untranslated region(UTR) from Cassava Vein Mosaic Virus (Verdaguer et al, Plant MolecularBiology 1996, 31(6); 1129-1139) and flanked by the 3′ UTR (including thetranscriptional terminator and polyadenylation site) from open readingframe 23 (ORF23) of Agrobacterium tumefaciens pTi15955 (Barker et al.,Plant Molecular Biology 1983, 2(6); 335-50).

The vectors were assembled using the IN-FUSION™ Advantage Technology(Clontech, Mountain View, Calif.). Restriction endonucleases wereobtained from New England BioLabs (NEB; Ipswich, Mass.) and T4 DNALigase (Invitrogen) was used for DNA ligation. Plasmid preparations wereperformed using NUCLEOSPIN® Plasmid Kit (Macherey-Nagel Inc., Bethlehem,Pa.) or the Plasmid Midi Kit™ (Qiagen) following the instructions of thesuppliers. DNA fragments were isolated using QIAquick Gel ExtractionKit™ (Qiagen) after agarose Tris-acetate gel electrophoresis. Coloniesof assembled plasmids were initially screened by restriction digestionof miniprep DNA. Plasmid DNA of selected clones was sequenced by acommercial sequencing vendor (Eurofins MWG Operon, Huntsville, Ala.).Sequence data were assembled and analyzed using the SEQUENCHER™ software(Gene Codes, Ann Arbor, Mich.). The resulting plasmid constructs:pDAB107827 (ZFN 28051-2A-28052, FIG. 13, SEQ ID NO:273) and pDAB107828(ZFN 28053-2A-28054, FIG. 14, SEQ ID NO:274) were confirmed viarestriction enzyme digestion and via DNA sequencing.

Design and Construction of “Donor” Vectors for NHEJ-Directed DNA Repair

Two strategies of integration of DNA into Fad3 were undertaken; genesplicing, where an expression cassette was integrated into a singleZFN-induced double-stranded break and gene-editing where a portion ofthe gene was removed by the use of two ZFN-induced double-strandedbreaks and an expression cassette was inserted to repair the gap.

For each integration method, gene splicing or gene-editing, two vectorswere constructed. The first encoded a turboGFP (tGFP) gene expressioncassette and the second encoded a gene expression cassette to conferresistance to the antibiotic hygromycin. The tGFP expression cassetteincluded the promoter, 5′ untranslated region and intron from theArabidopsis thaliana polyubiquitin 10 (UBQ10) gene (Norris et al, PlantMolecular Biology 1993, 21(5), 895-906) followed by the tGFP codingsequence (Evrogen, Moscow, Russia). The tGFP coding sequence wascodon-optimised for expression in dicot plants and the 3′ untranslatedregion (UTR) comprising the transcriptional terminator andpolyadenylation site of open reading frame 23 (ORF23) of A. tumefacienspTi15955 (Barker et al, Plant Molecular Biology 1983, 2(6), 335-50). Thehygromycin resistance gene expression cassette included the 19S promoterincluding a 5′ UTR from cauliflower mosaic virus (CaMV) (Cook and PenonPlant Molecular Biology 1990 14(3), 391-405) followed by the hygromycinphosphotransferase (hph) gene (Kaster et al Nucleic Acids Research 198311 (19), 6895-6911). The hph gene was codon-optimised for expression indicotyledonous plants and was flanked by a 3′UTR comprising thetranscriptional terminator and polyadenylation site of Open ReadingFrame 1 (ORF1) of A. tumefaciens pTi15955 (Barker et al, Plant MolecularBiology 1983, 2(6), 335-50). Both cassettes were synthesized by acommercial gene synthesis vendor (GeneArt, Life Technologies,Regensberg, Germany).

Vectors for the gene splicing experiments were constructed by cloningtwo tandem copies of the ZFN recognition sequence targeted by the ZFNencoded in the vector pDAB10782. Vectors for the gene editingexperiments were constructed by cloning one copy of each of the ZFNrecognition sequences targeted by the ZFNs encoded in the vectorspDAB107827 and pDAB107828. In both cases the two ZFN recognitionsequences were separated by the recognition sequences for BamHI and NotIrestriction endonucleases. The tGFP and HPH cassettes were cloned intothe BamHI and NotI sites of each vector resulting in four “donor”vectors: pDAS000340 (hygromycin-resistant gene-splicing donor: SEQ IDNO:275, FIG. 15), pDAS000341 (tGFP reporter gene splicing donor: SEQ IDNO:276, FIG. 16), pDAS00342 (hygromycin-resistant gene-editing donor:SEQ ID NO:277, FIG. 17) and pDAS000343 (tGFP reporter gene editingdonor: SEQ ID NO:278, FIG. 18).

Colonies of the assembled plasmids were initially screened byrestriction endonuclease digestion of DNA purified from overnightcultures of E. coli. Restriction endonucleases were obtained from NewEngland BioLabs™ (NEB, Ipswich, Mass.) and Promega™ (PromegaCorporation, WI). Plasmid preparations were performed using the QIAprepSpin Miniprep Kit™ (Qiagen, Hilden, Germany) or the Pure Yield PlasmidMaxiprep System™ (Promega Corporation, WI) following the instructions ofthe suppliers. After the restriction fragments were confirmed by agarosegel electrophoresis of resulting fragments, plasmid DNA of selectedclones were sequenced using ABI Sanger Sequencing and Big Dye Terminatorv3.1™ cycle sequencing protocol (Applied Biosystems, Life Technologies).Sequence data were assembled and analyzed using the Sequencher™ software(Gene Codes, Ann Arbor, Mich.).

Maintenance of Plant Material for Protoplast Isolation

Mesophyll derived protoplasts were isolated from three-week old sterileshoot cultures of Brassica napus (DH10275). The corresponding seeds weregerminated following the methods herein described. The seeds weresurface-sterilized using 70% ethanol for 1 minute and gently shakenfollowed by 3-4 rinses in sterile double-distilled water. The seeds weresubsequently sterilized using 20% bleach and 10 μl of Tween 20. Theseeds were further treated with the bleach on a table top shaker atapproximately 100 RPM, for 15 minutes followed by 3-4 rinses in steriledouble-distilled water, seeds were carefully transferred to a sterilefilter paper to remove the excess moisture and plated on seedgermination medium (½ strength MS/B5 Vitamins+1% sucrose+0.8% Agar; pH5.8.

Approximately, 50-60 mL of media was poured into each Petri™ dish(15×100 mm) and the plates were placed with a slight angle using asupport. Approximately 50 seeds were placed on each plate. The plateswere incubated upright at 22° C. in 16 h/d light (20 μmol m-2 s-1) for 6days. Hypocotyl segments of 0.5 cm size were dissected from the six dayold seedlings and cultured on shoot induction medium (MS/B5 Vitamins+3%sucrose+500 mg/L MES+BAP (13 μm)+Zeatin (5 μm)+Silver Nitrate (5mg/L)+0.8% Agar (pH 5.8). The medium was poured into a 100×20 mm sterilePETRI™ dish, approximately 20 explants were placed on the medium perplate. Shoot meristems that appeared after 3-4 weeks were transferred toshoot elongation medium (MS/B5 Vitamins+2% sucrose+500 mg/L MES+BAP (2μm)+GA-3 (0.1 μm)+0.8% Agar (pH 5.8) and poured in 250 mL culturevessels) and the cultures were maintained in this medium for 4 weekswith one round of sub-culturing in between. Shoots of 2-3 cm height werethen transferred to root initiation media (½ strength MS/B5 Vitamins+1%sucrose+500 mg/L MES+IBA (2.5 μm)+0.6% Agar (pH 5.8) and poured in 700mL culture vessels) for root development. Rooted shoots weresub-cultured in fresh root initiation media at 3-4 weeks intervals asstem cuttings for two-three rounds before use. The cultures weremaintained throughout at 22° C. in 16 h/d light (30 μmol m-2 s-1).

Isolation and Purification of Mesophyll Protoplasts

In vitro grown DH12075 Brassica napus plants were used as the explantsource for isolating mesophyll protoplasts. To isolate the protoplasts,the 3rd to 4th upper fully expanded leaves from 3-4 weeks old plantletswere cut with a sharp scalpel into small strips (0.5 to 1 mm) forprotoplast isolation. Enzymatic digestion was carried out by treating250-500 mg of leaf material with 25 mL of digestion buffer (1.2% (w/v)Cellulase “Onozuka™” R10 and 0.2% (w/v) Macerozyme® R10 dissolved in K4media (Spangenberg et al., 1998)). The PETRI™ dish containing the leafmaterial and digestion buffer was sealed with Parafilm™ and incubated atroom temperature for 12 to 15 h in darkness. After overnight incubationthe digests were filtered through a BD® cell strainer (mesh size 70 μm).Protoplast suspensions (5-6 mL) collected in a 14 mL round bottomed tubewas over layered with 1 mL of W5 washing buffer (154 mM NaCl, 125 mMCaCl2, 5 mM KCl and 5 mM glucose; pH 5.8 Menzel et al. (1981)).

The protoplast suspensions were further centrifuged at 400 RPM for 10min. After centrifugation, protoplasts that floated in the interphasewere withdrawn and washed by centrifugation using 10 mL of W5 buffer at400 RPM for 10 min. After the final wash, isolated protoplasts wereresuspended at a density of 1×106 protoplasts per mL of W5 buffer andincubated for 1 hour before transfections.

Assessment of Protoplast Yield and Viability

Protoplasts yield was assessed using a haemocytometer following themethod of Sambrook and Russell, (2006). The cell viability was testedusing 400 mg/L of Evans blue stain dissolved in 0.5 M of mannitol asdescribed by Huang et al. (1996) with few minor modifications to theprotocol.

PEG 4000 Mediated DNA Delivery

Before delivery to B. napus protoplasts, plasmid DNA of each donor andZFN construct was prepared from cultures of E. coli using the Pure YieldPlasmid Maxiprep System® (Promega Corporation, Madison, Wis.) followingthe instructions of the suppliers. Aliquots of donor and ZFN plasmid DNAwere prepared in three molar ratios: 1:1 (30 μg of each plasmid), 5:1(donor plasmid to ZFN plasmid to a total of 30 μg of plasmid DNA) and10:1 (donor plasmid to ZFN plasmid to a total of 30 μg of plasmid DNA).Additionally, donor-only and ZFN-only aliquots (30 μg) were prepared ascontrols. The amounts of DNA delivered to the B. napus protoplasts viathe PEG4000 mediated transformation are summarized in Table 9.

TABLE 9 Quantities of ZFN and donor DNA delivered to protoplasts Totalquantity of DNA (μg) delivered to 1 million Molar Ratio of plasmid DNAprotoplasts Splicing Donor plasmid only 30 ZFN plasmid only (pDAB107827)30 1:1 Donor:ZFN 60 5:1 Donor:ZFN 30 10:Donor:ZFN 30 Editing Donorplasmid only 30 1:1:ZFN plasmids 30 (pDAB107827 and pDAB107828) 1:1:1Donor:ZFN:ZFN 90 5:1:1 Donor:ZFN:ZFN 30 10:1:1 Donor:ZFN:ZFN 30

Each aliquot of plasmid DNA was applied to one million protoplasts(viability ≧95) suspended in 100 μl of transformation buffer (15 mMMgCl2, 0.1% (w/v) morpholinoethanesulphonic acid (MES) and 0.5 MMannitol; pH 5.8) followed by 150 μl of PEG solution (40% (w/v) PEG 4000in 0.4 M Mannitol and 0.1 M Ca (NO3)2 (pH 6-7) Spangenberg and Potrykus(1995). After 10-15 min of incubation at room temperature, 5 mL of W5buffer was added in a drop wise manner and the protoplasts were gentlymixed. Another 5 mL of W5 buffer was added as a slow stream to theprotoplasts suspension. Protoplasts were mixed gently and centrifuged at400 RPM for 10 min and the W5 supernatant was removed carefully leavingbehind the protoplasts in the form of a pellet. Transfected protoplastswere then incubated in 1 mL of W5 buffer at room temperature until theywere embedded in bead type cultures. The transfected protoplasts wereembedded following the sodium alginate method as described below.

Culturing of Mesophyll Derived Protoplasts to Recover Viable MicrocallI

Before embedding within the medium, the transfected protoplasts werecentrifuged at 400 RPM for 10 minutes and the W5 buffer was carefullyremoved. The protoplasts were then resuspended in 1.0 mL of 0.5 MMannitol and incubated on ice. To the protoplast solution, an equalvolume of 1.0% sodium alginate was added and mixed gently. Theprotoplasts suspension was incubated in ice until it was embedded. Beadforming solution (0.4 M Mannitol+50 mM CaCl2 (pH 5.8)) was transferredto a sterile six well plate (3-4 mL per well) using a serologicalpipette. Exactly 1.0 mL of the protoplasts suspension was added in adrop wise manner using a 1 mL pipette into the bead forming solution andeach transfected sample (ca. 5×105 protoplasts) was embedded per well.The protoplasts suspension was incubated for 1-2 hours at roomtemperature to form sodium alginate beads. After the incubation periodthe bead forming solution was carefully removed and replaced with 4-5 mLof 1:2 mixture of K3+H:A media (Spangenberg et al 1998) supplementedwith 1.5 mg/L of hygromycin. The protoplasts were cultured for 3-4 weeksin darkness at 22° C. in a shaker (50 RPM). After 3-4 weeks theresistant microcalli (0.5-1.0 mm) were released by treating withdepolymerisation buffer (0.3 M Mannitol+20 mM Sodium Citrate (pH 5.8)).After removing the liquid media, 3-4 mL of depolymerisation buffer wasadded to each well containing the bead-type cultures and incubated atroom temperature for 2 hours. Using a sterile forceps the beads weregently mixed to enhance the efficient release of the microcalli. Next asterile 1.0 mL pipette was used to gently mix gelling agent that wasreleased in the depolymerisation buffer and subsequently removed. Themicrocalli was washed twice using 5 mL of liquid A media and themicrocalli was resuspended in sufficient quantity of liquid A (50 mL ofliquid A was used for one mL of the settled cell volume (SCV: this wasmeasured after transferring all the released microcalli to a sterile 50or 15 mL falcon tube and allowed to settle down for 5 min)). Aftermixing the microcalli uniformly, 0.5 mL of the microcalli suspended inthe liquid A media was transferred to B1 media (MS/MS Vitamins+3.5%Sucrose+500 mg/L MES+BAP (5 μm)+NAA (5 μm)+2, 4-D (5 μm)+1.5 mg/Lhygromycin+0.7% Agarose Type I (pH 6.0) and poured in 100×20 mm sterilePETRI™ dish) and using 1-2 mL of additional liquid A media themicrocalli was distributed uniformly in the B1 media and the excessliquid A media was carefully removed from each plate. The plates weresealed using a micropore tape which enhanced the embryo maturation. Thecultures were maintained at 22° C. in 16 h/d light (30 μmol m-2 s-1).

Proliferation and Regeneration of Shoots from Mesophyll DerivedProtoplasts

Hygromycin resistant colonies were picked from B1 media (microcalliderived from both SA and SP methods) after 2-3 weeks of incubation andtransferred to B2 media (MS/MS Vitamins+3.0% Sucrose+500 mg/L MES+500mg/L PVP+5 mg/L Silver nitrate+5 mg/L 2i P+NAA (0.5 μm)+GA-3 (0.3μm)+1.5 mg/L Hygromycin+0.7% Agarose Type I (pH 5.8) and poured in100×20 mm sterile PETRI™ dish). Approximately 25-30 calli were placedper plate and the plates were sealed using Parafilm™ and incubated at22° C. in 16 h/d light (30 μmol m-2 s-1). Hygromycin resistant colonieswere subsequently recovered after 5-6 rounds of sub-culturing in B2media at two weeks interval. The number of calli per plate was reducedto 12-15 after a third round of sub-culturing. Shoot primordias thatappear after 10-12 weeks were carefully recovered along with theresidual calli and transferred to shoot elongation medium (MS/B5Vitamins+2% sucrose+500 mg/L MES+BAP (2 μm)+GA-3 (0.1 μm)+300 mg/LTimentin+1.5 mg/L Hygromycin+0.8% Agar (pH 5.8) and poured in 250 mLculture vessels). The shoots that survive after 2-3 rounds of Hygromycinselection were transferred to rooting media (½ strength MS/B5Vitamins+1% sucrose+500 mg/L MES+IBA (2.5 μm)+1.5 mg/L Hygromycin+0.6%Agar (pH 5.8) and poured in 700 mL culture vessels).

Isolation of Genomic DNA from Mesophyll Protoplasts

Transfected protoplasts were transferred from the 3 cm PETRI™ dish to a2 mL microfuge tube. The cells were pelleted by centrifugation at 70 gand the supernatant was removed. To maximize the recovery of transfectedprotoplasts, the PETRI™ dish was rinsed three times with 1 mL of washbuffer. Each rinse was performed by swirling the wash buffer in thePETRI™ dish for 1 minute, followed by transfer of the liquid to the same2 mL microfuge tube. At the end of each rinse, the cells were pelletedby centrifugation at 70 g and the supernatant was removed. The pelletedprotoplasts were snap frozen in liquid nitrogen before freeze drying for24 h in a Labconco Freezone 4.5® (Labconco, Kansas City, Mo.) at −40° C.and 133×10−3 mBar pressure. The lyophilized cells were subjected to DNAextraction using the DNeasy® Plant DNA Extraction Mini kit (Qiagen)following the manufacturer's instructions, with the exception thattissue disruption was not required and the protoplast cells were addeddirectly to the lysis buffer.

Isolation of Genomic DNA from Callus Tissue

Individual calli was snap frozen in liquid nitrogen before freeze dryingfor 24 h in a Labconco Freezone 4.5® (Labconco, Kansas City, Mo.) at−40° C. and 133×10−3 mBar pressure. The lyophilized calli was subjectedto DNA extraction using the DNeasy® Plant DNA Extraction Maxi kit(Qiagen, Hilden, Germany) following the manufacturer's instructions.

Isolation of Genomic DNA from Leaf Tissue

Thirty (30) mg of young leaf tissue from regenerated plants was snapfrozen in liquid nitrogen before freeze drying for 24 h in a LabconcoFreezone 4.5® (Labconco, Kansas City, Mo.) at −40° C. and 133×10−3 mBarpressure. The lyophilized calli was subjected to DNA extraction usingthe DNeasy® Plant DNA Extraction Maxi kit (Qiagen, Hilden, Germany)following the manufacturer's instructions.

PCR Assays of Genomic DNA for NHEJ-Mediated Splicing and Editing ofFad3C

Detection of integration of donor DNA to the Fad3C gene of B. napus wasdone by a series of PCR where at least one primer was specific to theFad3C locus (Table 10) and a second primer specific to either thepromoter or terminator of the gfp cassette (Table 10 and FIG. 19A).Specificity was obtained by designing oligonucleotides where the lastbase pair aligned to a SNP that differentiated the Fad3C genomicsequence from the other copies of Fad3 genes and included aphosphorothioate internucleotide linkage before this base pair asindicated by an asterisk [*]. This design, used in combination with apolymerase having proofreading activity, directed specific amplificationof each Fad3C or Fad3A allele and excluded other Fad3 copies as noted.Each primer set was empirically tested for amplification of the correctgene copies through Sanger-based sequencing of the PCR amplificationproducts obtained from wild type B. napus.

TABLE 10 Oligonucleotide sequences used to detect integration ofDNA into ZFN-induced double-stranded breaks SEQ ID Primer NamePrimer Sequence NO: Specificity 1 FAD3CNHEJ- gattcctaagcattgttgggt*c 279Fad3C only L4-F2 2 FAD3CNHEJ- gaaaatctcatatcgaacgtgcg*t 280 Fad3C onlyL4-R2 3 FAD3CNHEJ- cgcttaccctctctatctggta*a 281 Does not amplify L6-F1Fad3C′ or Fad3C″ 4 FAD3CNHEJ- ccttgcctctgtaccaaggca*g 282 Fad3C onlyL6-R2 5 19SPNHEJ-R2 gtgtgtgggaatcttatcttcgg 283 n/a 6 AtORF1NHEJ-caagtcaggtattatagtccaagca 284 n/a F1 7 AtUbiNHEJ-R1caagaatatcctgatccgttgac 285 n/a 8 AtORF23tNHEJ- tggcagttgaaatactcaaacc286 n/a F1 9 FAD3aCNHEJ- gtcctttgagatccatgagcta*t 287 Fad3A only L4-F110 FAD3aCNHEJ- gattcctaagcattgttgggt*a 288 Fad3A only L4-F2 11FAD3aNHEJ- tgcgttcaagaaatcaaagac*a 289 Fad3A only L4-R1 12 FAD3aNHEJ-gaaaatctcatatcgaacgtgcg*g 290 Fad3A only L4-R2 13 FAD3aNHEJ-tctggtaaatcctaattcct*c 291 Fad3A only L6-F1 14 FAD3aNHEJ-ccttgcctctgtaccaaggca*a 292 Fad3A only L6-R2 15 FAD3aNHEJ-cttgcctctgtaccaaggcaactt*c 293 Excludes Fad3C L6-R1 *Indicatesphosphorothioate internucleotide linkages to direct specificamplification (with proofreading polymerase) of Fad3C or Fad3A toexclusion of other copies of Fad3 as noted. Each primer set wasempirically tested for amplification of the correct gene copies bySanger-based sequencing of the PCR amplification products obtained fromwild type B. napus.Detection of Gene Addition to Fad3C by Non-Homologous End Joining inProtoplasts

Genomic DNA was extracted from protoplast pools (one million protoplastper pool) to which donor DNA encoding a functional tGFP reportercassette (pDAS000341 or pDAS000343), ZFN DNA (pDAB107827 or pDAB107828)or a mixture of donor and ZFN DNA had been delivered twenty-four hoursearlier. Quantities of DNA delivered for transformation are describedabove. PCR products were cloned into plasmid vectors. The genomicediting occurs independently in each cell giving rise to a variety ofdifferent insertion events, by cloning into a plasmid vector, eachgenomic edit can be sequenced without ambiguity. Several clones weresequenced on an ABI3730XL® automated capillary electrophoresis platform.Analysis of gene sequences was done using Sequencher SOFTWARE v5.0™(GeneCodes, Ann Arbor, Mich.).

Evidence of gene addition to the Fad3C locus by editing or splicing wasprovided by amplification of both the 5′ and 3′ Fad3C-cassette junctionsfrom genomic DNA extracted from protoplasts using the primers describedin Table 10. Products of PCR amplification with primers“FAD3CNHEJ-L4-F2” and “AtUbiNHEJ-R1” was completed to amplify the 5′junction of tGFP cassette and Fad3C. PCR amplification with primers“FAD3CNHEJ-L4-R2” and “AtORF23tNHEJ-F1” was completed to amplify the 3′junction of tGFP cassette and Fad3C. PCR amplification with primers“FAD3CNHEJ-L4-F2” and “FAD3CNHEJ-L4-R2” was completed to amplify acrossthe double strand breaks induced by ZFN 28051-2A-28052. No amplificationwas observed from protoplasts to which ZFN plasmid or donor plasmidalone had been delivered. All junction sequences were indicative ofinsertion of the tGFP cassette at the Fad3C locus via an NHEJ-mediatedrepair pathway. Deletions of varying lengths from either or both thegenome and the cassette were observed as well as the addition ofsequences derived from the vector backbones (either from the donor orZFN) being inserted between the genome and the cassette (FIG. 20A andFIG. 20B).

Detection of Gene Addition to Fad3C by Non-Homologous End Joining inCallus Tissue Regenerated from Protoplasts

Further evidence of splicing and editing of the Fad3C locus was obtainedfrom callus tissue regenerated from protoplasts on selection (1.5 mg/Lhygromycin, as described above) to which donor DNA encoding an hphcassette (pDAS000340 or pDAS000342), ZFN DNA only (pDAB107827 orpDAB107828) or donor and ZFN DNA had been delivered (quantities of DNAdelivered are given in Table 9). DNA was extracted from approximately 80calli for each ratio, except editing 1:1:1, for which no calli survived,four weeks after protoplast transfection.

Integration of the hph cassette into the B. napus genome (fwat Fad3C orrandomly) was confirmed by Taqman™ qPCR using primers (SEQ ID NO:294;F-5′ CTTACATGCTTAGGATCGGACTTG 3′, SEQ ID NO:295; R-5′AGTTCCAGCACCAGATCTAACG 3′) and probe (SEQ ID NO:296; 5′CCCTGAGCCCAAGCAGCATCATCG 3′) specific to the hph gene. Theseprimer-probe pairs were used in a duplex reaction with primers (SEQ IDNO:297; F-5′ CGGAGAGGGCGTGGAAGG 3′, SEQ ID NO:298; R-5′TTCGATTTGCTACAGCGTCAAC 3′) and probe (SEQ ID NO:299; 5′AGGCACCATCGCAGGCTTCGCT 3′) specific to the B. napus high mobility groupprotein I/I (HMG FY), which is present as a single copy on the A genome(Weng et al., 2004, Plant Molecular Biology Reporter). Amplification wasperformed on a C1000 thermal cycler with the CFX96 or CF384 real-timePCR detection System™ (BioRad, Hercules, Calif.). Results were analyzedusing the CFX Manager™ (BioRad) software package. Relativequantification was calculated according to the 2-ΔΔCt method (Livak andSchmittgen, 2001), which provided an estimation of the number of copiesof hph cassette inserted into the genome.

Evidence of NHEJ-mediated splicing and editing of Fad3C was obtained byconducting PCR assays with one primer specific to Fad3C and a secondprimer specific to either the promoter or terminator of the hph cassette(Table 9 and FIG. 19B). Due to limited quantities of DNA obtained fromcallus tissue, only integration in the sense orientation was assayed.PCR products were gel-purified using QiaQuick MiniElute PCR PurificationKit™ (Qiagen) and sequenced using a direct Sanger sequencing method. Thesequencing products were purified with ethanol, sodium acetate and EDTAfollowing the BigDye® v3.1 protocol (Applied Biosystems) and sequencedand analysed as above.

The numbers of calli containing the donor cassette in each experimentare given in Table 11. Evidence of donor gene addition to the Fad3Clocus by editing and/or splicing was provided by PCR amplification (withprimers shown in Table 10) across the ZFN cut sites and both the 5′ and3′ Fad3C-hph cassette junctions. PCR amplification of the genomic DNAisolated from callus tissue recovered from control protoplasts whichwere transformed with only the hph plasmid (pDAS000340 and pDAS000342)or only the ZFN plasmid (pDAB107827 and pDAB107828) did not result inthe production of PCR amplification products.

The PCR amplicons produced from the amplification of the 5′ and 3′Fad3C-hph cassette junctions were purified from the agarose gel andsequenced to confirm specificity of the integration within the Fad3Cgenomic locus. The results of the sequencing analysis of the PCRproducts indicated that each isolated callus which was generated from anindividually transformed protoplast only produced a single PCRamplification product and did not contain cells of mixed genotypes.

In NHEJ-mediated integration of donor sequences within the Fad3C genomiclocus experiments the frequency of addition to the target locus (asdefined by any part of the donor DNA vector being amplified from thetarget locus) was 42%, 46% and 32% for the DNA concentrations of 1:1,5:1, and 10:1 (Donor DNA: ZFN DNA), respectively. See, Table 12. Thefrequency of on-target splicing was determined by assaying whether bothcassette junctions were amplifiable and from the sequencing of the PCRproducts. These results verified that the cassette was inserted at thetarget locus in the correct orientation. The frequency of integrationwas calculated as 4%, 3% and 3% for the 1:1, 5:1 and 10:1 of Donorplasmid DNA: ZFN plasmid DNA concentrations, respectively. In geneediting experiments the frequency of addition to the target locusdefined by any part of the donor DNA vector being amplified from thetarget locus, was 66% and 65% for the 5:1:1 and 10:1:1 of Donor plasmidDNA: ZFN plasmid DNA concentrations, respectively. See, Table 13. Thefrequency of on-target editing, was determined by both cassettejunctions being amplifiable and producing a sequence of PCR products.These results verified that the cassette was inserted at the targetlocus in the correct orientation at frequencies of 3% and 6% for the5:1:1 and 10:1:1 of Donor plasmid DNA: ZFN plasmid DNA concentrations,respectively. As observed in the protoplast assays, the base pairs wereeither deleted or additional bases were inserted between the genome andthe cassette as a result of the cleavage of the genomic locus by the ZFN(FIGS. 21-22).

In certain instances the PCR products resulted in an addition ofnucleotide sequences within the target locus, no PCR product, or alarger PCR product than observed in wild-type samples. These resultswhich were produced from the PCR amplification using primers flankingthe cut site indicated that the locus had been disrupted in both pairsof chromosomes (FIGS. 21-22). In some of the instances more than oneband was amplified at the splice junctions (FIGS. 21-22) indicating thatdifferent insertions had occurred independently in each copy of thegenome.

TABLE 11 Number of calli positive for presence of hph after four weekson selection Molar Ratio of Number of Number of calli positive VectorsDonor DNA:ZFN calli for hph after four weeks delivered DNA sampled onselection pDAS000340 1:1 88 76 DAB107827 5:1 88 35 10:1  87 37pDAS000342 1:1:1 — — DAB107827 5:1:1 80 38 DAB107828 10:1:1  79 52

TABLE 12 Number of calli with hph inserted by splicing at FadC locus atthe DSB induced byZFN28051-2A-28052 Number calli from Number of MolarNumber of Number of calli which calli from Ratio of calli positive fromwhich at at least one which both Donor for hph after least one perfect*splicing Vectors DNA:ZFN four weeks on splicing border border bordersdelivered DNA selection amplified amplified amplified pDAS000340 + 1:176 32 0 3 DAB107827 5:1 35 16 0 1 10:1  37 12 0 1 *number base pairsdeleted or additional base pairs inserted at cut site

TABLE 13 Number of calli with hph inserted by editing at FadC locus atthe cut sites induced by by ZFN28051-2A-28052 and ZFN28053-2A-28054Number calli from Molar Number of Number of calli which Number of Ratioof calli positive from which at at least one calli from Donor for hphafter least one perfect* which both Vectors DNA:ZFN four weeks onsplicing border border editing borders delivered DNA selection amplifiedamplified amplified pDAS000342 + 5:1:1 38 25 2 1 DAB107827 + 10:1:1  5234 2 3 DAB107828 *number base pairs deleted or additional base pairsinserted at cut siteDetection of Gene Addition to Fad3C by Non-Homologous End Joining inPlants

DNA was extracted from plants that were regenerated from protoplasts andtransferred to potting medium (as described above). The majority ofplants recovered were estimated to contain only 1-2 copies of the hphcassette encoded in the donor DNA. Plants were analyzed with the samesuite of assays described for callus tissue as well as with assays todetermine if the cassette had inserted in an antisense orientation or adonor integration at the Fad3A locus.

TABLE 14 Estimated copy number of plants regenerated from protoplasts.For each ratio three transfections of one million protoplasts wereperformed # plants # plants # plants with Molar Ratio of with with 5 ormore Vectors Donor DNA:ZFN 1-2 copies 3-4 copies copies delivered DNAhph hph hph pDAS000340 1:1 37 16 34 DAB107827 5:1 18 14 30 10:1  16 1318 pDAS000342 1:1:1 0 1 1 DAB107827 5:1:1 22 14 18 DAB107828 10:1:1  2311 27 Total — 116 69 128

The frequency of on-target splicing for the linear donor designconstructs, where the hph cassette was inserted into Fad3C in eitherdirection, was 51%, 32% and 56% for Donor DNA:ZFN DNA at concentrationsof 1:1, 5:1 and 10:1, respectively (Table 15). Of these results, 35% 32%and 50% (1:1, 5:1 and 10:1) were inserted in the forward orientation(Table 15).

The frequency of on-target editing, where the hph cassette was insertedinto Fad3C in either direction, replacing the area from locus 4 to locus6, was 2% and 0% for Donor DNA:ZFN DNA:ZFN DNA at concentrations of5:1:1 and 10:1:1, respectively (Table 16). In addition, when both ZFNswere delivered at 5:1:1, 2% and spliced into locus 4 and 10% splicedinto locus 6 and when both ZFNs were delivered at 10:1:1 10% and splicedinto locus 4 and 15% spliced into locus 6. The PCR amplicons wereobtained and sequenced to determine the insert junction sequences. Theresulting sequences for specifically labeled plants are described inTable 17.

TABLE 15 Number of plants with hph inserted by splicing at FadC locus atthe DSB induced by ZFN28051-2A-28052 Both Orientations Forward Reverse(Forward & Events Orientation Orientation Reverse) Total Tested One OneBoth One One Both One Both Off- Positive Ratio 5′ In- 3′ In- 5′ & 5′ In-3′ In- 5′ & 5′ or 3′ 5′ & 3′ On- target for HPH 1:1 3 2 2 5 3 4 17 4 4047 87 5:1 8 2 1 — — — 3 — 14 48 62 10:1  8 2 1 2 — 2 9 2 26 21 47

TABLE 16 Number of plants with hph inserted by editing at FadC locus atthe cut sites induced by ZFN28051-2A-28052 and ZFN28053-2A-28054 BothOrientations Forward Reverse (Forward & Orientation Orientation Reverse)Events One One One One Tested border One Both border border Both borderBoth Total Positive 5′ In- border borders 5′ In- 3′ In- borders eitherborders On- Off- for RATIO out 3′ In-out 5′ & 3′ out out 5′ & 3′ 5′ or3′ 5′ & 3′ target target HPH 1:1 3 2 2 5 3 4 17 4 40 47 87 5:1 8 2 1 — —— 3 — 14 48 62 10:1  8 2 1 2 — 2 9 2 26 21 47

TABLE 17 Plant details of single copy hph, target inserted at Fad3Clocus at the cut sites induced by ZFN28051-2A-28052 andZFN28053-2A-28054 Sequence ID Plant barcode PCR/Sequence informationNumber 349711 Locus 4 upstream 353 349685 Locus 4 upstream 354 346258Locus 4 upstream 355 348918 Locus 4 upstream 356 359900 Locus 4 upstream357 346125 Locus 4 upstream 358 348919 Locus 4 upstream 359 349215cLocus 4 upstream 360 349216c Locus 4 upstream 361 346102 Locus 4downstream 362 346175 Locus 4 downstream 363 345888 Locus 6 downstream364 356731 Locus 6 downstream 365 346128 Locus 4 downstream antisense366 orientation 347359 Locus 6 upstream antisense 367 orientation

The frequency of on-target splicing, where the hph cassette was insertedinto Fad3C in either direction for the circular donor, was 51%, 32% and56% for 1:1, 5:1 and 10:1 respectively (Table 18; FIG. 23). Of these 35%32% and 50% (1:1, 5:1 and 10:1) were inserted the forward orientation(Table 18).

The frequency of on-target editing, where the hph cassette was insertedinto Fad3C in either direction, replacing the area from locus 4 to locus6, was 2% and 0% for 5:1: and 10:1:1 respectively (Table 19; FIG. 24).In addition, when both ZFNs were delivered at 5:1:1, 2% and spliced intolocus 4 and 10% spliced into locus 6 and when both ZFNs were deliveredat 10:1:1 10% and spliced into locus 4 and 15% spliced into locus 6.

TABLE 18 Number of plants with hph inserted by splicing at FadC locus atthe DSB induced by ZFN28051-2A-28052 Number of plants from Number ofwhich at plants from least one which both splicing splicing Molar Numberof border borders Ratio of plants amplified amplified Donor analysed(forward/ (forward/ Vectors DNA:ZFN (positive for reverse/ reverse/delivered DNA hph) either) either) pDAS000340 + 1:1 60 21/23/31 4/7/8DAB107827 5:1 37 12/4/12 3/1/3 10:1  46 23/12/26 4/4/7 * no base pairsdeleted or additional base pairs inserted at cut site

TABLE 19 Number of plants with hph inserted by editing at FadC locus atthe cut sites induced by ZFN28051-2A-28052 and ZFN28053-2A-28054 Numberof plants from Number of which at plants from least one which bothsplicing splicing Molar border borders Ratio of Number of amplifiedamplified Donor plants analysed (forward/ (forward/ Vectors DNA:ZFN(positive for reverse/ reverse/ delivered DNA hph) either) either)pDAS000342 + 5:1:1 39 17/11/24 0/1/1 DAB107827 + 10:1:1  63 27/27/340/0/0 DAB107828 * no base pairs deleted or additional base pairsinserted at cut siteTargeted Integration of Brassica napus Omega-3 Fatty Acid Desaturase viaHDR

The donor vectors containing the tGFP and HPH cassettes are modified toinclude 1 kb of FAD3 upstream and downstream donor sequences. The FAD3upstream and downstream donor sequences are 100% identical to the nativeFAD3 sequence and are obtained from the FAD3 zinc finger binding site;GCCCAAGGAACCCTTTTCTGGGCCATCTTCGTACTCGGCCACGACTGGTAATTTAAT (SEQ IDNO:255) or AGCGAGAGAAAGCTTATTGCAACTTCAACTACTTGCTGGTCGATCGTGTTGGCCACTC(SEQ ID NO:256). The resulting four “donor” vectors are similar topDAS000340 (hygromycin-resistant gene-splicing donor), pDAS000341 (tGFPreporter gene splicing donor), pDAS00342 (hygromycin-resistantgene-editing donor) and pDAS000343 (tGFP reporter gene editing donor),wherein the only modification is the inclusion of 1 Kb of FAD3 genomicupstream and downstream sequences. The zinc finger nuclease plasmids(pDAB107827 and pDAB107828) previously described for NHEJ mediatedintegration are used for the HDR mediated integration.

Transformation of Brassica napus

Mesophyll derived protoplasts are isolated and prepared from Brassicanapus (DH10275) plants as described above. The protoplasts aretransformed with purified plasmid DNA. Aliquots of donor and ZFN plasmidDNA are prepared in three molar ratios: 1:1 (30 μg of each plasmid), 5:1(donor plasmid to ZFN plasmid to a total of 30 μg of plasmid DNA) and10:1 (donor plasmid to ZFN plasmid to a total of 30 μg of plasmid DNA).Additionally, donor-only and ZFN-only aliquots (30 μg) are prepared ascontrols. The amounts of DNA delivered to the B. napus protoplasts via aPEG4000 mediated transformation are summarized in Table 20. Thetransformed protoplast cells are cultured as previously described,wherein the selection medium is glufosinate selection medium, andputative transformants are assayed via qPCR analysis for transgeneinsertions.

TABLE 20 Quantities of ZFN and donor DNA delivered to protoplasts Totalquantity of DNA (μg) delivered to 1 million Molar Ratio of plasmid DNAprotoplasts Splicing Donor plasmid only 30 ZFN plasmid only 30 1:1Donor:ZFN 60 5:1 Donor:ZFN 30 10:Donor:ZFN 30 Editing Donor plasmid only30 1:1:ZFN plasmids 30 1:1:1 Donor:ZFN:ZFN 90 5:1:1 Donor:ZFN:ZFN 3010:1:1 Donor:ZFN:ZFN 30Detection of Gene Addition to Fad3 by HDR in Protoplasts

Genomic DNA is extracted from protoplast pools (one million protoplastper pool) to which donor DNA encoding a functional reporter cassette orselectable marker cassette, ZFN DNA or a mixture of donor and ZFN DNAare delivered twenty-four hours earlier. Quantities of DNA delivered fortransformation are described above. PCR products are cloned into plasmidvectors. The genomic editing occurs independently in each cell givingrise to a variety of different insertion events, by cloning into aplasmid vector, each genomic edit can be sequenced without ambiguity.Several clones are sequenced on an ABI3730XL® automated capillaryelectrophoresis platform. Analysis of gene sequences is done usingSEQUENCHER SOFTWARE V5.0™ (GeneCodes, Ann Arbor, Mich.).

Evidence of gene addition to the FAD3 locus by editing or splicing isprovided by amplification of both the 5′ and 3′ FAD3-cassette junctionsfrom genomic DNA extracted from protoplasts. No amplification isobserved from protoplasts to which ZFN plasmid or donor plasmid alonehad been delivered. All junction sequences are indicative of insertionof the cassette at the FAD3 locus via an HDR-mediated repair pathway.Deletions of varying lengths from either or both the genome and thecassette are observed as well as the addition of sequences derived fromthe vector backbones (either from the donor or ZFN) being insertedbetween the genome and the cassette.

Detection of Gene Addition to Fad3 by HDR in Callus Tissue Regeneratedfrom Protoplasts

Further evidence of splicing and editing of the FAD3 locus was obtainedfrom callus tissue regenerated from protoplasts on selection to whichdonor DNA encoding a cassette, ZFN DNA only, or donor and ZFN DNA aredelivered. DNA is extracted from approximately 80 calli for each ratio.

Integration of the cassette into the B. napus genome is confirmed byTAQMAN™ qPCR using primer and probes specific to the donor insert andthe genomic flanking sequences. Relative quantification is calculatedaccording to the 2^(−ΔΔCt) method (Livak and Schmittgen, 2001), whichprovided an estimation of the number of copies of cassette inserted intothe genome. Evidence of NHEJ-mediated splicing and editing of FAD3 isobtained by conducting PCR assays with one primer specific to FAD3 and asecond primer specific to either the promoter or terminator of thecassette. PCR products are gel-purified using QIAQUICK MINIELUTE PCRPURIFICATION KIT™ (Qiagen) and sequenced using a direct Sangersequencing method. The sequencing products are purified with ethanol,sodium acetate and EDTA following the BIGDYE® v3.1 protocol (AppliedBiosystems) and sequenced and analyzed as above.

The numbers of calli containing the donor cassette in each experimentare determined. Evidence of donor gene addition to the FAD3 locus byediting and/or splicing is provided by PCR amplification across the ZFNcut sites and both the 5′ and 3′ FAD3-cassette junctions. PCRamplification of the genomic DNA isolated from callus tissue recoveredfrom control protoplasts which are transformed with only the plasmid oronly the ZFN plasmid do not result in the production of PCRamplification products.

The PCR amplicons produced from the amplification of the 5′ and 3′FAD3-cassette junctions are purified from the agarose gel and sequencedto confirm specificity of the integration within the FAD3 genomic locus.The results of the sequencing analysis of the PCR products indicate thateach isolated callus which is generated from an individually transformedprotoplast only produce a single PCR amplification product and do notcontain cells of mixed genotypes.

Detection of Gene Addition to Fad3 by HDR in Plants

DNA is extracted from plants that are regenerated from protoplasts andtransferred to potting medium. The majority of plants recovered areestimated to contain only 1-2 copies of the cassette encoded in thedonor DNA. Plants are analyzed with the same suite of assays describedfor callus tissue as well as with assays to determine if the cassettehad inserted in the FAD3 locus.

The frequency of on-target splicing, where the cassette is inserted intoFAD3 locus is determined using the PCR assays described above. Theamplicon bands obtained are sequenced to determine the flankingsequences. Additionally, plants are screened for off-target insertionsto determine the frequency of integration of the cassette at sites otherthan FAD3.

Example 9: Targeted Integration of Brassica napus Omega-3 Fatty AcidDesaturase (Fad3) with an Agronomically Important Gene

Constructs containing the DGT-28 transgene (International PatentApplication No. WO/2013/116700, herein incorporated by reference) thatconfers resistance to the herbicide glyphosate are designed and builtfor integration within the FAD3 genomic loci of Brassica napus. Theconstructs and associated zinc finger nuclease constructs (e.g.,(pDAB107827 and pDAB107828)) are transformed into Brassica napus cellsas previously described above. Transformants are identified andconfirmed via molecular confirmation assays as previously described. TheFAD3 chromosomal integrants, comprising an integrated dgt-28 transgeneare isolated. The integration of the dgt-28 transgene within the FAD3locus is exemplified via NHEJ mediated integration and HDR mediatedintegration. The integration within the FAD3 locus can be directed intothe FAD3 endogenous sequence or into the previously described ETIP(pDAS000271-pDAS000275) that is stably integrated within the FAD3 locus.The integration within the FAD3 locus via an NHEJ mediated mechanism canbe made using linearized donor or circular donor DNA designs.Transformed DGT-28 Brassica napus events are obtained and tested forrobust expression of the DGT-28 and the subsequent resistance to theherbicide glyphosate.

While certain exemplary embodiments have been described herein, those ofordinary skill in the art will recognize and appreciate that manyadditions, deletions, and modifications to the exemplary embodiments maybe made without departing from the scope of the following claims. Inaddition, features from one embodiment may be combined with features ofanother embodiment.

What may be claimed is:
 1. A transgenic cell comprising an exogenousnucleotide sequence integrated into a FAD3A, FAD3A′, FAD3A″, FAD3C,FAD3C″ and/or a FAD3C′ gene, wherein the exogenous nucleotide sequenceis integrated into a target site using a nuclease that binds to thetarget site as shown in SEQ ID NOs: 20-23, SEQ ID NOs: 25-38, SEQ IDNOs: 40-45, SEQ ID NO: 47 and SEQ ID NO:
 49. 2. The transgenic cell ofclaim 1, wherein the exogenous nucleotide sequence comprises a sequenceencoding a polypeptide.
 3. The transgenic cell of claim 1, wherein theexogenous nucleotide sequence is a non-coding sequence.
 4. Thetransgenic cell of claim 2, wherein the polypeptide confers herbicideresistance.
 5. The transgenic cell of claim 1, wherein the exogenousnucleotide sequence is integrated into some but not all copies of theFAD3A, FAD3A′, FAD3A″, FAD3C, FAD3C″ and/or a FAD3C′ gene.
 6. Atransgenic plant or seed, comprising the transgenic cell of claim
 1. 7.The transgenic cell of claim 1, wherein presence of the exogenousnucleotide sequence in the FAD3A, FAD3A′, FAD3A″, FAD3C, FAD3C″ and/or aFAD3C′ gene does not negatively influence the agronomic or qualityproperties of a plant comprising the cell.
 8. A method for making a cellaccording to claim 1, the method comprising: cleaving, in a sitespecific matter, a FAD3A, FAD3A′, FAD3A″, FAD3C, FAD3C″ and/or a FAD3C′gene, using a nuclease that binds to the target site as shown in SEQ IDNOs: 20-23, SEQ ID NOs: 25-38, SEQ ID NOs: 40-45, SEQ ID NO: 47 and SEQID NO: 49, to thereby generate a break in the FAD3 gene; integratinginto the break the exogenous nucleotide sequence.
 9. The methodaccording to claim 1, wherein the nuclease comprises a DNA-bindingdomain and a cleavage domain or cleavage half-domain into the cell,wherein the nuclease binds with specificity to the target site andcleaves at or near the target site to thereby generate the break. 10.The method according to claim 9, wherein the DNA-binding domain isselected from a group comprising a meganuclease DNA-binding domain, aleucine zipper DNA-binding domain, a transcription activator-like (TAL)DNA-binding domain, a recombinase, a RNA-guided CRISPR-Cas9, a zincfinger protein DNA-binding domain, and chimeric combinations of any ofthe foregoing.
 11. The method according to claim 9, wherein the cleavagedomain or cleavage half-domain is selected from a group consisting of acleavage half-domain from a type IIS restriction endonuclease, acleavage half-domain from FokI endonuclease, a cleavage half-domain fromStsI endonuclease, and a homing endonuclease.
 12. The method accordingto claim 9, wherein the zinc finger protein is a zinc finger nuclease.13. The method according to claim 12, wherein the zinc finger nucleasecomprises from three to six zinc finger domains, each zinc finger domaincomprising a recognition helix region, wherein the zinc finger proteincomprises the recognition helix regions ordered and shown in a singlerow of Table
 3. 14. The method according to claim 8, wherein thecleaving in a site specific manner is specific for some but not allcopies of a FAD3A, FAD3A′, FAD3A″, FAD3C, FAD3C″ and/or a FAD3C′. 15.The method according to claim 8, wherein the cell is a plant.
 16. Themethod according to claim 8, wherein the break is a double strand break.17. The method according to claim 8, wherein the exogenous nucleotidesequence encodes a protein.
 18. The method according to claim 17,wherein the nucleic acid sequence of interest is selected from the groupconsisting of insecticidal resistance genes, herbicide tolerance genes,nitrogen use efficiency genes, water use efficiency genes, nutritionalquality genes, DNA binding genes, and selectable marker genes.
 19. Themethod according to claim 8, wherein the exogenous nucleotide sequenceof interest comprises a DNA-binding domain binding site.
 20. The methodaccording to claim 8, wherein the nuclease is introduced into the cellas a polynucleotide encoding the fusion protein.